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 ABSTRACT 
 
Nontyphoidal Salmonella (NTS) are a major cause of invasive disease in young children 
and HIV-infected adults in Sub-Saharan Africa. To develop a vaccine for NTS, an 
improved understanding of immunity to NTS is required. This thesis investigates the 
role of opsonic antibody in protection against NTS. First, we defined the optimal serum 
handling conditions to preserve complement function. We determined minimal titres of 
antibody and complement required for cell-mediated killing of Salmonella and found 
they are higher than for cell-free killing. We demonstrated impaired blood cell killing of 
NTS opsonised with sera from HIV-infected Africans. Developing a method to purify 
anti-LPS antibodies, we showed that high titres of anti-LPS antibodies in these sera 
inhibit cell-mediated killing while lower titres are opsonic and induce cell-mediated 
killing of NTS. For most children, antibody acquired during NTS bacteraemia effected 
cell-mediated killing of NTS. High antibody titres were not necessarily protective, but 
for some sera, dilution prior to opsonisation, induced killing. The sensitivity of 
Malawian NTS isolates to opsonic antibody varied, with resistance to cell-mediated and 
bactericidal killing correlating. Overall, this thesis emphasises the importance of 
opsonic antibody in protecting against NTS and supports the development of a vaccine 
which induces antibody to Salmonella. 
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CHAPTER 1. 
INTRODUCTION 
 
1.1 THEME AND OVERVI EW 
The theme of this thesis is the role of antibody in cell-mediated immunity to 
Nontyphoidal Salmonella (NTS). The requirement for opsonic antibody for immunity to 
NTS in HIV-infected African adults and in African children with NTS bacteraemia is 
investigated. The requirement of antibody and complement for blood cell killing of 
Salmonella compared to cell-free complement-dependent killing is studied as well as 
the susceptibility of invasive African isolates to antibody-mediated killing. This chapter 
will discuss Salmonella and the epidemiology of NTS infections. The pathogenesis, host 
immune response to infection and the development of vaccines for protection against 
Salmonella will also be discussed.  
 
1.2.1 SALMONELLA  
Salmonella is a genus of Gram-negative, rod shaped bacteria. They are approximately 
0.7 to 1.5 µm in diameter and 2.0 to 5.0 µm in length. They are classed as 
chemoorganotrophs, obtaining their energy from oxidation and reduction reactions 
using organic sources. Salmonellae are mostly motile as they possess flagella which 
project in all directions.  
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1.2.2 TAXONOMY 
The genus Salmonella is classified as a member of the Enterobacteriaceae family (1). 
The genus is divided into two species; Salmonella bongori and Salmonella enterica. S. 
bongori is largely restricted to cold-blooded animals (2). S. enterica is divided into six 
subspecies, based on genome phylogeny and biochemical and antigenic characteristics:  
enterica (I), salamae (II), arizonae (IIIa), diarizonae (IIIb), hotenae (IV), and indica (VI). 
Within these six subspecies are more than 2400 serotypes (3). These serotypes are 
classified using the Kauffman-White scheme, according to O (carbohydrates associated 
with LPS) and H (flagellar proteins) antigens (4). 
 
1.2.3 SALMONELLAE AS PATHOGENS 
The majority of serovars which cause human disease, including Typhimurium, 
Enteritidis, Paratyphi and Typhi are within S. enterica enterica (subspecies I) (5). 
Infection with each of these serotypes results in a different disease state, which is 
dependent on the infecting serotype, the host species and the host’s immune state. 
Infection with typhoidal Salmonella (S. Typhi, S. Partyphi A, B and C) cause enteric fever, 
whereas infection with nontyphoidal Salmonellae (including S. Typhimurium and S. 
Enteritidis) cause gut-associated gastroenteritis and sometimes invasive bacteraemia. 
Some serotypes are restricted in terms of the hosts they infect. For example, Salmonella 
Typhi and S. Paratyphi A are host-restricted to humans and cause typhoid fever (1) and 
S. Gallinarium is host restricted to chickens, and causes typhoid-like disease (6).  Some 
serotypes such as S. Typhimurium are promiscuous as they are able to infect different 
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animals as well as humans. In mice, S. Typhimurium infection causes a fatal enteric 
fever with symptoms similar to those in humans infected with S. Typhi (7). However, in 
humans, infection with S. Typhimurium usually results in enterocolitis, and in rare cases 
develops into a systemic infection. 
 
1.3 EPIDEMIOLOGY OF NTS INFECTIONS 
1.3.1 SALMONELLA  INFECTIONS IN DEVELOPED COUNTRIES 
The global burden of NTS gastroenteritis is estimated to be 93.8 million cases, resulting 
in 155,000 deaths annually (8). NTS has been identified as the leading cause of death 
from foodborne illness in the United States of America (9). Salmonellosis is usually a 
foodborne zoonosis with foods such as poultry, eggs, milk, fruit and vegetables 
implicated in transmission (10;11). Symptoms of NTS enterocolitis appear 12 to 72 hs 
after ingestion (12), and infected individuals experience mild, self-limiting 
gastrointestinal illness involving diarrhoea, abdominal cramps, fever, nausea and 
vomiting (13;14). In industrialised countries, development of blood stream infections 
are rare (15) except in immunocompromised individuals (16). 
1.3.2 SALMONELLA  INFECTIONS IN AFRICA 
It is estimated that there are 50 cases of Salmonella Typhi per 100,000 people per year 
in Africa (17) and S. Typhi is the predominant invasive serotype in North Africa. In sub-
Saharan Africa, NTS bacteraemia is a major public health problem (18-21) . The burden 
of NTS infection is estimated to be 175-338 cases per 100,000 children aged 3-5 years 
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(20;22;23) and 2000-7500 cases per 100,000 HIV-infected adults (19;24;25). 
Salmonella serovars Typhimurium and Enteritidis are most frequently associated with 
diarrhoeal and bloodstream infections in Africa (26-28) (Figure 1.1). The mode of 
transmission is unknown, but it is thought that person-to-person transmission is 
important (13;29).  
 
In African adults, invasive NTS disease is associated with HIV-infection (30). In a study 
in Malawi, 92-96% of febrile adults admitted to hospital with NTS bacteraemia were 
HIV-positive (31), and 80% had peripheral blood CD4 counts less than 200 cells/µl  
(30;31). Case fatality rates for HIV-infected adults with NTS bacteraemia are reported to 
be 47% (30). Recurrent infections are common in HIV-infected adults, with 22-44% of 
patients having further NTS infections, usually within 2-3 months (16;32). These 
recurrent infections are associated with recrudescence rather than re-infection (33), 
and a decline in recurrence is observed once anti-retroviral therapy is commenced (34).  
 
Infection with NTS is also common in African children below 2 years of age (20;28), 
with less than one in five cases HIV-associated (26). The incidence of NTS bacteraemia 
is high with a mortality rate of 24% despite treatment with antibiotics (20;28;35). NTS 
can also cause meningitis (36), with the fatality rate increasing to 50% (31;37). 
1.3.3 CLINICAL PRESENTATION 
A lack of specific clinical presentation of invasive NTS infection makes diagnosis difficult 
(28). Patients often present with a febrile systemic illness (38;39), but gastrointestinal 
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Figure 1.1 Map of Africa highlighting blood stream infection studies. 
Results of a meta-analysis of studies investigating the cause of blood stream infections 
(BSI) in African children and adults (Figure taken from (24)). 
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symptoms are often absent (40) (Figure 1.2). Given the high incidence of malaria and 
pneumonia in sub-Saharan Africa, and that the clinical presentations for these diseases 
can overlap (39;41;42), mis-diagnosis is common. A blood culture is required for 
correct diagnosis of bacteraemia, but many hospitals and clinics lack such facilities.   
 
1.3.4 TREATMENT 
Antimicrobials are commonly prescribed to treat NTS bacteraemia, but multi-drug 
resistance is a growing problem. In Malawi, 90% of invasive NTS isolates are resistant 
to ampicillin, chloramphenicol and cotrimoxazole (31;43). Alternative antibiotics such 
as cephalosporins and fluoroquinolones are now prescribed, though these are 
expensive and drug-resistance against these antibiotics is likely to develop (44). 
Therefore, it is essential that a vaccine which provides protection against NTS is 
developed. 
 
1. 4 RISK FACTORS FOR  INV ASIV E NON TYPHOI DAL SALMONELLA  
DISEASE IN AFRICA 
A high incidence of malaria, HIV and malnutrition are common in Africa and these 
together with young age are associated with the high disease burden of non-typhoidal 
salmonellosis in Africa. A significantly higher number of cases of NTS infection are 
observed during the wet season compared to the dry season, (43;46;47) suggesting that 
water sanitation is a risk factor for NTS disease. However, the prevalence of malaria and 
malnutrition also increase during the rainy season (18). Overcrowding, limited access  
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Figure 1.2 Clinical presentations of invasive NTS disease in African children and 
adults.  
A lack of blood culture facilities and an absence of specific clinical presentation makes 
NTS difficult to diagnose (Figure taken from (45)). 
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to fresh water and poor sanitation are likely to further aid human to human 
transmission of NTS.  
 
1.4.1 ENVIRONMENTAL RISK FACTORS 
1.4.2 YOUNG AGE 
Young age is a risk factor for mortality in Africa (28;48).  A peak incidence of NTS 
bacteraemia is observed in African children aged between 6 and 24 months (20;49). 
Antibody passively acquired during the final trimester of pregnancy provides protection 
against NTS infection for the first few months of life, but as this maternal antibody titre 
wanes, infants are at increased risk of invasive disease as they are not yet able to 
produce their own antibody (50). A study of 352 cases of infants with bacteraemia at 
the Queen Elizabeth Central Hospital (QECH), Malawi in 2003-2004 found that NTS 
bacteraemia was commonest in children between 4 and 24 months of age which 
corresponded with an absence of antibody (50). An observed decrease in incidence in 
older children correlated with an increased acquisition of antibody (50). This supports 
the hypothesis that antibody is an important mechanism of protection against NTS.  
 
1.4.3 MALARIA AND MALARIAL ANAEMIA 
The association between malaria and invasive salmonellosis is well established. It was 
observed in British Guiana in the 1920’s that NTS septicaemia was common during 
malaria outbreaks (51). A similar association has since been reported in children from 
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Nigeria, the Gambia and Malawi (16;35) where cases of malaria parasitaemia were 
significantly higher in children with bacteraemia caused by NTS compared to those with 
bacteraemia caused by other pathogens (28). 
 
NTS bacteraemia is also associated with anaemia in young children in Africa (28;52;53). 
Severe malarial anaemia, where plasma haemoglobin levels drop below 5 g dl–1, is 
particularly linked with NTS bacteraemia (54). One proposed mechanism for the 
association, is that malaria causes haemolysis of infected red blood cells which results 
in anaemia and in the release of free haemoglobin-derived heme from red blood cells 
(55). Free heme has cytotoxic effects and, to counteract this, host cells induce heme 
oxygenase-1 (HO-1) which removes heme and heme-derived metabolites (55). 
Phagocytosis and the subsequent oxidative burst are crucial mechanisms for destroying 
Salmonella. However, the activity of HO-1 suppresses the oxidative burst activity of 
granulocytes, consequently producing a niche for bacterial replication and overall 
increasing host susceptibility to NTS (56). 
 
 
1.4.4 HIV 
AIDS was first linked with Salmonella infection in the 1980s, at the outset of the AIDS 
pandemic (57;58). NTS has since been identified as the commonest blood stream 
bacterial isolate from febrile adults admitted to hospital in HIV-prevalent areas of Africa 
(35;38;59). Three immunological defects in HIV-infected adults have so far been 
identified which can help explain this association (45). Firstly, a loss of Th17 cells from 
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the gut mucosa has been identified in HIV-infected patients, leading to a failure to 
maintain the epithelial barrier and easier dissemination of bacteria from the gut into 
the blood stream (60). Secondly, an excess of antibody which targets the O-antigen 
chain of LPS on Salmonella Typhimurium has been observed in a proportion of HIV-
infected African adults, and it is thought that the excess antibody blocks or diverts the 
access of other bactericidal antibody to the bacteria’s surface (61). Finally, dysregulated 
cytokine production, particularly of TNF-α, IL-10 and IL-12 has been noted in HIV-
infected adults (62), which would explain the intracellular persistence of the bacteria 
and the observed recurrent infections. 
 
Although salmonellosis in African children was a common problem before the HIV 
epidemic, an association between HIV infection and NTS bacteraemia has also been 
observed in children, with 20% of children presenting with NTS bacteraemia also 
testing positive for HIV (21;26). 
 
1.4.5 MALNUTRITION 
Over 50% of blood isolates from children admitted to QECH, Malawi, with bacteraemia 
and severe malnutrition were identified as NTS (28;31), highlighting the association 
between malnutrition and NTS. A similar finding was observed in Uganda, where 
bacteraemia was reported in 17-22% of malnourished children (63;64), of which NTS 
was the commonest cause. It is thought that the intestinal lining and therefore the 
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normal immune response is disturbed in malnourished children, thereby permitting 
easier access of bacteria into the bloodstream.  
 
1.5 SALMONELLA  PATHOGENESIS  
S. Typhimurium infection in mice provides an insight into the likely pathogenesis of 
Salmonella. The severity and outcome of the infection is dependent on several factors, 
including; the virulence of the infecting strain, the dose, route of infection, genetic 
makeup as well as the immunological status of the host (65).  
 
Salmonellae usually infect their host through the oral ingestion of contaminated food or 
water. A proportion of the ingested inoculum will survive the low pH environment of 
the stomach to enter the small intestine (Figure 1.3). Once in the intestine, Salmonellae 
invade the epithelial cells and M cells in the Peyer’s patches using a type III  secretion 
system (TTSS) encoded by genes within Salmonella Pathogenicity Island-1 (SPI-1) (66). 
The TTSS encodes a needle like complex which injects effector proteins (1) such as 
SopE1, SopE2 and SopB from the bacterial cell into the host cell cytoplasm (67). These 
proteins activate intracellular signalling cascades, cytoskeletal rearrangements and 
stimulate the uptake of the bacteria by macropinocytosis (68;69). Salmonellae which 
are deficient in these virulence effector proteins are still able to invade the mucosal 
epithelia of the host (70). These bacteria are taken up by activated dendritic cells which 
have been recruited from the blood to the site of infection. These dendritic cells sample  
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Figure 1.3 Distribution of Salmonella in the mouse model.  
Salmonellae first invade epithelial and M cells and are engulfed by resident 
macrophages and dendritic cells. The bacteria initiate caspase-1 mediated cell death of 
the host macrophage, leading to production of interleukin – 1β and interleukin-18, 
mediating the recruitment of polymorphonuclear phagocytes (PMNs).  The bacteria 
enter the mesenteric lymph nodes and blood and are captured by phagocytes in the 
spleen and liver forming pathological lesions (Figure taken from (74)). 
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the luminal contents and engulfed bacteria are then transported into the blood by the 
dendritic cells (71). 
Regardless of the route used by the bacteria to cross the epithelium, an early local 
inflammatory response is induced (72). Invasion of the epithelial cells leads to the 
production of interleukin-1β and IL-18 which mediate the infiltration of 
polymorphonuclear leukocytes into the intestinal lumen from the blood (72). As the 
neutrophils migrate through the epithelial layer, there is an accumulation of protein 
rich fluid in the intestinal lumen, causing diarrhoea, 8-72 hs after bacterial colonisation 
(73). Once across the epithelium, the bacteria are engulfed by macrophages  (74) and 
spread to the mesenteric lymph nodes and then into the blood (75). A transient state of 
bacteraemia is formed, but Salmonella which have avoided killing by the phagocytes are 
rapidly opsonised by antibody and complement, and are efficiently phagocytosed by 
neutrophils and monocytes in the spleen and liver (76;77). The phagocytes induce 
killing of the ingested bacteria through the generation of reactive oxygen species (ROS) 
and reactive nitrostative intermediates (RNI), activating lysosomal enzymes and 
defensins. This mechanism controls the spread of the bacteria and initially reduces the 
number of Salmonellae. However, Salmonellae are capable of intracellular survival. 
Several Salmonella virulence genes are upregulated upon entry into the phagosome 
(2;78) which modify the host environment, impair the activity of anti-microbial NADPH 
oxidase and allow the formation of a Salmonella containing vacuole where Salmonella 
can replicate, prior to initiating caspase-1 mediated apoptosis of the macrophage (79) 
and release into the extracellular compartment.  
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Within 24 hours, the number of bacteria within the spleen and liver increase. The 
bacteria grow within distinct foci, but once the number of bacteria reaches a certain 
threshold, the bacteria escape and spread through the organ and enter previously non-
infected cells to form new infection foci (74). It is unclear how bacteria spread from one 
focus of infection to another (74). In this way, the number of killed bacteria is 
insignificant compared to the exponential increase in the number of bacteria 
distributed within the organ (80;81).  
 
Within 72 hours, there is systemic bacterial spread and bacteria are present in large 
numbers within the blood. Endotoxic shock and subsequent death of the mouse follow 
(82). It is unknown if systemic S. Typhimurium infection in African children and HIV-
infected adults follows the same process. 
 
1.6 SALMONELLA  VIRULENCE AND RESISTANCE TO KILLING 
During pathogenesis, Salmonellae use numerous mechanisms to both evade the host 
immune system and manipulate immune cell functions (83). Successful colonisation of 
the host depends on the expression of virulence proteins by Salmonella and also on the 
ability of Salmonellae to survive within the macrophage (84). Mutant strains of 
Salmonella which are not able to grow within macrophages are avirulent (84). 
Salmonellae have approximately 4500 genes and over 100 of these genes have been 
implicated in virulence (85;86). Variations in genes encoding for surface structures 
such as LPS and flagella, as well as for factors which modify host cell physiology affect 
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the virulence of the bacteria (5), and offer an explanation as to why some serotypes 
have increased virulence. 
 
1.6.1 SALMONELLA  PATHOGENICITY ISLANDS 
Salmonella pathogenicity islands (SPIs) are DNA segments encoding important 
virulence genes. They are the product of multiple horizontal gene transfers from other 
bacteria during the course of evolution (87). Salmonellae have numerous SPIs, though 
SPI-1 and SPI-2 are the most important as they are central to Salmonella pathogenesis 
and virulence. SPI-1 is required for the invasion of non-phagocytic host cells, namely 
intestinal epithelial cells. SPI-1 encodes for a TTSS which transports effector proteins 
into the cytosol of the host cell, resulting in rearrangement of the cytoskeleton and the 
uptake of the bacteria into a membrane bound vesicle (88).  
Unlike SPI-1 which is present in the genome of all species of Salmonella (89), SPI-2 is 
only present in S. enterica. SPI-2 also encodes TTSS apparatus and effector proteins 
which modify the intracellular environment within the host macrophage and 
consequently enhance Salmonella survival (90). The SPI-2 effectors direct the formation 
and maturation of the Salmonella containing vacuole (SCV), and also impairs the 
recruitment of NADPH oxidase to the phagosome (90). 
1.6.2 LPS  
The lipopolysaccharide (LPS) molecule of Salmonella plays an important role in 
infection (91).  LPS is known to protect bacteria from serum complement killing. Rough 
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mutants, which have either no O-antigen or a truncated O-antigen, are more sensitive to 
bactericidal antibody and complement than the corresponding smooth strain (92). The 
length of the LPS O-antigen can also influence the interaction with complement and 
macrophages (93) and the size and distribution of the O-antigen can determine serum 
resistance (94). It is possible that LPS confers resistance to complement-dependent 
killing through diverting the deposition of membrane attack complex away from the 
bacterial surface (95). 
 
1.6.3 PHOP/Q  
PhoP/Q is an important two-component regulator of Salmonella virulence (96). It 
controls the expression of over 40 virulence genes. PhoP controls adaptation to the 
intraphagosomal environment and PhoQ is a sensor protein that is responsive to 
antimicrobial peptides, acid pH and low Mg2+ concentrations (97). Together they 
control the expression of genes and thus proteins involved in the formation of SCVs, 
macrophage-induced apoptosis, LPS regulation (98) and resistance to acidic pH (99) 
and antimicrobial peptides (100). 
 
1.7 IMMUNITY TO SALMONELLA  
Salmonellae are facultative intracellular organisms which are adapted to survive within 
macrophages (84) but are also capable of extracellular growth in the blood. Immunity 
against NTS is complex (101;102) and different stages of infection require collaboration 
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between different mechanisms of innate and acquired immunity, and involve both cell-
mediated and humoral immunity (Figure 1.4). 
  
The course of a primary sub lethal infection in the mouse model can be divided into four 
phases: phase 1 which involves the clearance of bacteria from the blood, phase 2 which 
corresponds to exponential growth of the bacteria in macrophages, phase 3, 
suppression of bacterial growth associated with the onset of the adaptive immune 
response and phase 4, the clearance of remaining organisms from the tissues (102). 
 
1.7.1 PHAGOCYTES 
Phagocytes express many different pattern recognition receptors that permit the 
recognition of pathogen microbial components. Toll-like receptor-4 (TLR-4) is a pattern 
recognition receptor which in conjunction with CD14, an LPS binding protein (103), 
recognises LPS on Salmonella. Flagellin is detected by TLR-5. TLR-4 knockout mice are 
more susceptible to infection, highlighting the importance of this interaction to the host 
(104;105). 
 
During the first phase of infection, the majority of ingested Salmonellae pass through 
the epithelial cells in the gut and enter the blood stream, where phagocytes play a 
central role in controlling the infection. Neutrophils are the first type of phagocyte to  
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Figure 1.4 Phases of primary Salmonella infection. 
The solid line shows the course of sub lethal infection in wild-type immune-competent 
mice and the immune mechanisms involved during each phase of infection. (Figure 
taken from (102)). 
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recognise and engulf opsonised Salmonella, hence their importance in the initial stage of 
infection. Most of the bacteria are cleared from the blood within 1-2 hours (76) 
throughopsonisation with antibody and complement and subsequent uptake by 
phagocytes. The bacteria are phagocytosed through a process in which the bound 
pathogen is surrounded by the cell membrane and engulfed in a membrane-bound 
vesicle called the phagosome 
 
Once within the cell, macrophages are able to kill, or at least limit the replication of 
intracellular bacteria through the production of antimicrobial peptides, lysosomes and 
toxic reactive oxygen and nitrogen species via the respiratory burst phagocyte oxidase 
(phox) and inducible nitric oxide synthase (iNOS) (90;106). The respiratory burst 
oxidase, NADPH oxidase, is a membrane bound enzyme complex comprised of gp91 and 
p22 subunits, which form cytochrome b558, and cytosolic components; p40, p47, p67 
and Rac1 proteins which assemble in the cytoplasmic membrane upon phagocyte 
activation (106). This enzymatic system is responsible for reducing molecular oxygen to 
superoxide, a cytotoxic precursor of oxygen radicals (107;108), in a process of rapid 
oxygen consumption, known as the respiratory burst. The products of the respiratory 
burst are toxic to the bacteria. The initial respiratory burst is followed by a longer, more 
sustained bacteriostatic production of nitric oxide (109;110) by inducible nitric oxide 
synthase (iNOS), which catalyses the production of NO from oxygen, NADPH and L - 
arginine. Together these mechanisms maximise the initial reduction in bacterial 
numbers but minimise the side effects to the host (106).  
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The importance of the respiratory burst in killing ingested bacteria is demonstrated in 
patients with chronic granulomatous disease (CGD)(106). CGD is an inherited disorder 
in which mutations occur in X-linked (gp91) or autosomal (p22, 47, 67) genes encoding 
subunits of the NADPH oxidase. Patients with CGD have recurrent infections and 
develop septicaemia as although they can phagocytose the invading bacteria, they are 
unable to mount a successful respiratory burst which would kill the bacteria , or acidify 
the lysosome so that lysosomal enzymes can work at their optimal pH. Recurrent 
infections occur from birth (111) and IFNγ is administered to reduce the number of 
severe infection, with a bone marrow transplant often required. Salmonella has been 
identified as the second most prevalent cause of frequent and severe infections in CGD 
patients (112). 
 
1.7.2 CYTOKINES 
Cytokines such as TNF-α, and Interleukin-1 (IL-1), IL-6, IL-12, IL-18 are produced by 
macrophages, and other secreted cytokines such as IL-10 and IL-4, and TNF-α and IFN-γ 
are produced by Th2 and Th1 cells respectively. The production and release of these 
cytokines is a hallmark of invasive Salmonella infection (113) and are important for 
defence against disease. 
1.7.2.1 TNF- ΑLPHA 
TNF-α is one of the first cytokines to be released by macrophages during Salmonella 
infection. Both TNF-α and IFN-γ have been shown to play an important role in 
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preventing systemic infection by wild type S. Typhimurium in orally inoculated mice 
(114) and pre-treatment with exogenous TNF-α of susceptible mice infected  with 
Salmonella resulted in increased survival (115). Furthermore, TNF-α receptor p55 
deficient mice succumb earlier to virulent Salmonella challenge (116), highlighting the 
importance of this cytokine in host defence.   
  
1.7.2.2 IFN-γ 
 
The internalisation of Salmonella by macrophages induces the production of IL-12 
which stimulates NK cells and T cells to produce IFN-γ (117) which activates the 
macrophages and enhances anti-bacterial activity (118). Gordon et al showed that 
priming with IFN-γ increased the numbers of internalized Salmonella by human 
monocyte-derived macrophages compared to un-primed cells (119). The importance of 
the role of IFN-γ in immunity to NTS is highlighted by the observed increased 
susceptibility to recurrent NTS infections in patients who have CGD or genetic 
deficiencies in either the IFN-γ or in the IL-12/IL-23/IFN-γ axis (120;121). The 
administration of IFN-γ to infected mice, a few days after challenge with a virulent 
strain reduced the severity of the infection (122) and cessation of this anti-IFN-γ 
treatment (123) or depletion of IFN-γ using anti-IFN-γ antibody enhanced the severity 
of the infection (124).  
 
1.7.2.3 IL-12 
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IL-12 strongly induces IFN-γ production by lymphocytes and is therefore a key cytokine 
in immunity against Salmonella. The importance of IL-12 has been demonstrated in 
mice and humans. Neutralisation of IL-12 increases the number of Salmonellae found in 
the spleen of mice and results in impaired survival (125), while treatment with 
exogenous IFN-γ increases host survival (126).  Patients with IL-12 or IL-12 receptor 
deficiencies are highly susceptible to severe Salmonella infections (127;128) and 
subcutaneous IFN-γ is prescribed along with antibiotics to treat infections (127;128). 
 
1.7.2.4 IL-15 
IL-15, which has very similar biological activities to IL-12 (129;130), is produced by 
activated macrophages and monocytes and is involved in the activation of NK cells and 
γδ-T cells in mice (131;132). 
 
1.7.2.5 IL-18 
IL-18 is also produced by monocytes and macrophages (133) and together with IL-12, 
induces both IFN-γ and TNF-α production by human NK and T cells (134;135). In mice, 
neutralisation of IL-18 results in increased bacterial growth in the spleen and liver and 
diminished host survival, and treatment with IL-18 decreases the number of bacteria 
found in these tissues and increases host survival (135).  
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1.7.2.6 IL-10 AND IL-4  
IL-10 has an inhibitory effect on host immunity to NTS by antagonizing the effect of IFN -
γ on macrophages. Impaired killing of Salmonella by macrophages is observed in mice 
expressing the IL-4 gene (136) and increased resistance to Salmonella infection is 
observed in IL-4-deficient mice compared with wild-type mice (137).  
 
1.7.3 T CELLS 
Although the innate immune response controls the initial infection, adaptive immunity 
and a Salmonella-specific T-cell response is required to eradicate the remaining bacteria 
and provide protection against subsequent infections (1). Salmonella infection induces 
both CD4+ T cells and CD8+ T cells, with CD4+ T cells, which mediate protection by 
producing cytokines such as IFN-γ, playing a central role in clearance of the bacteria 
from tissues, with little contribution from CD8+ T cells. The depletion of CD4+ T cells, 
rather than CD8+ T cells has a greater effect on both control of the primary infection 
and protection induced by vaccination with attenuated strains of Salmonella 
Typhimurium (82). Furthermore, protection against infection was increased when 
CD4+ T cells from vaccinated mice were transferred into naïve mice compared with 
when CD8+ T cells were transferred (138-140) reinforcing the importance of CD4+ T 
cells over CD8+ T cells. Furthermore, in the absence of CD4+ T cells, phagocytes are 
unable to clear bacteria from their cells due to impaired antibacterial function, causing 
severe infection (140).  
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The Salmonella-specific T cell response is directed against Salmonella protein antigens 
such as porins and flagellin (102). McSorley et al have shown that the flagellar filament 
protein FliC, is a major target of CD4+ T cells during both primary and secondary 
infection and can protect naïve mice from fatal Salmonella infection (141). CD8+ T cells 
control Salmonella infection through lysing infected macrophages with poor 
bactericidal activity (140) thus, causing the release of bacteria into the blood, and 
exposing them to antibody and complement. Cytotoxic CD8+ T cells also contain 
granulysin which has antimicrobial activity against Salmonella (142). 
 
γδ-T cells may also play a role in immunity to Salmonella infection, although, mice 
deficient in γδ -T cells are able to control systemic infection with an attenuated strain of 
S. Typhimurium (122). Mice with defects in αβ-T cells infected with attenuated strains 
of Salmonella Typhimurium fail to control infection though and develop chronic disease, 
suggesting that αβ-T cells are more important than γδ-T cells (1).  
 
1.7.4 B CELLS 
B cells display a range of functions in the immune response against infection with 
Salmonella, including antigen presentation and the production of antibodies and 
cytokines. B cells contribute to early protection in mice challenged with Salmonella, and 
together with antibodies, provide protection against secondary challenge.  B cell-
deficient mice demonstrate impaired resistance to primary Salmonella infections, 
caused by a defect in antibody production (102). Furthermore, impaired production of 
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Th1 cytokines, IL-12 and IFNγ is also observed in B cell-deficient mice, resulting in the 
failure to control virulent Salmonella infection (143).  
 
1.7.5 COMPLEMENT  
The complement system is an important component of the innate immune system and 
plays an essential role in host defence against pathogens (77). It is composed of a series 
of heat-labile serum proteins, which can be activated via three different pathways 
(Figure 1.5) to generate a series of effector proteins which help to destroy the invading 
pathogen.  The classical pathway is activated by the binding of C1q (144) to IgM, IgG1 
and IgG3 bound to the bacterial surface. The alternative pathway is continuously 
activated due to a low level of spontaneous hydrolysis of C3. The lectin pathway is 
activated by mannose-binding lectin binding to mannose residues on the bacteria’s 
surface. Invasive strains of Salmonella Typhimurium activate complement via the 
alternative and classical pathways but do not activate mannose-binding lectin 
bactericidal complement (50). Although the pathways are activated differently, the 
pathways converge to activate C3 convertase which cleaves C3. The fragment C3b is a 
major opsonin and can covalently bind to the bacteria enhancing phagocytosis (145) 
and destruction of the bacteria. Fragments C3a, C4a and C5a are inflammatory 
activators which recruit and activate phagocytes. C5b triggers the assembly of 
fragments C5b-C9 into the membrane attack complex (MAC) which is deposited and 
inserted into the bacterial cell membrane (146). Consequently, the lipid bilayer and 
cellular homeostatis is disrupted and the bacteria is destroyed (95). It is essential that  
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Figure 1.5 Activation and function of the three complement pathways.  
All three pathways that activate the complement cascade converge at the formation of 
C3 convertase. C3 convertase cleaves C3 into components C3a and C3b, ultimately 
leading to opsonisation of the pathogen, release of inflammatory mediators, and the 
formation of the membrane attack complex. (Figure taken from (154)). 
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complement activation is carefully regulated. Factor H is the main inhibitor of the 
alternative pathway and both C1 inhibitor and C4bp inhibit the classical pathway (147). 
 
1.7.6 ANTIBODY 
Although NTS are intracellular bacteria they are also capable of extracellular growth in 
the blood, and antibody plays a key role in preventing extracellular growth and 
controlling infection (50) (Figure 1.6). Adoptive transfer studies in mice have shown 
that optimal protection against Salmonella infection is conferred by both antibody and T 
cells (148;149). Antibody to Salmonella has also been shown to reduce bacteraemia in 
mice, as well as prevent primary infection and impede hematogenous spread of 
Salmonellae (150). Young African children who lack antibody to NTS, but have 
functional complement are more susceptible to NTS infection (50). When sera from 
these children are supplemented with IgG, killing is restored, indicating the importance 
of bactericidal antibody in controlling extracellular growth in the blood (50). 
Furthermore, an absence of antibody in these young African children impedes oxidative 
burst and cellular killing of NTS and when exogenous IgG is added, optimal killing of 
Salmonella is observed (151). The importance of antibody in immunity to Salmonella is 
also highlighted by patients with primary immunodeficiencies (152). For example, 
persistent diarrhoea, caused by Salmonella, was reported in patients with X-linked 
agammaglobulinaemia (153).  
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Figure 1.6 The key immunological factors that control the intracellular and 
extracellular phases of infection in humans.  
Salmonellae grow within the phagocytic cells and cell-mediated immunity enhances the 
antimicrobial functions of the host phagocyte, such as the production of reactive oxygen 
intermediates, killing a proportion of the ingested bacteria but also releasing some 
bacteria into the extracellular space (80;81). Once in the extracellular space, antibody 
and complement can be deposited on the bacteria, opsonising it and facilitating uptake 
by phagocytes expressing the corresponding Fc receptor, enhancing bacterial 
internalisation and forming new infection foci. Furthermore, when in the extracellular 
space, antibody-dependent, complement-mediated killing of Salmonella can occur, and 
in humans significant killing of invasive NTS is observed via this mechanism  (Figure 
taken from (74)). 
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Infection with NTS initially induces IgM antibody, followed by IgG and IgA (102). 
Antibody is produced against a variety of antigens, including lipopolysaccharide, 
flagellin and outer membrane proteins (82;155). Studies in mice and rabbits have 
shown that antibody against LPS (156-159) and porins (160) is protective against 
challenge with virulent Salmonellae. There is evidence for a role for both bactericidal 
and opsonic antibody in immunity to Salmonella (95;161). Antibodies against NTS can 
be opsonic and bind to the pathogen thus facilitating recognition and uptake by 
phagocytes. Binding of the Fc region of the antibody to the FcR expressed on the surface 
of the phagocyte is key in activating the cell’s effector functions (162). The IgG 
subclasses differ in their affinity for Fc receptors, and consequently the efficiency of the 
uptake of opsonised bacteria depends on the IgG subclass and the type of FcR available 
(163).  IgG3 is the most effective opsonin, followed by IgG1 and IgG4 which all have a 
high affinity for FcγRI, and IgG2 is weakly opsonic but has a higher dependency on 
FcγRIIa than FcγRI (163). Enhanced bacterial uptake was observed when bacteria were 
opsonised with serum from immunised mice  (145), and in African children, optimal 
uptake of bacteria is observed when Salmonella are opsonised with both antibody and 
complement (151). Antibody is also able to protect the host against Salmonella infection 
through activating the classical complement pathway and inducing complement-
mediated lysis (95;161). IgM is more efficient than IgG and IgA in triggering 
complement-mediated killing of bacteria. 
 
The majority of studies on immunity to Salmonella have focused on cell-mediated 
immunity to NTS. However, studies in both animals and humans also show a clear 
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requirement for antibody in immunity to NTS (50;148;149;151;152). It is likely that 
cell-mediated immunity controls the infection when the bacteria are residing within the 
phagocytes and humoral immunity controls the spread of bacteria once they are 
released from the cells and are in transit between cells (74). This suggests that a 
successful vaccine needs to induce both antibody and cell-mediated responses to NTS.  
 
1.8 VACCINES AGAINST SALMONELLA  
Following the recognition of the disease burden caused by NTS in Africa and the 
emergence of resistance to antibiotic treatment, there is a growing need for a cheap and 
effective vaccine which will protect against Salmonella infection. There are currently no 
licenced vaccines for S. Paratyphi A, S. Typhimurium or S. Enteritidis for use in humans. 
Live attenuated Salmonella vaccines have been shown to induce increased protection 
than killed vaccines (164). However, live vaccines can be potentially dangerous for 
patients with immunodeficiencies who are more susceptible to Salmonella infection. 
This could be an issue in Africa, where immune suppression and dysregulation 
secondary to HIV infection are common. In addition to this, the ideal live attenuated 
Salmonella vaccine strain should harbour multiple independent attenuating mutations 
to make them safer. Attenuated S. Typhimurium and S. Enteritidis strains with two 
attenuations in genes encoding for guanine biosynthesis and a protease regulator were 
tested in mice (165). The strains were found to be highly attenuated, but still 
immunogenic, and induced high titers of anti-LPS and anti-flagellin antibodies and 
protected against challenge with wild-type invasive strains (165). This suggests the 
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potential for an oral live-attenuated bivalent vaccine which would protect against S. 
Typhimurium and S. Enteritidis. 
 
Over the last century, several vaccines which provide protection against typhoid fever 
caused by Salmonella Typhi have been produced. These vaccines have ranged greatly in 
efficacy and reactogenicity (166;167) but only two vaccines remain in use. These are 
the Vi vaccine; a subunit vaccine based on an unconjugated purified Vi polysaccharide 
of S. Typhi (168) which is licensed for children over 2 years of age (169). In adults, a 
single intramuscular dose of Vi vaccine provides 70% protection, falling to 50% after 3 
years (170). The other vaccine in current use is the Ty21a vaccine, an oral live 
attenuated galE mutant (171). This is not licensed for use in children under 6 years old 
(172-174). Furthermore, it requires 3 or 4 doses and its efficacy is only 51% (167). 
 
To improve the antibody response and immunological memory, vaccine antigens are 
often conjugated to a carrier protein, such as diphtheria toxoid, tetanus toxoid or 
CRM197 (a non-toxic mutant of diphtheria toxin). Conjugation of the Vi polysaccharide to 
non-toxic recombinant Pseudomonas aeruginosa exotoxin A (rEPA) enhanced the 
immune response and was shown to be protective even in 2-5 year old children 
(175;176). However, it is not yet licenced for use in humans. Recently, the O-
polysaccharide of S. Typhi has been conjugated to diphtheria toxoid, and it induced 
significantly higher levels of IgG in immunised mice than the polysaccharide alone 
(177). 
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Novartis Vaccines Institute for Global Health have developed a Vi-CRM197 conjugate 
vaccine, using Vi from Citrobacter which is immunologically indistinguishable from S. 
Typhi Vi but is from a safer source as it is a BSL-1 category organism, compared to S. 
Typhi which is a BSL-3 category organism (178). This conjugate vaccine has been 
shown to be immunogenic in mice (179;180) and in European adults, inducing higher 
anti-Vi antibodies than the licenced Vi vaccine (181). However, only S. Typhi and S. 
Paratyphi C express Vi, so this vaccine will not protect against NTS.  
 
It is still unclear exactly which antigens are responsible for protection against invasive 
NTS  (75) particularly in Africa, and because a large number of different Salmonella 
serotypes are implicated in causing disease in humans, identification of common 
antigens is difficult. OmpD, a porin found in most Salmonella serovars but not S. Typhi is 
a possible vaccine candidate (182) and SseB, a secreted effector protein, has been 
identified as a prominent antigenic target in both murine salmonellosis and in 
bacteraemic African children (183). As well as identifying a suitable target antigen, 
vaccine developers need to consider that a successful vaccine against NTS for use in 
Africa, must induce protective immunity in infants as well as immuncompromised 
adults, be low cost, heat stable, easy to administer and ideally require a single dose. 
 
1.9 AIMS AND OBJECTI VES 
The aims of this thesis are: 
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1. To develop methods to better understand the role of opsonic antibody in immunity to 
invasive African isolates of NTS. 
2. To examine how opsonic antibody, in particular, anti-LPS antibody, enhances or 
inhibits cell-mediated killing of NTS in HIV-infected Malawian adults. 
3. To study the role of antibody in killing of NTS by phagocytic cells in Malawian 
children with acute NTS bacteraemia and in convalescence.  
4. To investigate the sensitivity of Malawian NTS isolates to opsonic antibody and 
identify how this relates to sensitivity to bactericidal antibody.   
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CHAPTER 2. 
MATERIALS AND METHODS 
2.1 ETHICAL APPROVAL  
Ethical approval for the collection of blood and Salmonella isolates from bacteraemic 
African children, and blood from HIV-infected and non-HIV infected African adults was 
granted by The College of Medicine Research and Ethics Committee, University of 
Malawi. Ethical approval for the use of blood and serum samples collected in the UK 
was granted by the Life and Health Sciences Ethical Review Committee of the University 
of Birmingham.  
 
2.2 LABORATORY METHODS 
2.2.1 BACTERIA  
Strains of Salmonella enterica serovar Typhimurium and Enteritidis (listed in Table 2.1) 
which were used throughout this study were isolated from blood cultures from children 
presenting to Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi with 
bacteraemia caused by infection with nontyphoidal Salmonella between 2003 and 2004. 
In addition to these wild type strains, an LPS mutant, galE-, expressing a truncated LPS 
molecule lacking O-antigen was kindly provided by R. Kingsley, Wellcome Trust Sanger 
Institute, UK.  
2. 2. 1.2 PREP AR ATI ON OF S ALMONELLA  EN TERI CA S ERO VAR  
TYPHIMURIUM STATIONARY PHASE CULTURE  
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Serovar Isolate Source 
Typhimurium D23580 Blood culture from human, Malawi 2003 - 2004 
Typhimurium D24545 Blood culture from human, Malawi 2003 - 2004 
Typhimurium D24871 Blood culture from human, Malawi 2003 - 2004 
Typhimurium D25352 Blood culture from human, Malawi 2003 - 2004 
Typhimurium D23005 Blood culture from human, Malawi 2003 - 2004 
Typhimurium D24953 Blood culture from human, Malawi 2003 - 2004 
Typhimurium D26104 Blood culture from human, Malawi 2003 - 2004 
Enteritidis D24954 Blood culture from human, Malawi 2003 - 2004 
Enteritidis D24359 Blood culture from human, Malawi 2003 - 2004 
Enteritidis D24793 Blood culture from human, Malawi 2003 - 2004 
Enteritidis D23682 Blood culture from human, Malawi 2003 - 2004 
Typhimurium D23580 galE- galE- mutant, D23580 parent isolate 
 
Table 2.1 Salmonella isolates used throughout this study. 
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A single colony of bacteria was selected from a culture of Salmonella on an LB agar 
(Sigma) plate using a sterile loop, and inoculated into 10 ml LB broth (Sigma). This 
universal tube was incubated (loose capped) overnight at 37˚C in an incubator (New 
Brunswick Scientific) resulting in Salmonellae stationary phase.  
 
2. 2. 1.3 PREP AR ATI ON OF S ALMONELLA  TYPHIMURIUM IN  
LOGARITHMIC PHASE  
100 μl overnight stationary phase Salmonella culture was added to 10 ml pre-warmed 
(at 37˚C) LB broth (Sigma) in a tight capped universal tube, and incubated for 2 or 3 h 
depending on the concentration of Salmonella required, at 37˚C on a rocker plate 
(Stewart Scientific) at 20 rpm. The required quantity of inoculum was centrifuged at 
3300 x g in microfuge tubes for 5 min. The bacteria were washed twice by the addition 
of 1 ml Phosphate Buffered Saline (PBS) (Sigma), centrifuging at 3300 x g, and 
discarding the supernatant. The bacteria were re-suspended in PBS to give the desired 
Salmonella concentration. The precise concentration was determined with Miles and 
Misra serial dilution and plating on LB agar. 
 
2.2.2 PREPARATION OF HUMAN SERUM  
Blood was taken from healthy adult volunteers and left to clot at room temperature. 
Once sufficiently clotted, the blood was centrifuged for 20 min at 4˚C, 4000 x g in a 
Megafuge (Hereus, Germany). The supernatant was centrifuged again for 20 min, at 4˚C, 
before aliquoting into microfuge tubes. The aliquots were immediately stored at -80˚C. 
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2.2.3 SERUM BACTERICIDAL ASSAY (SBA)  
10 μl of washed Salmonella Typhimurium inoculum at a concentration of 1 x 107 cfu/ml 
(prepared as described in section 2.2.1.3) was added to 90 μl of serum either in a 
microfuge tube or 96 well round bottom plates (Sarstedt, Germany) to give a final 
concentration of 1 x 106 cfu/ml.  Samples were incubated at 37˚C on a rocker plate 
(20rpm) for 180 min. At 45, 90 and 180 min, 10 μl of each sample was serially diluted 
with 90 μl of PBS in a 96 well plate following the Miles and Misra method. A 10 μl 
aliquot of each serial dilution was plated in triplicate on LB agar. The agar plates were 
incubated at 37˚C overnight, and the number of viable colonies counted and 
concentration of Salmonella calculated. By subtracting the original concentration of 
Salmonella from the concentration of Salmonella at each time point, the net growth or 
killing of Salmonella by serum was determined. An increase in bacterial count from the 
starting inoculum concentration indicated net bacterial growth and a decrease 
indicated net killing of bacteria (Figure 2.1). 
 
2.2.4 PREPARATION OF WASHED BLOOD CELLS  
Blood was taken from healthy adult volunteers, into a tube containing heparin, at a final 
concentration of 4 U per ml of blood. The blood was washed twice to remove 
endogenous complement and antibody with RPMI-1640 (Sigma) and centrifuged in a 
bench-top centrifuge at 250 x g, 4˚C for 10 min. The washed blood cells were re-
suspended in RPMI to the original blood volume.  
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Figure 2.1 Serum bactericidal assay analysis. 
Sample analysis of serum bactericidal assay showing bacterial growth (red line) over 
180 min compared to the starting Salmonella concentration, and decrease in bacterial 
numbers, indicating killing of the bacteria (green line). 
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2.2.5 INTRACELLULAR BLOOD CELL KILLING ASSAY  
To opsonize the bacteria, 10 μl of washed Salmonella Typhimurium inoculum at a 
concentration of 1 x 107 cfu/ml (prepared as described in section 2.2.1.3) was added to 
90 μl of serum or PBS (as a negative control) in a microfuge tube, for 20 min at room 
temperature. 90 μl of washed blood was aliquoted into each microfuge tube, and 10  μl 
of opsonised Salmonella was added to give a final concentration of bacteria of 1 x 105 
cfu/ml. Samples were gently vortexed and incubated at 37˚C on a rocker plate, at 20 
rpm, for 180 min. At 45, 90 and 180 min, 10 μl of each sample was serially diluted with 
90 μl of PBS in a 96 well plate following the Miles and Misra method. A 10 μl aliquot of 
each serial dilution was plated in triplicate on LB agar. The agar plates were incubated 
at 37˚C overnight, and the number of viable colonies counted and concentration of 
Salmonella calculated. By subtracting the original concentration of Salmonella from the 
concentration of Salmonella at each time point, the net growth or killing of Salmonella 
by blood cells was determined. An increase in bacterial count from the starting 
inoculum concentration indicated net bacterial growth and a decrease indicated net 
killing of bacteria.  
2. 2. 6 QU AN TIFI CATION  OF  PH AGOCY TIC  ACTI VI TY  OF  NEUTR OPHILS  
AN D MON OCY TES IN WASHED BLO OD IN R ESP ON SE TO STIMUL ATION  
WITH SALMONELLA   
2.2.6.1 LABELLING OF SALMONELLAE WITH FITC  
10 mg Fluorescein isothiocynate (FITC) (Sigma) was dissolved in 10 ml PBS, giving a 1 
mg/ml solution. This was incubated at room temperature in the dark for 10 min and 
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filter sterilized using a 0.2 μm filter. To FITC-label Salmonella, 2.5 μl of FITC solution 
was added to 100 μl Salmonella Typhimurium (grown for 3 h and re-suspended in PBS 
at a final concentration of 1 x 1010 cfu/ml and heat-killed by incubation at 72˚C for 30 
min) in a foil covered microfuge tube. The mixture was incubated on a rocker plate at 
20 rpm, 37˚C for 20 min. The FITC-labelled Salmonellae were washed twice with 1 ml 
PBS, centrifuged for 5 min at 3300 x g, and the supernatant aspirated each time to 
remove any excess FITC solution. The FITC-labelled Salmonellae were re-suspended in 
100 μl PBS and stored in a foil-covered microfuge tube to protect from the light.  
 
2.2.6.2 PHAGOCYTOSIS ASSAY 
50 μl of washed blood (following the method outlined in section 2.2.4) was aliquoted 
into 5 ml BD FACS tubes and placed in an ice bath at 0˚C for 10 min. 10 μl of FITC-
labelled Salmonellae were opsonised with 90 μl of PBS (as a negative control) or serum, 
for 20 min at room temperature. 10 μl of opsonised–FITC-labelled-bacteria was added 
to the blood. For each sample there was a paired control tube which remained on ice, 
with the sample tube transferred to a water bath at 37˚C. To stop phagocytosis, after the 
10 min incubation, sample tubes were immediately placed into the ice bath and 50 μl of 
0.16% trypan blue dye (Sigma) was added to quench the fluorescent signal from non-
internalised bacteria. The tubes were mixed by vortexing. 1.5 ml of PBS was added to 
each tube and tubes were then vortexted and centrifuged at 250 x g, 4˚C for 5 min. The 
supernatant was aspirated and the remaining cells were washed for a second time. 1  ml 
of 1 x FACS lysing solution (Becton Dickinson) (diluted 1:10 from 10 x stock with 
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deionised water) at room temperature was added to each tube to lyse the red cells, and 
the tubes were incubated at room temperature in the dark for 20 min. The tubes were 
then centrifuged at 250 x g, 4˚C for 5 min and the supernatant discarded. The cells were 
washed for a second time with 1.5ml PBS and centrifuged, followed by aspiration of the 
supernatant as before. Finally, 100 μl of propidium iodide (Sigma) at a concentration of 
20 μg/ml was added to each tube to identify non-viable cells during subsequent 
analysis, and the samples were incubated in the dark on ice for 10 min.  
 
Data from samples was acquired using a FACS Calibur flow cytometer (Becton 
Dickinson) and Cellquest Pro software within 60 min. Non-viable cells were excluded by 
gating the negative population in the FL2 channel. Phagocytosing neutrophils and 
monocytes were gated according to forward and side scatter characteristics (Figure 
2.2). The percentage of neutrophils and monocytes which have phagocytosed bacteria 
was determined for each sample from data acquired in the FL1 channel.  
 
2. 2. 7 QU ANTIFI C ATI ON OF OXI DATI VE BURS T A CTI VITY OF  
NEU TROPHIL S AN D MON OCY TES IN WASHED BL OO D IN RES PON SE TO  
STIMULATION WITH SALMONELLA  TYPHIMURIUM  
This assay is adapted from the Bursttest kit (Orpegen Pharma, Germany). 10 μl of heat-
killed Salmonellae (grown for 3 h and re-suspended in PBS at a concentration of 1 x 1010 
cfu/ml, before heat-inactivating at 72˚C for 30 min) was opsonized with 90 μl of serum 
or PBS for 20 min at room temperature. 50 μl of washed blood was aliquoted into 5ml  
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Figure 2.2 Identification of neutrophil and monocyte populations in peripheral 
blood with flow cytometry.  
(A)Dot plots with FL-2 channel gating to exclude non-viable cells. (B) Typical side 
scatter/forward-scatter dot plots with gates (R2) on neutrophils and (R3) on 
monocytes. FL-1 histograms showing percentage (M2 % gated) of neutrophils (C) and 
monocytes (D) which have phagocytosed bacteria. 
A     B 
C 
D 
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FACS tubes, and stimulated with 10 μl of opsonised Salmonella for 10 min at 37˚C in a 
water bath. 10 μl of dihydrorhodamine-1,2,3 (Orpegen Pharma, Germany) was added to 
each tube and all tubes were incubated for a further 10 min at 37˚C. The 
dihydrorhodamine is oxidised to rhodamine (which fluoresces) by oxidative burst 
activity. The amount of fluorescence detected in the FL1 channel represents the 
oxidative burst activity within the cells following stimulation with Salmonella. 1.5 ml 1 x 
FACS Lysing solution was added to each tube to lyse red cells and samples were 
vortexed and incubated for 20 min at room temperature in the dark.  Samples were 
then centrifuged at 250 x g, 4˚C for 5 min, and the supernatant discarded. The cells were 
washed twice with 1.5 ml PBS, centrifuged at 250 x g, 4˚C for 5 min and supernatant 
aspirated each time. Following the second wash, 100 μl propidium iodide (20 μg/ml) 
was added to each tube and the samples were incubated on ice for 10 min before 
analyzing using a FACS Calibur flow cytometer and Cellquest Pro software. Neutrophils, 
monocytes and lymphocytes were gated according to forward scatter (FSC) and side 
scatter (SSC) characteristics. The geometric mean fluorescence intensity in the FL1 
channel representing the average oxidative burst activity for each cell type was 
determined in each sample.   
 
2. 2. 8 ENZYM E-LINK ED IMMUNO SOR BENT AS S AY  (ELIS A) TO Q UANTIFY  
RELATIVE AMOUNT OF ANTI-LPS ANTIBODIES IN SERUM 
50 μl of 1 mg/ml Lipopolysaccharide (LPS) purified from Salmonella Typhimurium 
(Alexa) was diluted in 10 ml carbonate coating buffer (0.015 M Na2CO3, 0.035 M 
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NaHCO3 pH9.6) to give a final concentration of 5 μg/ml LPS. 96-well flat bottom 
maxisorp plates (Nunc) were incubated overnight at 4˚C, with 100 μl of 5 μg/ml LPS per 
well. The following day, plates were washed three times with ‘wash buffer’ (PBS 0.05% 
Tween) to remove any unbound LPS. Wash buffer was made by mixing 1 l PBS with 500 
μl Tween (Sigma). Following washing, plates were incubated with 200 μl ‘block buffer’ 
(PBS 1% BSA) per well for 1 h at 37˚C. Block buffer was made by mixing 100 ml PBS 
with 1 g Bovine Serum Albumin (BSA) (Sigma). Plates were washed again and 150 μl of 
a 1:10 dilution of each serum or column fraction in PBS 0.05% Tween 1% BSA was 
added to the first row of the plate and 100 μl of PBS 0.05% Tween 1% BSA was added to 
the remaining wells. Three-fold dilutions of each sample were made by transferring 50 
μl from the first well of each column to the second well and serially diluting 50 μl into 
each subsequent well (Figure 2.3). Plates were incubated at 37˚C for 1 h before washing 
three times with PBS 0.05% Tween to remove any unbound antibody. Goat anti-human 
alkaline-phosphatase conjugated secondary antibodies (Southern Biotech) were diluted 
1:2000 in PBS 0.05% Tween 1% BSA and 100μl of secondary antibody (IgG, IgA or IgM) 
were added to each well. The plates were incubated once more for 1 h at 37˚C. Finally, 
plates were washed three times with PBS 0.05% Tween to remove any unbound 
secondary antibody and 100 μl of Sigma-fast p-nitrophenyl phosphate substrate was 
added to each well. The substrate was prepared by dissolving 2 tablets of p-nitrophenyl 
phosphate (Sigma) in 20 ml distilled water. Plates were incubated again at 37˚C and 
optical density was measured after 60 min using an ELISA plate reader set at 405nm 
and SoftMax Pro software. 
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Figure 2.3 Dilution of serum in a 96 well ELISA plate. 
Each well of the 96 well plate contained 100 µl PBS+0.05% Tween+1% BSA, and 50 µl of 
diluted serum was added to the first row of the plate. 50 µl of the solution in each well 
was transferred to the next row, and this was repeated 8 times and 50 µl discarded 
from the final row of the plate. 
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2. 2. 9 FLO W CYTOMETRI C AN TI BO DY ASS AY TO Q UANTIFY BINDIN G OF  
ANTIBODY TO THE SURFACE OF SALMONELLAE 
Salmonellae were prepared as described in section 2.2.1.3 and the concentration 
adjusted to 2 x 109 cfu/ml before fixing with 37% formaldehyde (Sigma) to give a final  
concentration of 1% formaldehyde. 5 μl of fixed bacteria were added to 45 μl of serum 
diluted 1:10 with PBS or PBS (negative control) in microfuge tubes. After incubating for 
20 min at room temperature, 1 ml PBS was added to each tube and the samples were 
mixed by inversion before centrifuging for 5 min at 3300 x g. The supernatant was 
discarded and the samples were washed again with 1 ml PBS and centrifuging as before. 
This time the supernatant was aspirated, leaving a residual volume of 50 μl. 2 μl of 
FITC-conjugated polyclonal rabbit anti-human IgG, IgA or IgM antibody (Sigma) were 
added to each sample and the tubes were incubated for 20 min in the dark at room 
temperature. Samples were washed twice more with PBS as before and 200 μl 1% 
formaldehyde PBS was added to each sample to fix the bacteria. Samples were analysed 
by a FACS Calibur flow cytometer (Becton Dickinson) and Cellquest Pro software to 
acquire and analyse the data. The Salmonella population was identified using forward 
and side scattered light and fluorescence emission in the FL1 channel (Figure 2.4). The 
geometric mean fluorescence intensity (GMFI) in the FL1 channel was used as the anti-
Salmonella antibody titre.  
 
To measure complement deposition on the surface of the bacteria, the same assay was 
used but with 45 μl undiluted serum instead of a 1:10 dilution of the serum, and with  
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Figure 2.4 Identification of Salmonellae population with a flow cytometer. 
(A)Density dot plot using Cell Quest Pro software of forward-scattered/side scattered 
light with the Salmonella population detected in gate R1. (B) FL-1 histogram showing 
fluorescence detected in the FL-1 channel from the FITC emission spectrum. The 
geometric mean fluorescence intensity (GMFI) in the FL-1 channel is the anti-Salmonella 
antibody titre.  
 
A 
B 
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different FITC-conjugated antibodies. To measure C3 deposition a FITC-conjugated anti-
C3 antibody (Dako Cytomation) was used, and to measure MAC binding, an anti-C5b-9 
antibody in combination with a rabbit-anti-mouse FITC conjugated antibody (Dako 
Cytomation) was used in place of anti-Ig antibodies. 
2.2.10 HAEMOLYTIC ASSAYS 
Radial immunodiffusion assays (The Binding Site, UK) were used to determine the 
alternative and total haemolytic activity of human serum. The assay comprises plates 
which are composed of chicken erythrocytes (Alternative Pathway Hemolytic 
Complement kit) or sheep erythrocytes (Total Hemolytic Complement kit). 5 μl of 
human serum was added to individual wells in the plate and the plates were incubated 
overnight at 4˚C to allow the complement components to diffuse into the agarose. The 
plates were then incubated at 37˚C to allow the activation of complement. For the 
alternative pathway, the chicken erythrocytes will bind C3b spontaneously formed in 
the absence of antibody leading to the formation of C3 convertase , which further 
activates the alternative complement pathway and leads to the haemolysis of the 
erythrocytes. For the total pathway kit, the sheep erythrocytes are coated with anti-
sheep-erythrocyte antibody (haemolysin) which activates the classical complement 
pathway leading to haemolysis of the erythrocytes. After incubating for 2 h at 37˚C, 
zones of haemolysis are produced around wells proportional to the amount of 
functional complement in each sample (Figure 2.5). The diameters of these zones were 
measured and the amount of functional complement activity calculated, using a 
standard curve of known haemolytic activity. 
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Figure 2.5 Radial immunodiffusion assay to measure haemolytic complement 
activity. 
Zones of haemolysis are produced around wells containing serum samples. The 
diameter of the zone is proportional to the amount of functional complement in each 
sample. If no clear zone is present then complement within the serum sample is not 
functional. 
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2. 2. 11 ABS ORPTI ON OF AN TI -LPS AN TIBODI ES FR OM HUMAN SERUM  
USING LPS ATTACHED TO A SOLID MATRIX 
50 μl of 1 mg/ml Lipopolysaccharide (LPS) purified from Salmonella Typhimurium 
(Alexa) was diluted in 10 ml carbonate coating buffer (0.015 M Na2CO3, 0.035 M 
NaHCO3 pH 9.6) to give a final concentration of 5 μg/ml final concentration of LPS. A 96-
well flat bottom Maxisorp plate (Nunc) was incubated overnight at 4˚C with 100 μl of 5 
μg/ml LPS per well. The following day, the plate was washed three times with ‘wash 
buffer’ (PBS 0.05% Tween) to remove any unbound LPS. Following washing, 100  μl of 
serum was added to each well in the first column of the plate and the plate was 
incubated for 30 min at 4˚C. After 30 min, the serum was transferred from the first 
column to the second column of the well and the plate incubated at 4 ˚C for 30 min again 
(Figure 2.6). After 12 transfers, the anti-LPS antibody-depleted serum was frozen at -
80˚C in microfuge tubes.  
 
2. 2. 12 DEPLETIO N OF AN TI-SALMONELLA  TYPHIMURIUM D23580 
ANTIBODIES FROM HUMAN SERUM 
Salmonella Typhimurium was cultured as described in section 2.2.1.2. Stationary phase 
cultures were washed with PBS and re-suspended in PBS to give a final concentration of 
1 x 1011 cfu/ml. Re-suspended Salmonella and freshly thawed serum were pre-cooled to 
4˚C. 1 ml of serum was then incubated with 100 μl of S. Typhimurium D23580 1 x 1011 
cfu/ml for 1 h at 4˚C with continuous mixing. The mixture was then centrifuged at 3300 
x g, 4˚C for 5 min to remove the bacteria, and the supernatant removed by aspiration.  
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Figure 2.6 Anti-LPS antibody depletion of human serum. 
100 μl of serum was added to the first well in a 96-well flat bottom plate which was 
coated with 5 μg/ml LPS and incubated for 30 min at 4˚C and then transferred to the 
next well (round 1). This was repeated until 12 rounds of incubations and transfers 
were completed. 
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100 μl of S. Typhimurium D23580 was added to the supernatent and the mixture was 
incubated again for 1 h at 4˚C prior to centrifugation. This step was repeated once more. 
The final supernatant was removed by aspiration and filtered using a 0.2 μm syringe 
filter to ensure all bacteria had been removed, and stored at -80˚C until required. 
2. 2. 13 AFFINI TY PURI FIC ATION OF ANTI -O -AN TIGEN ANTI BO DY FROM  
HUMAN SERUM USI NG AC TIV ATED O -AN TIGEN LINKED TO NHS -
SEPHAROSE RESIN 
2.2.13.1 PREPARATION OF O-ANTIGEN FROM LPS 
LPS from S .Typhimurium D23580, a clinical isolate of NTS, was used as the source of O-
antigen (OAg).  OAg was purified using a new method developed at Novartis Vaccines 
Institute for Global Health, Italy (Patent PAT054746). Lipid A was removed by acetic 
acid hydrolysis of LPS. 100 μl of acetic acid (1% in solution) was added to 10 ml 
bacterial culture and the solution was heated for 1 h at 100˚C, and then centrifuged at 
3300 x g overnight. The supernatant was recovered, and neutralized to pH 6 with 1 M 
sodium hydroxide (Sigma). Absolute ethanol was added to give a final concentration of 
80%, causing the OAg to precipitate. The solution was centrifuged again at 3300 x g and 
the pellet dried overnight using a SpeedVac vacuum centrifuge (Thermo) at room 
temperature, 500 mtorr. The amount of OAg recovered was quantified using a phenol 
sulphuric assay. 
2.2.13.2 PHENOL SULPHURIC ASSAY 
A phenol sulphuric assay is a colorimetric technique used to quantify the amount of 
sugar present in a solution. It was used to measure the concentration of activated OAg 
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which had not bound to the NHS-Sepharose resin. 20 mg of glucose (Sigma) was 
solubilized in 40 ml distilled water to give a concentration of 0.5 mg/ml. 5 g phenol 
(Sigma) was added to 100 ml distilled water to produce 5% phenol (w/v). Each sample 
was diluted 1:10 with distilled water in 4 ml glass tubes (Becton Dickinson) to give a 
final volume of 200 μl. 200 μl of 5% phenol solution was added to each tube, followed 
by 1 ml concentrated sulphuric assay. The samples were left for 10 min then vortexed 
and incubated for a further 30 min. The absorbance at 490 nm was measured using a 
spectrophotometer.  
 
2.2.13.3 ACTIVATION OF O-ANTIGEN WITH ADH 
Two methods were used to link purified OAg to adipic dihydrazide (ADH). The first 
method links the NH2 of the hydrazide group of ADH to the C=0 of the ketone group of 
the KDO sugar at the end of the core region of LPS. The second method involves the 
oxidation of the OAg chain structure at multiple points, resulting in the formation of 
C=O aldehyde groups, prior to activation with ADH, and consequently the linking of 
more than one ADH molecule to the OAg chain through the formation of an amino link.  
2.2.13.4 ACTIVATION OF O-ANTIGEN WITH ADH TO PRODUCE OAGADH 
16.7 mg of purified OAg (see 2.2.13.1) was solubilized in 0.42 ml 0.1 M sodium acetate 
(Sigma) buffer pH 4.5 and 20 mg of ADH and 20 mg sodium cyanoborohydride was 
added and the mixture heated for 1 h at 30˚C. The mixture was purified by desalting 
against water using a 5 ml HiTrap PD10 desalting column (GE Healthcare) and an ACTA 
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purifier (GE Healthcare).  The reaction product was then dried overnight using a 
SpeedVac vacuum centrifuge as before and stored at 4˚C until required.  
 
2. 2. 13. 5 AC TIV ATI ON OF O -ANTI GEN WITH ADH TO PRO DU CE 
OAGOXADH 
16.7 mg of OAg was solubilized in 1.5 ml 0.1 M sodium acetate buffer pH 4.5, and 100 μl 
100 mM freshly prepared sodium metaperiodate was added to oxidise the OAg. The 
mixture was incubated for 2 h at room temperature in the dark, and purified by 
desalting against water using a 5 ml PD10 HiTrap desalting column (GE Healthcare) and 
an ACTA purifier (GE Healthcare), prior to drying overnight in a SpeedVac vacuum 
centrifuge (Thermo), at room temperature, 500 mtorr. This oxidized OAg was then 
activated with ADH following the same procedure described in section 2.2.13.4 to 
produce OAgoxADH. 
 
2. 2. 13. 6 IMMO BILIZ ATION O F ACTIV ATED O -ANTI GEN TO THE R ESIN  
OF HITRAP NHS COLUMNS 
6.6 mg of activated OAg (OAgADH or OAgoxADH) was dissolved in 1 ml coupling buffer 
(0.2 M NaHCO3, 0.5 M NaCl pH 8.3 (Sigma)). Two 1 ml HiTrap NHS-Sepharose columns 
(GE Healthcare) were washed with 6 ml 1 mM HCl to remove the isopropanol storage 
solution. The dissolved activated OAg was slowly passed through the column using a 5 
ml syringe connected to the column, and the flow through was collected to allow 
quantification of bound OAg to the column. The columns were incubated overnight at 
4˚C to allow maximum binding of the NH2 group of the ADH molecule with the N-
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hydroxy-succinamide group of the resin, forming an amido group. Following the 
incubation, both columns were washed with 6 ml 0.5 M ethanolamine, 0. 5M NaCl pH 
8.3 to block and deactivate any sites on the resin which had not bound OAg, followed by 
6 ml 0.1M sodium acetate, 0.5 M sodium chloride pH 4 which washes away unbound 
OAg. All washes were collected and the amount of OAg detected using a phenol 
sulphuric assay (see 2.2.13.2). This allowed for the quantification of the amount OAg 
un-linked to the resin and by subtracting the amount of activated OAg lost in the flow 
through and wash steps from the original amount of OAg loaded onto the column, the 
amount of OAg linked to the column could be quantified. The column was stored in 0 .05 
M Na2HPO4, 0.1% NaN3 pH 7 at 4˚C until further use.  
 
2.2.13.7 AMMONIUM SULPHATE PRECIPITATION OF SERUM PROTEINS 
0.5 g ammonium sulphate (Sigma) was added to 1 ml serum to give a final 
concentration of 0.5 g/ml and the solution was incubated overnight at 4˚C. The 
following day, the sample was centrifuged at 4˚C, 3300 x g for 5 min, and the 
supernatant removed by aspiration. The precipitate was washed twice with 1 ml 0.5g 
/ml ammonium sulphate, centrifuging at 3300 x g, 4˚C for 5 min and the supernatant 
removed. The pellet was re-suspended in 1 ml PBS and transferred into pre-soaked 
dialysis membrane (Spectrum labs) with a molecular weight cut off 6-8 kDa. The 
precipitate was dialysed against 500 ml PBS for 24 h, with the PBS replaced four times 
during this period.  
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2.2.13.8 AFFINITY PURIFICATION OF ANTI -S.  TYPHIMURIUM O-
ANTIGEN ANTIBODIES FROM HUMAN SERUM  
1 ml HiTrap NHS-Sepharose columns (GE Healthcare) with activated OAg linked to the 
resin (see 2.2.13.6) were washed with 6 ml PBS using a 5 ml syringe connected to the 
column, to equilibrate the resin. The washes were discarded.  300 μl of antibody 
precipitate (see ammonium sulphate procedure 2.2.13.7) was applied slowly to the 
column and the flow through collected. After an overnight incubation at 4˚C, the column 
was washed with 6 ml PBS, followed by 6 ml NaPi 50 mM, NaCl 500 mM pH 7.2, to 
remove any unbound antibody. All washes were collected. To elute bound antibody, 3 
ml 0.1 M glycine 0.1 M NaCl, pH 2.4 was injected into the column and the eluted 
antibodies collected in 500 μl aliquots which were neutralized immediately with 40 μl 2 
M Tris HCl pH 9 (Sigma). All washes and eluates were tested in an ELISA using plates 
coated with LPS (as described in method in section 2.2.8) and eluates containing anti-
LPS antibodies were pooled. The pooled eluates were loaded into pre-soaked and 
washed dialysis membrane (Spectrum Labs) with a molecular weight cut-off 6-8 kDa. 
The pooled eluates were dialyzed against 500 ml PBS for 24 h, with the PBS changed 
four times during this period. After dialysis, the eluates were stored at 4˚C in microfuge 
tubes.  
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CHAPTER 3.  
STABILITY OF COMPLEMENT-MEDIATED BACTERICIDAL 
ACTIVITY IN HUMAN SERUM AGAINST  
NONTYPHOIDAL SALMONELLA  
 
3.1 INTRODUCTION 
The complement system is an important component of the innate immune system. It 
comprises a set of plasma proteins that facilitate the killing of pathogens (184;185) 
through the activation of three different pathways which generate a series of effector 
proteins. The complement fragment C3b can bind to bacteria and act as an opsonin 
increasing uptake by phagocytic cells (145). Complement can also kill bacteria in a cell-
independent manner through formation of the membrane attack complex (186). 
Previous work in our lab has shown that whole human serum from Africans is able to 
effect both cell-independent bactericidal killing (50) and cell-mediated killing (151) of 
African invasive isolates of nontyphoidal Salmonella. Both mechanisms require 
complement and antibody to Salmonella (50;151). 
 
Research undertaken throughout this PhD will involve the use of whole human serum in 
assays to investigate immunity to Salmonella Typhimurium. These studies involve the 
use of sera from African patients and consequently are of limited supply. Blood from 
these children and adults was taken and sera processed in clinics in Malawi between 
2004 and 2008, transported to the UK and stored continuously at -80°C. The assays we 
use rely on the integrity of endogenous complement in the serum. Therefore care needs 
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to be taken when processing and manipulating both blood and serum in order to  
preserve complement function (187) and to minimise the waste of such valuable 
samples as it has long been known that complement is labile. Antibody molecules are 
relatively resistant to degradation, heat treatment (188) and can tolerate freeze-thaw 
cycles. Complement activity though is particularly heat-labile (189;190) and is 
destroyed by incubating at 56°C for 30 min. Consequently, it is generally advised that 
serum is promptly separated from clotted blood and stored at -80°C in aliquots to avoid 
potentially detrimental freeze-thaw cycles. It is also normal practice for serum aliquots 
to be used only on the day they are thawed and that experiments involving complement 
are carried out at 4°C. 
 
The stability of complement is also of clinical importance, since while it is normally 
recommended for functional complement studies that serum be separated as soon as 
possible following venesection and sent frozen, such instructions are often not adhered 
to, and it is common for there to be a delay before samples arrive at the laboratory. 
Hence, the finding of reduced or absent functional complement activity in clinical 
samples is often due to sub-optimal processing and handling rather than a bona fide 
complement deficiency. 
 
Many published studies about the stability of complement components have used 
haemolytic assays and focused on animal serum, in particular guinea pig serum (190). 
Nevertheless, there are many functional differences in complement between species, 
including human (191), and findings from these studies may not be valid for use with 
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human serum. There is very limited published literature about the stability of the 
human complement components required to induce killing of bacteria in vitro. 
Therefore, a better understanding of the permissible range of conditions under which 
serum complement activity is preserved, particularly longevity of complement activity 
at different temperatures and resistance to freeze-thaw cycles would be very helpful.  
 
3.2 OBJECTIVES 
In order to minimise the waste of such rare sera we conducted a study to determine the 
acceptable conditions for the manipulation of human serum that would not be 
detrimental to its ability to kill Salmonella in our serum bactericidal assay. We 
determined whether freeze-thaw cycles have a detrimental effect on complement 
activity. We explored the longevity of complement-dependent bactericidal activity of 
human serum when stored at different temperatures, in particular whether once 
thawed, serum can be stored at 4°C and used on consecutive days to minimise the waste 
of serum.   The effect of delayed separation of serum from blood and the relevance in a 
clinical setting was also investigated. 
  
3.3 RESULTS 
3. 3. 1 HUMAN S ER A US ED IN TH E STUDY C ON TAI NED SALMON ELLA-
SPECIFIC ANTIBODY  
The ability of fresh adult human serum to kill NTS has previously been shown to depend 
on specific anti-Salmonella IgG or IgM antibody activating the classical complement 
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pathway and the consequent deposition of membrane attack complex on the bacterial 
surface (50). In order to ascertain that the sera used in the study contained antibody 
directed against Salmonella, we assessed the presence of anti-Salmonella antibody 
targeting S. Typhimurium D23580 by flow cytometry. Sera from all four healthy 
European adult subjects (two male, two female) contained IgG, IgA and IgM classes of 
antibody capable of binding D23580 (Figure 3.1), indicating that these sera could 
activate complement deposition on D23580 via the classical complement pathway (50).  
 
3. 3. 2 S ERUM BAC TERICIDAL  AC TIVITY  AGAIN ST NTS I S R ETAIN ED  FOR  
AT L EAS T 35 DAYS WHEN S ERA I S S TOR ED AT 4 °C AN D THR EE FR EEZE -
THAW CYCLES DO NOT H AVE AN EFFECT ON COM PLEMENT STABILITY 
In order to assess the effect of freeze-thaw and storage on serum bactericidal activity, 
serum was optimally prepared to maintain complement integrity. Blood was venesected 
from four healthy European adults (two male, two female) and left to clot at 4°C fo r 8 h, 
rather than 22°C to preserve complement integrity, before separating by centrifugation 
at 4°C. Aliquots were immediately frozen at -80°C. To determine the effect of freeze-
thaw cycles on complement stability, samples underwent zero, one, two or three freeze-
thaw cycles, by thawing at 22°C and immediately re-freezing at -80°C. Once thawed on 
day 1, samples were maintained at 4°C. Serum bactericidal assays against Salmonella 
Typhimurium D23580 were used to monitor complement function, as killing of S. 
Typhimurium is dependent on complement as well as antibody.   D23580 is sensitive to 
antibody-dependent complement-mediated killing, undergoing a one to three log10 
reduction in bacterial numbers within 3 h of exposure to serum from healthy adults at  
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Figure 3.1 Levels of anti-S. Typhimurium D23580 IgG, IgA and IgM antibodies in 
human sera used in the study as assessed by flow cytometry.  
Serum from four healthy adults was incubated with Salmonella Typhimurium D23580 
and the presence of IgG, IgA and IgM classes of antibody targeting S. Typhimurium 
D23580 were measured using flow cytometry. Data are from one experiment. The anti-
Salmonella antibody titre is the Geometric Mean Fluorescence intensity of fluorescence 
labelling as measured by flow cytometry using Cell Quest Pro software.  
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37⁰C (50). A 1.0 log10 cfu/ml kill is designated as ‘normal’ kill. To assess the longevity of 
complement, assays were repeated daily for the first week and then weekly, for a total 
of 91 days. During the first five weeks of the experiment (up to day 35), each serum 
killed D23580 by approximately 2.0 log10 cfu/ml (Figure 3.2 A-D). Thereafter, serum 
from subject 1 was unable to effect a 1.0 log10 cfu/ml kill (Figure 3.2 A), while serum 
from the remaining three subjects maintained killing for 70 days (Figure 3.2 B-D). We 
also observed no detectable difference in the ability of serum which had undergone 
zero, one, two or three freeze-thaw cycles to kill S. Typhimurium D23580 (Figure 3.2 A-
D).   
 
3.3.3 CLASSICAL AND ALTERNATIVE PATHWAY HAEMOLYTIC 
COMPLEMENT ACTIVITY IS REDUCED OVER TIME 
Invasive strains of Salmonella Typhimurium, such as S. Typhimurium D23580 can 
activate complement via the alternative and classical pathways but not the mannose -
binding lectin pathway (50). To monitor the classical and alternative pathway 
complement activity over 91 days, haemolytic complement assays were performed by 
radial immunodiffusion. Only whole sera which had undergone no freeze-thaw cycles 
were tested. 
 
A gradual reduction in classical pathway haemolytic complement activity was observed 
with serum from each subject. Each serum had over 1000 CH100 units/ml on day 0, less 
than 600 CH100 units/ml by day 28 to 42 and serum from 3 of the subjects had no  
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Figure 3.2 Effect of duration of storage of human serum at 4°C and freeze-thaw 
cycles on its ability to kill S. Typhimurium D23580. 
Serum from four healthy adults (subjects 1-4 corresponding with panels A.-D.) 
following one (1 FT), two (2 FT), three (3 FT) or no (0 FT) freeze-thaw cycles, was 
maintained at 4˚C and examined at intervals for ability to kill in the serum bactericidal 
assay. Normal killing designated as a reduction of 1.0 log10 cfu/ml viable bacteria. 
Numbers of viable Salmonellae after 180 min in the assay are plotted against number of 
days serum kept at 4°C. Negative values show a decrease in viable bacteria compared 
with initial concentration. Each panel represents data using serum from one adult. 
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detectable activity on day 49, 63 or 84 (Figure 3.3 A). Alternative pathway haemolytic 
complement activity was maintained at over 90% normal activity for 42 days in all sera, 
fell to less than 50% by day 77 and no activity was detectable at 84 or 91 days (Figure 
3.3 B).  
 
3. 3. 4 S ERUM HAS REDUC ED L ON GEVITY OF BACTERICI DAL ACTI VITY  
AGAINST NTS WHEN STORED AT 22˚C AND 37˚C  
To investigate the effect of increasing the temperature at which serum is stored on its 
bactericidal activity against S. Typhimurium, aliquots of sera from the same four 
subjects were thawed and maintained at either 22˚C (Figure 3.4 A) or 37˚C (Figure 3.4 
B) post-thawing. Serum bactericidal assays were performed daily using sera stored at 
22°C for 15 days. Sera kept at 22˚C could effect a 2.0 to 3.0 log10 kill after 180 min for 8 
to 10 days after which bactericidal activity fell to less than 1.0 log10 cfu/ml. Sera kept at 
37˚C were assessed six- to twelve-hourly for bactericidal activity against D23580. At 
this temperature, bactericidal activity fell more rapidly than at 22°C and was less than 
1.0 log10 cfu/ml after 54 h for two sera and after 72 h for the other two sera. 
 
3. 3. 5 THE P ERC EN TAGE OF HUM AN S ERUM REQUI RED TO KILL N TS  
INCREASES INCREMENTALLY WITH TIME  
The previous experiments were conducted with whole serum with a steady level of 
killing of Salmonella in the bactericidal assay present for a minimum of 35 days, 8 days  
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Figure 3.3 Classical and alternative pathway haemolytic complement activity in 
human serum stored at 4˚C for 91 days. 
Serum from four healthy adults was stored at 4˚C and classical (A) and alternative (B) 
pathway haemolytic complement activity assessed at intervals using radial 
immunodiffusion assays. Each panel represents data using serum from four adults.  
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Figure 3.4 Effect of duration of storage of human serum at 22°C and 37°C on 
ability to kill S. Typhimurium D23580.  
Serum from the same four adults as in Figure 1 was thawed and maintained at (A) 22°C 
or (B) 37°C with serum bactericidal assays performed daily (for samples at 22°C) or six - 
to twelve-hourly (for samples at 37°C) using 106 cfu/ml bacteria. Viable bacteria at 180 
min in each serum bactericidal assay are plotted against duration of serum storage. 
Each panel represents data using serum from four adults. 
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or 42 hours, dependent on storage temperature. In order to detect whether during this 
time there is any degradation of bactericidal potential within the sera, we repeated the 
experiment using serum from two of the four subjects stored at room temperature, 
whilst assessing the ability of different dilutions of serum to kill Salmonella. When first 
thawed serum concentrations of 20% or above are required to achieve a 1.0 log10 
cfu/ml kill of Salmonella at 180 min in the serum bactericidal assay (Figure 3.5 A - B).  
 
When subsequently kept at 22°C, the ability of the diluted sera to effect a normal kill 
decreased more rapidly than with whole serum. The most dilute sera lost the ability to 
kill first: 20% sera was unable to effect normal killing after one to three days, 30% 
serum after three to four days, 40% serum after four to five days and 50% after five to 
six days (Figure 3.5 C and D). 
 
3. 3. 6 DEL AY ED SEP AR ATI ON OF S ERUM FROM CLO T TED HUMAN  
BLO OD FOR UP TO FO UR  DAY S POS T -V EN ES EC TION DOES NOT REDU CE 
ABILITY TO KILL NTS  
Delayed separation of serum from blood often occurs due to delays in transportation of 
blood samples from the clinic to the laboratory. To investigate the effect of up to four 
days delay in separation of serum from blood on Salmonella killing, we performed the 
serum bactericidal assay using blood kept at either 4°C (Figure 3.6 A, C, E, G) or 22°C 
(Fig 3.6 B, D, F, H) post-venesection that was either separated on the day of venesection 
or after one to four days. Assays were performed on all samples a total of four days 
post-venesection and compared with the killing activity of the respective freshly- 
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Figure 3.5 Percentage of human serum stored at 22°C required to kill S. 
Typhimurium D23580 and anti-S. Typhimurium antibody levels in study sera. 
Killing of bacteria by different percentages of freshly thawed serum from (A) subject 1 
and (B) subject 2 at 45, 90 and 180 min in the serum bactericidal assay using 106 cfu/ml 
S. Typhimurium D23580: 10% (red circles), 20% (green squares), 30% (blue triangles), 
40% (purple diamonds) and 50% (orange inverted triangles) serum diluted with PBS, 
100% PBS (black crosses) and 100% fresh serum (pink vertical crosses). Initial 
concentration of bacteria 106 cfu/ml with numbers of viable bacteria plotted against 
duration of assay. Killing of bacteria by different percentages of serum from (C) subject 
1 and (D) subject 2 at 180 min following storage at 22°C. Change in viable count 
(cfu/ml) plotted against duration of time serum stored at 22°C. Each panel represents 
data using serum from one adult. 
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Figure 3.6 Effect of delayed separation of serum from clotted human blood on 
ability to kill S. Typhimurium D23580.  
Blood from four healthy adults (subjects 1-4 corresponding with panels A.-B.,C.-D., E.-F. 
and G.-H. respectively) was kept at 4°C (A., C., E., G.) or 22°C (B., D., F., H.) post-
venesection and serum separated the same day (day 0) or after one (day 1), two (day 2), 
three (day 3), or four (day 4) days after venesection. Separated sera were then 
maintained at 4°C without freezing for a total of four days post venesection before being 
compared to freshly thawed serum (fresh) in the serum bactericidal assays. Changes in 
cfu/ml are plotted against the duration of assay. Each panel represents data using 
serum from one adult. 
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thawed serum. There was no significant difference in the bactericidal activity of the 
serum after 1, 2, 3 or 4 days delay in separation from whole blood at any of the three 
assay time points (45, 90, 180 min), regardless of whether the blood had been stored at 
4°C (ANOVA p=0.09 to 0.74) or 22°C (ANOVA p=0.19 to 0.99). 
 
3.4 DISCUSSION 
Research undertaken throughout this PhD involves the use of a limited supply of sera 
from African patients to investigate immunity to Salmonella Typhimurium. To minimise 
the waste of such valuable serum we needed to establish the parameters for the optimal 
acceptable handling and storage of these samples as complement is known to be labile. 
Much of the available scientific literature describing experimental studies on 
complement activity date from the first half of the 20th century. Most of these data relate 
to studies of animal, rather than human complement, and use haemolytic complement 
assays to assess complement function. These assays may not reflect the bactericidal 
activity against Salmonella or bacteria in general, which usually depend on the 
combined action of antibody and complement.  
 
A common assumption is that frozen aliquots of serum should be used on the day of 
thawing when required for bactericidal assays. Our findings surprisingly indicate that 
this is not the case, since thawed serum stored at 4°C effects normal levels of killing of 
Salmonella for 35 days. For three of the four sera, killing was still obtained after 70 days 
at 4°C. Our group have previously shown that classical pathway of complement is 
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required for bactericidal activity against invasive African isolates of Salmonella (50). 
These current findings are consistent with only a small level of classical pathway 
activity being required for this activity, a level that can be undetectable by haemolytic 
radial immunodiffusion assay. 
 
Mechanistically, these data are compatible with the hypothesis that once the classical 
pathway has initiated C3b deposition on Salmonella, this is sufficient for the 
deployment of the alternative pathway that then becomes the critical determinant of 
bactericidal activity. It is surprising that serum from subject 1 had only half the duration 
of bactericidal activity of the other three sera when stored at 4°C. Our data do not 
provide an explanation for this, since longevity of classical and alternative pathway 
haemolytic complement activity for this serum was no less than that for the other three 
sera. The difference in longevity of bactericidal activity between this serum and the 
others was less apparent at 22°C and 37°C.  
 
Functional complement activity was retained in serum stored at 22°C for at least 9 days 
and 66 hours when stored at 37°C confirming that the longevity of bactericidal activity 
of human serum against Salmonella is reduced with increased storage temperature 
post-thawing. This finding has also been described using haemolytic assays (189;190). 
The experiments using diluted human serum support the theory of complement 
degradation over time. 20% fresh serum is able to kill Salmonella, but when stored at 
22°C and tested over a 15 day period, the percentage of fresh serum required to induce 
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the same level of killing increases to 50%, suggesting that a higher percentage of serum 
is required to provide the same amount of functional complement. Furthermore, 
previous work by our group shows that when serum is heated at 56°C for 30 min, all 
complement is destroyed and serum is no longer able to kill Salmonella (50). 
Supplementing this heat-inactivated serum with fresh serum restored killing of 
Salmonella proving that in this assay, complement, but not antibody, is rate limiting 
(50).  
 
Given the accepted view that freeze-thaw cycles are to be avoided in the context of 
preservation of complement function (187), then perhaps the most surprising finding of 
the study was the lack of any discernible effect on bactericidal activity of up to three 
freeze-thaw cycles. Consistent with this finding, a report from 1927 found that guinea 
pig serum could be subjected to twelve freeze-thaw cycles without an appreciable 
decrease of haemolytic activity (188). Further experiments are required though to 
determine exactly how many freeze-thaw cycles human serum can endure without loss 
of bactericidal activity. 
 
The clinical and diagnostic implications of this study are important. There can often be a 
delay between blood being taken in clinics and arriving in the laboratory for testing, 
making it difficult to decide whether impaired complement function is due to an 
infection or poor sample handling. Our observation of no  difference in complement 
integrity whether serum is separated immediately from clotted blood or up to 5 days 
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post-venesection, and stored at either 4°C or 22°C during this time, provides evidence 
to suggest that any difference with complement function is likely to be due to a defect 
such as an infection or disease rather than poor sample handling. 
 
One of the limitations of this study is that blood and serum handling was conducted 
under optimal conditions. Different findings could be expected if for example, frozen 
serum had been stored at temperatures higher than -80°C, or if during freeze-thaw 
cycles, serum had been left thawed for extended periods of time before refreezing. 
Furthermore, only sera from four subjects were tested in this study, which was due to 
the large number of assays required to determine the conditions for serum 
manipulation. Killing of Salmonella by serum from three donors was maintained over a 
longer period of time when stored at 4°C, confirming that the longevity of complement 
function varies between individuals. This may be due, for example, to polymorphisms of 
the alleles encoding C4. Also, all donors tested in this study were healthy, and the 
stability of complement function may be reduced in patients with hepatitis C infection 
or autoimmune diseases causing complement-consumption. Ideally, serum for each new 
donor should be tested in an established assay system prior to using it routinely.  
 
The practical implications of this study are that if thawed human serum is to be used 
over an extended number of days, it is important that it is kept refrigerated. This will 
help to minimise the waste of serum which has been thawed. It is also important to note 
that human complement does not necessarily behave the same as animal complement 
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in bactericidal assays (191) and these findings may not apply to animal serum. The 
findings of the study indicate that the current guidelines concerning manipulation and 
storage of serum to preserve complement integrity and function leave a large margin 
for safety. However, it must be noted that the disparity in the storage conditions 
required for maintenance of haemolytic activity against Salmonellae and for 
complement haemolytic assays may be due to the presence of complement inactivators 
on mammalian red blood cell surfaces necessitating much higher levels of complement 
activation for mammalian red blood cell haemolysis to occur. This makes mammalian 
red blood cell haemolytic assays very sensitive laboratory indicators of complement 
deficiency. However, for the purposes of bacterial killing, use of the specimen handling 
conditions they mandate may be unnecessarily stringent.   
 
3.5 CONCLUSIONS 
The aim of the present study was to evaluate the conditions under which human serum 
can be stored and manipulated while maintaining complement integrity, in order to 
minimise the waste of precious African serum samples. Surprisingly, serum bactericidal 
activity against Salmonella was maintained for a minimum of 35 days when stored at 
4°C, suggesting that once thawed serum stored at 4°C can be used over a number of 
days. The longevity of bactericidal activity was reduced when serum was stored at 
higher temperatures. Using diluted whole serum confirmed that complement 
degradation occurs over time. Our results also showed that complement is more robust 
than expected and that serum can undergo up to three freeze-thaw cycles with no 
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detrimental effect on bactericidal activity. A delay in the separation of serum for up to 
four days from clotted blood stored at 4°C or 22°C did not affect bactericidal activity 
which is useful in a clinical setting. These findings indicate that the current guidelines 
concerning manipulation and storage of human serum to preserve complement 
integrity and function leave a large margin for safety with regards to bactericidal 
activity against Salmonella.  
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CHAPTER 4. 
IDENTIFICATION OF AN EXOGENOUS COMPLEMENT SOURCE 
FOR KILLING OF S. TYPHIMURIUM BY BLOOD CELLS 
 
4.1 INTRODUCTION 
In order to develop effective vaccines against NTS, an improved understanding of the 
relative contributions of human antibodies against Salmonella antigens needs to be 
established. Our blood cell killing assay provides an in vitro model of killing of NTS by 
peripheral blood cells but uses whole human serum as an opsonin, thus making it 
difficult to identify the role of antibodies against particular targets. Therefore, to help 
identify the role of specific opsonic antibodies in immunity to NTS, we needed to dissect 
this assay and identify an exogenous complement source which could be used in 
conjunction with antibodies, or specific purified antibody, to opsonise Salmonella and 
induce killing by blood cells.  
 
A suitable complement source must not contain antibodies to S. Typhimurium. Since we 
have found that sera from all healthy adults contain naturally acquired antibody to 
invasive strains of NTS, regardless of exposure to these specific isolates, then sera from 
healthy adults are not a suitable source. Serum from young children aged 3 months to 2 
years often lack specific anti-Salmonella antibody (50) hence the peak of NTS 
bacteraemia in this population, but it is unethical to take blood from these children to 
act as a source of complement in experiments. We have obtained serum from patients 
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with primary antibody deficiencies such as common variable immunodeficiency and X-
linked agammaglobulinaemia prior to commencement of antibody replacement 
therapy, from the Department of Immunology, Addenbrooke’s Hospital, Cambridge, but 
these are of limited supply as patients usually begin therapy shortly after diagnosis. 
 
Due to the difficulties in obtaining human serum which is deficient in antibody, many 
investigators use baby rabbit serum (BRS), which is commercially available, as an 
alternative exogenous complement source. The World Health Organization 
recommends the use of baby rabbit serum from 3-4 week old rabbits as a source of 
exogenous complement in assessing human bactericidal responses to meningococcal 
polysaccharide vaccines (192-195). BRS has also been used to assess bactericidal 
activity against Salmonella Typhi (196). However, for meningococcal strains, it was 
found that the bactericidal antibody titre increased if BRS rather than human serum 
was used as the complement source (197;198), suggesting that differences in 
complement from different species is an issue. Therefore, if human complement is 
required, then one approach is to absorb antibodies to S. Typhimurium from human 
serum, by incubating serum with whole bacteria.  
 
4.2 OBJECTIVES 
We tested various sources of commercial BRS and depleted human serum of Salmonella 
antibodies to identify a complement source, which is not toxic to Salmonella in the 
absence of antibody, and when antibody is added can effectively opsonize Salmonellae 
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to initiate killing of NTS by peripheral blood cells. The percentage of complement and 
antibody required to induce cell killing and bactericidal killing was compared.  
 
4.3 RESULTS 
4. 3. 1 OP SO NIC ACTI VITY OF DILU TED HUM AN SERUM  IS R EDUC ED 
COMPARED TO WHOLE SERUM 
To determine if diluted human serum can kill S. Typhimurium in our blood cell killing 
assay, which measures the opsonic capacity of antibody and complement to induce 
killing by peripheral human blood cells, we opsonised S. Typhimurium with whole or 
diluted serum from 2 healthy donors which were known to contain anti-S. 
Typhimurium antibody (Figure 4.2) and measured the clearance from the blood after 
45, 90 and 180 min.  Opsonisation with whole serum from each donor resulted in a 2.0 
log10 kill of Salmonella after 180 min (Figure 4.1 A, B). When the sera were diluted with 
PBS, the highest dilution which could kill S. Typhimurium D23580 was 1:2. Dilutions of 
the sera to 1:4 and further resulted in bacterial growth. Killing in this assay is 
complement-dependent as heat-inactivation of the serum at 56⁰C for 30 min removed 
any killing capacity of the sera (Figure 4.1 A, B). This result highlights that the opsonic 
capacity of human serum is concentration-dependent and that as the serum is diluted, 
the ability to induce peripheral blood cell killing is titrated out, suggesting that an 
exogenous complement source is required when diluted human serum is used as the 
antibody source. Previous work by our group suggests that killing is limited by  
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Figure 4.1 Blood cell killing of S. Typhimurium D23580 opsonised with diluted 
human serum. 
The effect of opsonisation with diluted human serum on killing by peripheral washed 
blood cells was measured by opsonising S. Typhimurium D23580 with PBS (negative 
control), heat-inactivated serum (HI), fresh whole serum (whole serum) or serum 
diluted with PBS (1:2, 1:4, 1:8, 1:16) from 2 healthy adults (A and B). Opsonised 
Salmonellae were incubated with washed adult blood cells and viable bacteria counted 
after 45, 90 and 180 min. Initial concentration of Salmonella is 1 x 105 cfu/ml, with 
negative results showing a decrease in viable Salmonellae compared with the initial 
starting concentration. Each panel represents data using serum from one healthy adult.  
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complement as when diluted human serum was supplemented with heat-inactivated 
human serum killing was not enhanced (50).   
 
4. 3. 2 BR S DOES NO T C ON TAIN AN TI BO DIES TO S.  TYPHIMURIUM  
D23580  
Commercial BRS is often used as an exogenous complement source in serum 
bactericidal assays (192;196). We first verified that BRS from AbD Serotec or Pelfreez 
did not contain antibodies to S. Typhimurium D23580, using our FACS-based antibody 
assay (Figure 4.2). No IgG, IgA or IgM anti-Salmonella Typhimurium antibodies were 
detected in either source of BRS, but, both human sera used in the first assay (and for 
subsequent assays as an antibody source) contained anti-Salmonella IgG, IgA and IgM 
antibodies. 
 
4. 3. 3 BRS IS TOXIC TO S.  TYPHIMURIUM D23580 AT HIGH  
CONCENTRATIONS  
We next measured the toxicity levels of BRS to S. Typhimurium D23580 in our blood 
cell killing assay. S. Typhimurium D23580 was opsonised with 100%, 75%, 50%, 25% 
BRS from AbD Serotec and Pelfreez and PBS, and incubated with washed human 
peripheral blood cells, with viable Salmonella numbers determined after 45, 90 and 180 
min. Salmonellae opsonised with 100% BRS from AbD Serotec and Pelfreez underwent -
1.5 log10 kill (Figure 4.3 A) and -2.5 log10 kill (Figure 4.3 B) respectively suggesting that 
at high concentrations, BRS is toxic to Salmonella. Toxicity was diminished when BRS  
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Figure 4.2 Anti- Salmonella Typhimurium D23580 antibody levels in BRS and 
human serum. 
Anti-S. Typhimurium D23580 IgG, IgA and IgM deposition on S. Typhimurium D23580 
in BRS from AbD Serotec or Pelfreez and human serum (Donor 1 and Donor 2). PBS 
included as a negative control. Data are from one experiment. 
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Figure 4.3 Killing of S. Typhimurium D23580 opsonised with BRS alone or 
supplemented with antibody. 
Killing of S. Typhimurium D23580 opsonised with 100%, 75%, 50% or 25% fresh BRS 
from AbD Serotec (A) or Pelfreez (B) compared to opsonisation with PBS, fresh human 
serum (fresh serum), heat-inactivated human serum (HI serum), heat-inactivated BRS 
(100% AbD HI / 100% Pelfreez HI) by washed peripheral blood cells or by RPMI (100% 
AbD +RPMI, 100% Pelfreez+RPMI). Viable counts determined after 45, 90 and 180 min. 
40%, 30% and 20% of fresh BRS from AbD Serotec (C) and Pelfreez (D) were 
supplemented with diluted heat-inactivated human serum (10 fold dilution range 
starting at 1:4) and used to opsonise S. Typhimurium D23580 prior to incubating with 
adult washed blood cells. Change in Salmonella concentration after 180 min is plotted 
against the antibody dilution used to opsonise Salmonellae. Initial concentration of 
Salmonella is 1 x 105cfu/ml, with negative results showing a decrease in viable 
Salmonellae compared with the initial starting concentration. Data represent means +/- 
SD of 3 experiments. 
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was heat-inactivated or opsonised Salmonellae were incubated in RPMI rather than in 
washed blood cell suspensions. Opsonisation with 75% BRS and 50% BRS from both 
sources was also toxic to S. Typhimurium effecting a 1 log10 kill in the absence of 
antibody, but opsonisation with 25% BRS 75% PBS was not toxic, with 1 log10 growth 
observed after 180 min (Figure 4.3 A and B).  
 
We investigated whether killing of Salmonellae opsonised with BRS could be enhanced 
through the addition of exogenous antibody. Diluted heat-inactivated human serum 
from donor 1, known to contain anti-Salmonella antibody (Figure 4.2), was used as the 
antibody source. Since opsonisation with 50% BRS alone was toxic, but 25% was not, 
we tested dilutions of BRS below 50%. Killing of Salmonella opsonised with 40% BRS 
from AbD Serotec and antibody dilutions of 1:4 and 1:40 was increased compared to 
opsonisation with 40% BRS alone, but 40% BRS also effected a kill in the absence of 
antibody (Figure 4.3 C). Opsonisation with 30% BRS effected a 0.5 log10 kill and the 
addition of exogenous antibody, even at a dilution of 1:4, did not enhance killing. 
Although 20% BRS was not toxic, killing was not increased further when supplemented 
with antibody.  
 
When the assays were repeated with BRS from Pelfreez (Figure 4.3 D), 40% BRS 
induced a 1 log10 kill in the absence of antibody, which was increased to 1.5 log10 kill 
when antibody was added at a dilution of 1:4, but diminished as antibody was diluted 
further. Opsonisation with 30% BRS was not able to kill Salmonella, and a 0.5 log10 kill 
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was observed when heat-inactivated serum at a dilution of 1:4 and 1:40 was added and 
decreased as the heat-inactivated serum was diluted further. 20% BRS was not toxic, 
but no killing of Salmonella colonies was observed when supplemented with antibody. 
 
These results suggest that BRS from AbD Serotec or Pelfreez are not suitable 
complement sources for use in blood cell killing assays since they are toxic to 
Salmonellae at high concentrations, and when used at low concentrations and 
supplemented with diluted human heat-inactivated serum, killing of S. Typhimurium 
D23580 is not enhanced. Therefore, an alternative complement source is required.  
 
4. 3. 4 FUNC TION AL HUM AN C OMPLEM EN T REMAIN S I N S ERUM AF TER  
PRE-ABSORPTION OF ANTI - S.  TYPHIMURIUM D23580 ANTIBODIES  
An alternative complement source to BRS is to pre-absorb serovar-specific antibody 
from human serum by incubating serum with high concentrations of whole bacteria. We 
pre-absorbed antibodies to S. Typhimurium D23580 from serum taken from a healthy 
adult. After 3 rounds of incubations with bacteria, the anti-S. Typhimurium D23580 IgG, 
IgA and IgM titres, as assessed by flow cytometry, had decreased confirming that the 
majority of antibody had been depleted from the serum, providing a human 
complement source (Figure 4.4 A).    
 
One potential caveat with this antibody depletion process is the loss of complement 
activity, since complement can be deposited on the bacteria during the incubations. To  
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Figure 4.4 Antibody-depleted human serum contains no antibody to Salmonella 
but complement remains functional.   
(A)Decreased anti-S. Typhimurium D23580 IgG, IgA and IgM deposition on S. 
Typhimurium D23580 in antibody-depleted serum after each round of absorptions 
compared to whole serum prior to pre-absorptions. (B) An SBA was performed with S. 
Typhimurium D23580 mutant galE- and different percentages of pre-absorbed human 
serum (PA 100%, PA 75%, PA 50%, PA 25%) and compared to killing of bacteria with 
fresh non-pre-absorbed serum (Fresh serum). Pre-absorbed heat-inactivated serum 
(PA HI) and heat-inactivated non-pre-absorbed serum (HI serum) were negative 
controls. Initial concentration of Salmonella was 1x106cfu/ml, with negative results 
showing a decrease in viable Salmonellae compared with the initial starting 
concentration. Data are from one experiment. 
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verify that complement within the antibody-depleted serum remains functional, a 
serum bactericidal assay using a galE- mutant of S. Typhimurium D23580 which has a 
truncated OAg and can be killed in the absence of antibody (50), was performed with 
pre-absorbed serum and whole serum.  A 3.0 log10 kill of S. Typhimurium D23580 galE- 
at 180 min was observed for whole non-pre-absorbed serum and for serum which had 
been through 3 rounds of antibody-depletion, even at percentages as low as 25% 
(Figure 4.4 B), confirming that complement remained functional in the pre-absorbed 
serum.  
 
4. 3. 5 AN TIBO DY-DEPLETED HUMAN S ERUM  IS A SUI TABLE 
COMPL EMEN T S OURC E FOR BLO OD CEL L KILLIN G OF S.  TYPHIMURIUM  
D23580 
In contrast to BRS, all percentages of antibody-depleted serum tested did not induce 
Salmonella killing by peripheral washed blood cells in the absence of antibody (Figure 
4.5 A). To determine whether killing of human antibody-depleted serum could be 
restored when supplemented with antibody, Salmonellae were opsonised with different 
percentages of antibody-depleted serum mixed with diluted heat-inactivated human 
serum and killing by washed blood cells measured (Figure 4.5 B). A minimum of 60% 
antibody-depleted serum was required to reliably induce a 1 log10 kill of Salmonella, 
which is classed as ‘normal’ kill of Salmonella by healthy, adult serum. Opsonisation 
with 90% complement and 10% antibody induced a 1 log10 kill after 180 min, but a 1:2 
dilution of the antibody source (i.e. equivalent to 5% heat-inactivated serum) removed 
killing. When the complement source was reduced to 80% or 70%, a 1 log10 kill was  
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Figure 4.5 Antibody-depleted serum and antibody requirement for blood cell 
killing of S. Typhimurium D23580. 
(A)S. Typhimurium D23580 was opsonised with 100%, 70%, 50%, 20% antibody-
depleted serum (PA) or heat-inactivated antibody-depleted serum (100% PA HI) and 
killing by washed adult peripheral blood cells assessed at 45, 90 and 180 min. (B) 
Killing of S. Typhimurium D23580 opsonised with varying percentages of antibody-
depleted serum (90%-10%) and supplemented with dilutions of heat-inactivated 
human serum as an antibody source (10%-90% neat, 1:2, 1:4, 1:8, 1:16). Neat 
corresponds to opsonisation with the maximum percentage of heat-inactivated serum 
possible, and dilutions correspond to 2 fold dilutions with PBS from this starting 
concentration.  Log change in Salmonella after 180 min plotted against the antibody 
dilution, with negative results showing killing of Salmonella and positive results 
representing bacterial growth. Data represent means +/- SD of 3 experiments.   
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observed when antibody was diluted further to 1:2. 60% complement with 40% 
antibody induced over a 1.5 log10 kill, but kill was decreased to 0.7 log10 when diluted to 
1:2.  We suggest the use of 60% pre-absorbed serum, with 40% heat-inactivated serum 
as the antibody source for future blood cell killing assays. 
 
4. 3. 6 COMPL EMENT AND ANTI BO DY REQUIREM ENT F OR SERUM  
BAC TERI CIDAL KILLI NG OF S.  TYPHIMURIUM D23580 I S L OWER TH AN  
THAT FOR BLOOD CELL KILLING 
We had previously observed that human serum diluted to 20% can kill Salmonella via 
cell-free antibody-dependent complement-mediated killing (50)(Chapter 3, Figure 3.1). 
This suggests that the complement requirement for bactericidal killing is lower than 
that observed for blood cell killing, where fresh human serum, when diluted to 1:4 , 
could not effect killing by peripheral blood cells (Figure 4.1 A, B).  We confirmed that 
the limitation of serum bactericidal activity against S. Typhimurium D23580 for serum 
from the 2 donors used in this study was at a dilution of 1:4 (Figure 4.6 A and B).  
 
To further identify differences in the antibody and complement requirement for the two 
different mechanisms of killing Salmonella, we compared the bactericidal activities of 
the same dilutions of antibody-depleted serum and heat-inactivated serum against S. 
Typhimurium D23580. As observed in the blood cell killing assay, pre-absorbed serum 
in the absence of antibody was not able to kill Salmonella (Figure 4.6 C). The minimal 
percentage of pre-absorbed serum required to induce a 1 log10 bactericidal killing of   
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Figure 4.6 Requirement of antibody and complement for bactericidal killing of S. 
Typhimurium. 
Serum bactericidal assays were performed using whole human serum from (A) donor 1 or 
(B) donor 2, or diluted with PBS (1:2, 1:4, 1:8, 1:16), or (C) varying percentages of antibody-
depleted human serum (PA). Viable bacterial numbers were determined after 45, 90 and 
180 min. (D) Serum bactericidal assays were also performed with varying percentages of 
antibody-depleted serum (90% PA-10% PA) and supplemented with dilutions of heat-
inactivated human serum as an antibody source ( 10%-90% HI neat, 1:2, 1:4, 1:8, 1:16). Neat 
corresponds to opsonisation with the maximum percentage possible, and dilutions 
correspond to 2 fold dilutions with PBS from this starting concentration, with log change in 
Salmonella after 180 min plotted against the antibody dilution. Initial concentration of 
Salmonella  was 1 x 106cfu/ml, with negative results showing a decrease in viable 
Salmonellae  compared with the initial starting concentration. A, B - each panel represents 
data using serum from one healthy adult. C, D – data represent means +/- SD of 3 
experiments. 
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Salmonella in the presence of antibody was 40% (Figure 4.6 D). This is lower than 60% 
pre-absorbed serum required for killing of Salmonella by peripheral blood phagocytes. 
A 1 log10 kill or greater was observed at antibody dilutions up to 1:8, with percentages 
of pre-absorbed serum ranging from 90% to 40%. At 70% and 60% complement, 
antibody could be diluted further and still induce a kill, with an antibody dilution of 
1:16 producing a -0.8 log10 Salmonella kill.  
 
4.4 DISCUSSION 
This work confirms an important requirement for antibody and complement in blood 
cell killing of Salmonella. We determined that endogenous complement in diluted 
human serum is insufficient to drive cell-mediated killing of Salmonella, and through the 
use of BRS and human antibody-depleted serum as exogenous complement sources, we 
evaluated the optimum percentages of complement and antibody required for 
peripheral blood cell killing of Salmonella.  
 
Unlike for some diseases, such as meningococcal infections, where a proportion of the 
population lack antibody against the bacteria and can serve as complement donors 
(192), we have been unable to find healthy adult donors who lack naturally-acquired 
anti-Salmonella antibody, and we only have a limited amount of serum available from 
patients with primary antibody deficiencies. Therefore, we tested serum from 3-4 week 
old rabbits sourced from Pelfreez and AbD Serotec as potential complement sources. 
BRS is recommended by the WHO as a source of complement for measuring bactericidal 
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responses to meningococcal vaccines (193), and has been used also for assessing 
bactericidal activity to S. Typhi (196). The benefits of using commercial BRS are that it is 
readily available, requires no preparation and can be used in standardised assays and 
shared between different laboratories (192). Although no anti-S. Typhimurium D23580 
antibodies were detected in either batch of BRS, it was toxic to Salmonella at high 
concentrations. At lower percentages of BRS, which were not toxic to Salmonella, killing 
could not be enhanced when supplemented with antibody, which rules out BRS as a 
complement source for our blood cell killing assays. It is likely that at low BRS 
percentages there is insufficient C3 deposition on the bacteria for phagocytosis. Lack of 
killing of Salmonella opsonised with high concentrations of BRS and incubated in RPMI, 
rather than blood, suggests that a component present in the blood causes the 
complement-dependent toxicity. It is possible that at high concentrations of BRS, there 
could be enough C3 deposition to trigger spontaneous uptake of the bacteria by blood 
phagocytes or that a little antibody remains in the washed blood cell suspensions, which 
together with deposition of sufficient quantities of BRS could stimulate phagocytosis.  
 
The use of human complement avoids compatibility issues when using assay 
components from different species and has the benefit of reducing the use of animals, 
but more importantly, the use of human complement as well as human antibody and 
blood cells makes the assay conditions more closely related to those in vivo. A potential 
caveat of this pre-absorption method though is the batch to batch variation of this 
process and the time taken to deplete the serum of antibodies. One other concern is the 
loss of functional complement during the pre-absorption cycles, but we showed that 
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even 25% pre-absorbed serum was able to kill a galE- mutant of the parent strain 
D23580.  
 
Human antibody-depleted serum was the most suitable complement source for use in 
our blood cell killing assay. A minimum of 60% pre-absorbed serum and 40% heat-
inactivated serum at a maximum dilution of 1:2 (i.e. 60% complement and 20% 
antibody), is required to kill Salmonella. Human antibody-depleted serum was also a 
useful complement source for assessing cell-free, antibody-dependent complement-
mediated killing of NTS. The percentage of complement and antibody required for 
killing Salmonella via this mechanism was much lower than that required for opsonic 
killing, with a minimum of 40% complement required and antibody dilutions of 1:8 and 
in some cases 1:16, able to effect bactericidal killing. The difference in requirement of 
antibody and complement using pre-absorbed serum and heat-inactivated serum 
mimics that seen with whole serum. Fresh whole serum at a maximum dilution of 1:2 
could kill in the blood cell assay, but the same serum could be diluted to 1:4 for the SBA, 
suggesting a greater requirement for antibody and complement for killing by blood cells 
compared to serum bactericidal killing. This is surprising given that for phagocytosis, in 
relation to requirement for complement, only C3 deposition is needed to act as an 
opsonin but for bactericidal killing, formation of the MAC is required, so it might be 
expected that the complement requirement would be higher for the SBA, but for our 
two models the opposite is demonstrated. The increased requirement for antibody in 
blood cell killing compared to serum bactericidal killing could be explained by IgG being 
the only antibody class that can act as an opsonin whereas both IgG and IgM are 
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complement fixing and can trigger MAC formation, with IgM being highly effective at 
this.  
 
We tested and defined the antibody and complement requirement for killing S. 
Typhimurium D23580, a representative invasive African NTS strain. However, the 
complement requirement could be different for other strains as it is known that 
different Malawian NTS isolates have varying susceptibility to opsonic antibody (see 
Chapter 8) or if a phagocytic cell line rather than fresh human peripheral blood cells are 
used. Furthermore, since the antibody titre can also affect the complement requirement, 
then higher antibody titres in some human serum, such as those post-vaccination, could 
alter the complement requirement.  This work has potential implications for vaccine 
development, as to test the efficacy of an NTS vaccine we need an assay which can be 
used to assess the activity of vaccine-induced opsonic antibody. By identifying a suitable 
complement source and the percentage of complement and antibody required to induce 
killing by peripheral blood cells in our blood cell killing assay, we have identified an 
assay which can be used to measure both the specific role of natural and vaccine 
induced opsonic antibody in immunity to NTS.  
 
4.5 CONCLUSIONS 
Although commonly used as a source of exogenous complement, BRS was unsuitable for 
use in our Salmonella blood cell killing assay and antibody-depleted human serum was 
preferred as a complement source. Opsonisation with a minimum of 60% complement 
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and 40% antibody effectively killed Salmonella. In comparison with cell-mediated 
killing, the threshold of complement and antibody needed to induce bactericidal killing 
of NTS was lower, highlighting a difference in requirement for antibody and 
complement in killing of NTS by cellular and bactericidal mechanisms. 
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CHAPTER 5. 
IMPAIRED CELL-MEDIATED IMMUNITY TO NTS IN  
HIV-INFECTED AFRICAN ADULTS 
 
5.1 INTRODUCTION 
Nontyphoidal Salmonella are a major cause of invasive bacterial disease in Africa 
affecting mainly young children (20;199) and HIV-infected adults (30). HIV-infected 
individuals with peripheral CD4 counts less than 200 cells/µl are susceptible to severe, 
recurrent invasive NTS disease (32) with resulting high mortality rates.  
 
Salmonellae are facultative intracellular bacteria (84) and cellular mechanisms of 
immunity are important for controlling intracellular infection. The increased 
susceptibility to NTS infection of patients with immunodeficiencies in the IL-12/23-
IFNγ axis (120;200) or with chronic granulomatous disease (111;112), who have 
mutations impairing oxidative burst activity, highlights this. 
 
Antibodies also play a critical role in both bactericidal (50) and cellular (151) 
mechanisms of immunity to NTS. Sera from young African children lack antibody to NTS 
and consequently complement-mediated killing of the bacteria is diminished (50). 
Killing of Salmonella by the oxidative burst within phagocytes is also absent, as although 
these children do not have a deficiency in their oxidative burst mechanism, a lack of 
antibody means that phagocytosis, which is a necessary intermediate step for triggering 
the oxidative burst, is also reduced (151) . Acquisition of antibody with age correlates 
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with a decline in NTS cases (50), highlighting the absolute requirement for complement 
and anti-Salmonella antibody in immunity to NTS.  
 
In order to develop an effective vaccine against NTS for use in Africa, the targets of 
human antibodies against Salmonella need to be established. Studies in mice and rabbits 
have provided evidence for the protective efficacy of antibody against Salmonella outer 
membrane proteins (160), in particular OmpD (182). There is also evidence that 
antibodies against the O-antigen (OAg) of the lipopolysaccharide (LPS) molecule of 
Salmonella are protective (156-159;201;202). Passive transfer of monoclonal 
antibodies raised to smooth LPS, but not rough LPS, that lacks OAg, conferred 
significant protection in mice (201). In addition, immunising mice with Salmonella OAg 
conjugates elicited antibodies that protected mice against challenge (156-159;202). 
 
However, there is a lack of evidence for a protective effect from serum LPS antibodies 
against NTS in humans. In fact, the opposite has been shown by MacLennan et al who 
observed dysregulated antibody-dependent complement-mediated immunity to NTS in 
some HIV-infected Malawian adults which have a higher titre of serum anti-LPS 
antibodies compared to HIV-uninfected Malawian adults (61) . The study also showed 
that antibodies to the outer membrane proteins of Salmonella were bactericidal, and 
proposes that antibodies targeting the LPS of S. Typhimurium block bactericidal 
antibodies from binding to their targets on the outer membrane and /or directs 
complement away from the membrane, resulting in a lack of lysis of the bacteria (61). 
Whether high titres of serum anti-S. Typhimurium LPS antibodies inhibit cell-mediated 
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killing of NTS is unknown. Given that an OAg-conjugate vaccine is a potential vaccine 
candidate it is important to establish the role of anti-OAg antibodies in cell-mediated 
immunity in both healthy and HIV-infected African adults.  
 
5.2 OBJECTIVES 
The main objective of this study was to determine whether cell-mediated immune 
responses to NTS are impaired in HIV-infected African adults. We further identified if 
antibodies targeting the LPS molecule of S. Typhimurium, which have previously been 
shown to be inhibitory to antibody-dependent, complement-mediated immune 
mechanisms, also inhibit intracellular killing of Salmonella by blood phagocytes or 
whether they can be opsonic and induce clearance of Salmonella from the blood.  
 
5.3 RESULTS 
5. 3. 1 KILLING OF  S.  TYPHIMURIUM D23580 BY PERIPH ERAL BLO OD 
CELL S IS  IMPAIR ED WH EN OP SO NIS ED WI TH S ERUM FROM A SU BS ET 
OF HIV-INFECTED AFRICAN ADULTS 
We utilized a blood cell killing assay to determine any differences in killing of S. 
Typhimurium D23580 opsonised with HIV-uninfected and HIV-infected serum from 
Malawian adults by washed human peripheral blood cells. Salmonella Typhimurium 
D23580 was opsonised with serum from 3 different groups of Malawian a dults (Table 
5.1). The first group of sera was from five, HIV-uninfected healthy Malawian adults and  
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Group HIV-uninfected HIV-infected 
non-inhibitory 
HIV-infected 
inhibitory 
Number 5 5 5 
Age (median and 
range) 
26 
(22-31) 
38 
(27-49) 
27 
(25-42) 
Gender 
(male:female) 
4:1 0:5 1:4 
CD4 count 
cells/µl (median 
and range) 
772 
(329-1356) 
110 
(66-213) 
105 
(20-241) 
 
Table 5.1 Clinical data for study participants.  
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are referred to as ‘HIV-uninfected sera’. The second group was from 5 HIV-infected 
adults whose serum is able to effect a 1.0 - 3.0 log10 kill of S. Typhimurium D23580 in 
the serum bactericidal assay, and these sera are referred to as ‘HIV-infected non-
inhibitory sera’. The third group was also from 5 HIV-infected Malawian adults, but 
these sera are referred to as ‘HIV-infected (bactericidal) inhibitory sera’ as they are 
unable to kill S. Typhimurium D23580 in the serum bactericidal assay (61). The HIV-
infected adult participants were recruited from the antiretroviral clinic at QECH, 
Blantyre, Malawi and HIV-uninfected adults were hospital or laboratory staff. No 
participant had a history of Salmonella disease.    
 
Washed blood cells from healthy non-HIV infected adults in the UK, were inoculated 
with opsonised Salmonella at a concentration of 1 x 105 cfu/ml, at 37˚C with viable 
Salmonella numbers determined at 45, 90 and 180 min.  Washed human blood cell 
suspensions are used as endogenous complement and antibody have been removed 
from these, and therefore only the exogenous antibodies and complement present in the 
opsonising serum can bind to the Salmonella. Human blood cells are used rather than a 
phagocytic cell line to replicate human in vivo conditions as closely as possible. 
 
The absolute requirement for both antibody and complement in killing  Salmonella in 
this assay is shown by an absence of bacterial killing (2.0 log10 growth) when 
Salmonella is opsonised with PBS or with antibody alone (heat-inactivated human 
serum) (Figure 5.1 A). This is in accordance with results of Gondwe et al who showed  
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Figure 5.1 Effect of opsonisation with HIV-uninfected and HIV-infected inhibitory 
and non-inhibitory sera on killing of Salmonellae by adult washed peripheral 
blood cells.  
In vitro killing of Salmonella opsonised with serum from HIV-uninfected Africans (B), 
non-inhibitory serum from HIV-infected African adults (C), and serum from HIV-
infected African adults which is known to be inhibitory to bactericidal killing (D) at 45, 
90 and 180 min. (A) shows PBS, heat-inactivated control pooled Malawian serum (CP 
HI), and control pooled serum as opsonins with Salmonellae incubated in RPMI rather 
than blood (CP + RPMI), showing the requirement for antibody and complement in 
opsonisation and that killing of Salmonella by this mechanism is cell dependent. Killing 
of Salmonella opsonised with HIV-infected bactericidal inhibitory serum is impaired 
compared to HIV-uninfected serum (45 min; un-paired t-test p<0.001, 90 min; 
p<0.0001, 180 min; p<0.0001) Initial concentration of Salmonella is 1x105 cfu/ml, with 
negative results showing a decrease in viable Salmonellae compared with the initial 
starting concentration. C1-C14; Malawian HIV-uninfected sera, S19-S139; HIV-infected 
bactericidal non-inhibitory sera, S17-S140; HIV-infected bactericidal inhibitory sera. 
Data represent means +/- SD of 3 experiments. 
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that antibody and complement are required for killing of Salmonella by peripheral 
blood phagocytes from African children (151). An absence of killing when opsonised 
Salmonella is incubated in RPMI rather than washed blood cells confirms that killing of 
Salmonella in this assay is cell-mediated (Figure 5.1 A).    
 
Salmonella opsonised with HIV-uninfected sera from African adults effected greater 
than a 1.5-2.0 log10 kill after 180 min incubation with washed blood cells (Figure 5.1 B). 
A 1 log10 kill at 180 min is designated ‘normal kill’ for serum from healthy HIV-
uninfected adults in this assay. Opsonisation with serum from HIV-infected adults, 
which was not inhibitory in the bactericidal assays, effected a 2.0 log10 kill after 180 
min, similar to the kill effected with the HIV-uninfected sera (Figure 5.1 C). The 
difference in kill between the HIV-uninfected and HIV-infected non-inhibitory sera were 
not statistically significant at any time point (t45, un-paired t-test p=0.867; t90, 
p=0.767; t180 p=0.967). However, killing of S. Typhimurium D23580 opsonised with 
serum from HIV-infected adults, which was determined to be inhibitory in the serum 
bactericidal assays, was reduced compared to the other 2 groups (Figure 5.1 D). 
Bacterial growth was observed after 45 min, bacteriostasis at 90 min, and only 2 of the 
5 sera effected a 1 log10 kill of bacteria after 180 min (Figure 5.1 D). The impaired killing 
observed for the HIV-infected bactericidal inhibitory sera compared to the HIV-
uninfected sera after 45 (un-paired t-test p<0.001), 90 (p<0.0001) and 180 min 
(p<0.0001) were all statistically significant.   
 
102 
 
5. 3. 2. PHAGO CYTOSI S OF S.  TYPHIMURIUM D23580 O PS ONIS ED WITH  
SERUM FROM SOME HIV-INFECTED AFRICAN ADULTS IS IMPAIRED 
Killing of Salmonella in the previous blood cell assay is cell-mediated, suggesting that 
this mechanism of clearance from the blood is dependent on phagocytosis. Therefore, 
we next investigated if the opsonic potential of serum to stimulate phagocytosis of S. 
Typhimurium D23580 was impaired for sera from a subset of HIV-infected Malawian 
adults. 
  
Heat-killed, FITC-labelled Salmonella Typhimurium D23580 were opsonised with PBS 
or sera from HIV-uninfected or HIV-infected adults, and the percentage phagocytosis by 
neutrophils and monocytes in washed peripheral human blood measured by flow 
cytometry. The mean phagocytic response by neutrophils and monocytes of Salmonella 
coated with PBS (no antibody or complement) was 3.65% and 2.15% respectively 
(Figure 5.2 A and B), emphasising the requirement of both antibody and complement in 
phagocytosis. Optimal phagocytosis of Salmonella was observed when S. Typhimurium 
D23580 were opsonised with sera from 5 HIV-uninfected adults (mean 80%) (Figure 
5.2 A and B).  
 
Stimulation of phagocytosis by Salmonella opsonised with HIV-infected non-inhibitory 
(mean 70%) serum was lower than that of non HIV-infected (mean 80%), but this 
difference was not statistically significant (un-paired t-test p=0.16 for neutrophils, 
p=0.07 for monocytes). Significantly less neutrophils (mean 63% versus mean 80%) 
and monocytes had phagocytosed Salmonella when opsonised with HIV-infected   
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Figure 5.2 Effect of opsonisation with HIV-uninfected and HIV-infected inhibitory 
and non-inhibitory sera on phagocytosis of Salmonellae by adult washed 
neutrophils and monocytes.  
(A)Percentage of phagocytosing washed neutrophils in response to FITC-labelled 
Salmonellae opsonised with PBS or serum from HIV-uninfected African adults (HIV-ve), 
was not significantly reduced (un-paired t-test p=0.16) compared to phagocytosis of 
Salmonellae opsonised with serum from HIV-infected non-inhibitory serum (HIV+ve 
non-inhibitory), but  phagocytic response of neutrophils to stimulation with 
Salmonellae opsonised with serum from HIV-infected African adults (HIV+ve inhibitory) 
was significantly lower (un-paired t-test p=0.008). The response for monocytes using 
the same serum is shown in (B). Points in each group of 3 are from 3 separate 
experiments.  
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inhibitory serum (un-paired t-test p=0.008 for neutrophils and p=0.02 for monocytes) 
(Figure 5.2 A and B).  The overall level of response by the monocytes (Figure 5.2 B) was 
lower than that of the neutrophils, and this was expected as blood had been taken from 
a healthy adult at rest so monocytes would not be activated. A lower response by 
monocytes was previously observed by Gondwe et al (151).  
 
The result of this assay is in agreement with the observed impaired killing of Salmonella 
opsonised with HIV-infected bactericidal inhibitory serum. This suggests that the 
impaired clearance of Salmonella from the blood could be caused by a reduced uptake of 
Salmonella Typhimurium D23580 by neutrophils and monocytes.  
 
5. 3. 3 OXIDATIV E BURS T BY BL OO D PHAGO CY TES IS NOT REDUC ED IN 
RESP ONS E TO S TIMUL ATI ON WITH S.  TYPHIMURIUM OP SO NI S ED WITH  
HIV-INFECTED OR HIV-UNINFECTED ADULT SER A 
Once the bacteria have been phagocytosed, the oxidative burst is induced and this kills 
the intracellular bacteria. To assess whether the oxidative burst is also impaired in 
response to stimulus with Salmonellae opsonised with HIV-infected inhibitory sera, 
heat-killed Salmonellae were opsonised, and the oxidative burst response by washed 
human neutrophils and monocytes, measured by the conversion of dihydrohodamine-
1,2,3 to fluorescent rhodamine, was assessed by flow cytometry. Oxidative burst activity 
by both neutrophils and monocytes was absent when S. Typhimurium were opsonised 
with PBS (Figure 5.3 A and B), confirming the requirement for antibody and  
105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Effect of opsonisation with control and HIV-infected inhibitory and 
non-inhibitory sera on oxidative burst of Salmonellae by adult washed 
neutrophils and monocytes.  
(A)Oxidative burst activity of washed neutrophils in response to Salmonellae opsonised 
with serum from healthy Africans (HIV-ve) and serum from HIV-infected African adults 
which is inhibitory to bactericidal killing (HIV+ve inhibitory), and serum from HIV-
infected African adults which is not inhibitory to bactericidal killing (HIV +ve non-
inhibitory) was not significantly different (neutrophils un-paired t-test p=0.28, 
monocytes un-paired t-test p=0.36-0.43). (B) The response for monocytes using the 
same sera. Points in each group of 3 are from 3 separate experiments. 
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complement for this mechanism of killing. The neutrophils produced a strong oxidative 
burst response (mean 1744 U for control, 1952 U for inhibitory, 1478 U for non-
inhibitory) which was independent of the serum used to opsonise the bacteria (Figure 
5.3 A). There was no statistically significant difference in oxidative burst activity 
between the HIV-uninfected serum and HIV-infected non-inhibitory (neutrophils, un-
paired t-test p=0.28; monocytes p=0.36), or between the HIV-uninfected and HIV-
infected inhibitory serum (neutrophils un-paired t-test p=0.28, monocytes p=0.43). The 
oxidative burst levels observed in the monocytes (Figure 5.3 B) were much lower than 
those observed for the neutrophils. Again, this was expected as the blood was taken 
from a healthy resting adult and so the monocytes would not be activated. 
 
5. 3. 4 BACTERICI DAL KI LLIN G OF  SAL MONELLAE  DOES N OT O CCUR  
DURING THE OPSONISATION PERIOD 
For the phagocytosis and oxidative burst assays, heat killed Salmonellae are used and 
consequently opsonisation with fresh serum cannot affect Salmonellae viability. For the 
blood cell killing assay, live bacteria are used and opsonisation takes place at room 
temperature for 20 min, prior to incubating with washed blood cells. Therefore, a 
possible explanation for the impaired blood cell killing, which was observed only with 
the HIV-infected bactericidal inhibitory serum, could be that bactericidal killing occurs 
during this opsonisation period, reducing the initial concentration o f Salmonella at the 
start of the assay, but for the HIV-infected bactericidal inhibitory serum, this killing 
cannot take place (61) and so the concentration of bacteria at the start of the assay 
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would be higher for these samples. To verify if cell-free bactericidal killing occurs 
during this 20 min opsonisation period, Salmonella concentration was determined 
before and after the 20 min opsonisation period and the log change in Salmonella 
concentration calculated. There was a 0 log10 change in Salmonella Typhimurium 
concentration at the end of the 20 min incubation for all of the sera tested (Figure 5.4) 
confirming that serum bactericidal killing of S. Typhimurium does not occur during the 
20 min opsonisation period. 
 
5.3.5 ALL SERA CAN DEPOSIT C3 ON SALMONELLA  
Since both antibody and complement are required for optimal phagocytosis and killing 
of S. Typhimurium by peripheral blood cells, it was important to examine whether a 
lack of complement deposition was the reason for impaired killing observed when 
Salmonellae were opsonised with HIV-infected inhibitory serum. Using confocal 
microscopy, it had previously been verified that all 15 sera tested were able to deposit 
C3 on the surface of the bacteria (61), therefore excluding lack of complement 
deposition as an explanation for the impaired blood cell killing.   
 
5.3.6 HIV-INFECTED INHIBITORY SERUM CAN KILL S.  TYPHIMURIUM 
D23580 WHEN DILUTED WITH HIV-UNINFECTED SERUM  
We wanted to verify if the inhibition of killing of Salmonella opsonised with HIV-
infected inhibitory serum could be removed by mixing the inhibitory serum with HIV  
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Figure 5.4 No bactericidal killing of S. Typhimurium D23580 occurs during the 20 
min opsonisation period. 
S. Typhimurium D23580 was opsonised with PBS (negative control) or 5 HIV un-
infected, 5 HIV-infected inhibitory or 5 HIV-infected non-inhibitory sera and viable 
Salmonella counts taken at time 0 and after 20 min opsonisation period and log 10 
change in Salmonella concentration plotted. Data are from one experiment. 
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un-infected serum which is able to effectively kill Salmonella. S. Typhimurium D23580 
were opsonised with varying percentages of HIV-infected inhibitory and HIV-uninfected 
serum, and incubated with adult washed blood cell suspensions. Number of viable 
Salmonella after 45, 90 and 180 min was determined. Killing was restored in all of the 
HIV-infected inhibitory sera when mixed with the HIV-uninfected serum (Figure 5.5). 
For some sera, a 1 log10 kill was only observed when Salmonella were opsonised with 
40% HIV-infected inhibitory and 60% HIV-uninfected sera. For other sera, killing was 
restored when diluted to 80% inhibitory and 20% HIV-uninfected. This result is 
consistent with the presence of an inhibitor in the HIV-infected serum which affects the 
cell-dependent killing of Salmonella. 
 
5.3.7 HIV-INFECTED INHIBITORY  SERA HAVE HIGHER SERUM ANTI-LPS  
IgG AND IgA TITRES 
 
We suspected that high anti-LPS antibody titres in the HIV-infected sera could be 
responsible for inhibiting Salmonella killing by washed blood cells. To test this we 
needed to determine the anti-LPS antibody titres of the serum. An ELISA was used to 
quantify IgG (Figure 5.6 A), IgA (Figure 5.6 B) and IgM (Figure 5.6 C) antibodies to 
Salmonella Typhimurium LPS in HIV-uninfected, HIV-infected inhibitory and non-
inhibitory serum. No difference in anti-LPS IgG titres were seen for the HIV-infected 
non-inhibitory samples relative to the HIV-uninfected samples (un-paired t-test 
p=0.656), while the anti-LPS IgG titres for the HIV-infected inhibitory sera was 
significantly higher (un-paired t-test p=0.0004) (Figure 5.6 A). As for anti-LPS IgG, anti-
LPS IgA titres were not statistically different for the HIV-infected non-inhibitory 
compared to HIV uninfected serum (un-paired t-test p=0.875), but the anti-LPS IgA  
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Figure 5.5 Inhibition of opsonic killing of S. Typhimurium by HIV-uninfected 
serum mixed with HIV-infected inhibitory serum. 
S. Typhimurium D23580 was opsonised with different percentages of HIV -infected 
inhibitory serum and HIV-uninfected serum and incubated with washed blood cells and 
log change in Salmonella at 180 min shown. Each line represents data from one HIV-
infected inhibitory serum. 
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Figure 5.6 HIV-infected inhibitory sera have higher anti-S. Typhimurium LPS IgG 
and IgA titres.  
Anti-S. Typhimurium IgG (A), IgA (B) and IgM (C) titres of 5 sera from HIV uninfected 
Malawian adults (HIV-ve), 5 HIV-infected non-inhibitory (HIV+ve non-inhibitory) and 5 
HIV-infected inhibitory adult sera (HIV+ve inhibitory) were quantified using S. 
Typhimurium LPS coated ELISA plates. Anti-Salmonella LPS IgG and IgA titres were 
significantly higher in the HIV-infected inhibitory sera compared to the HIV-uninfected 
sera (un-paired t-test, p=0.0004, p=0.0182). Data are from one experiment. 
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titres for the HIV-infected inhibitory serum were significantly increased (un-paired t-
test p=0.018) (Figure 5.6 B). There was no difference in anti-LPS IgM titres between the 
HIV-uninfected and HIV-infected non-inhibitory serum (un-paired t-test p=0.655) or 
HIV-infected inhibitory serum (p=0.861) (Figure 5.6 C).  
 
5. 3. 8 S.  TYPHIMURIUM MUTAN T GALE - OP SO NIS ED WI TH S ERUM  FROM  
MALAWIAN ADULTS IS KILLED BY PERIPHERAL BLOOD CELLS 
We suspected that high titres of anti-S. Typhimurium LPS antibodies which are found in 
a subset of HIV-infected adults were inhibiting the killing of Salmonella Typhimurium. 
Using a mutant of Salmonella Typhimurium D23580, which has a mutation in the galE 
gene, leading to a truncation in the OAg chain of the LPS molecule, then the effect of 
antibodies targeting the OAg could be determined. In theory, if high titres of antibody 
targeting the OAg of S. Typhimurium block the killing of bacteria, then all sera should be 
able to opsonise and kill the galE- mutant.  
 
The galE- mutant of S. Typhimurium D23580 was opsonised with PBS (as a negative 
control), HIV-uninfected, HIV-infected non-inhibitory and HIV-infected inhibitory 
serum prior to incubating with washed blood cells. The number of viable bacteria were 
determined after 45, 90 and 180 min incubation in the blood. S. Typhimurium galE- 
opsonised with PBS was not killed by washed blood cells (Figure 5.7 A). There was a 
1000 fold decrease (3.0 log10 kill) in bacteria after 180 min opsonised with each serum 
(Figure 5.7 A, B, C). It is unclear why opsonisation of S. Typhimurium galE- with one of  
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Figure 5.7 Effect of opsonisation with HIV-uninfected and HIV-infected inhibitory and 
non-inhibitory sera on killing of Salmonellae Typhimurium D23580 galE- mutant 
which has a truncated OAg chain by adult washed peripheral blood cells.  
In vitro killing of S.  Typhimurium D23580 galE-  mutant opsonised with (A) PBS (black line) 
and serum from HIV-uninfected Africans, (B) non-inhibitory serum from HIV-infected 
African adults, and (C) serum from HIV-infected African adults which is known to be 
inhibitory to bactericidal killing, at 45, 90 and 180 min. Initial concentration of Salmonellae  
is 1 x 105 cfu/ml, with negative results showing a decrease in viable Salmonellae compared 
with the initial starting concentration. Data are from one experiment. 
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the HIV-infected inhibitory sera (S117) is reduced at t45 and t90 min when compared 
to the other sera, although this serum has the highest anti-LPS antibody titre. This result 
suggests that all the sera have an inherent ability to opsonise S. Typhimurium D23580 
and that the presence of excess anti-LPS antibodies in serum from some HIV-infected 
adults, which target the OAg of Salmonella inhibit killing of the wild type strain.   
 
5. 3. 9 REM OV AL OF LP S AN TIBODI ES RESTORES KIL LING OF  
SALMONELLA  OPSONISED WITH HIV-INFECTED INHIBITORY SERUM 
In order to further test whether antibodies to the LPS of Salmonella Typhimurium were 
inhibiting killing, we examined the effect of removing anti-LPS antibodies from HIV-
uninfected (Figure 5.8 A) and two HIV-infected inhibitory serum (Figure 5.8 B, C) on 
killing by peripheral blood cells. We found that purified S. Typhimurium LPS affects 
blood cell viability, most likely through the toxic effects of lipid A. Therefore, we could 
not use LPS added to the serum to absorb antibodies prior to opsonisation. Removal of 
anti-LPS antibodies was achieved by incubating serum in an ELISA plate coated with 
purified Salmonella Typhimurium LPS. Serum which had undergone 1, 6 or 12 
incubations with LPS were tested in an ELISA to confirm that antibody had been 
removed, and the titre of anti-LPS antibody decreased in a step-wise fashion with very 
little antibody against LPS remaining after 12 incubations. The pre-absorbed sera were 
used to opsonise S. Typhimurium D23580 before incubating with washed blood cells. 
Viable bacteria were counted after 45, 90 and 180 min incubation with washed blood 
cells and log change in bacteria determined.  
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Figure 5.8 Effect of opsonising S. Typhimurium D23580 with HIV-uninfected or 
HIV-infected sera pre-absorbed with S. Typhimurium LPS. 
(A)Blood cell killing of S. Typhimurium opsonised with sera from (A) HIV-uninfected or 
(B, C) 2 HIV-infected inhibitory sera which had undergone 1 (STM 1), 6 (STM 6) or 12 
(STM 12) pre-absorption cycles with S. Typhimurium LPS to remove anti-LPS 
antibodies. Whole serum (before) which has undergone no pre-absorption cycles is 
included for comparison. Each panel represents data using serum from one African 
adult. 
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Killing of Salmonella opsonised with fresh HIV-uninfected sera (Figure 5.8 A) was 
enhanced after one pre-absorption cycle, compared to opsonisation with non-pre-
absorbed serum. But opsonisation with HIV-uninfected serum after 6 or 12 pre-
absorption cycles did not enhance the killing, with a reduced kill for Salmonella 
opsonised with serum after 12 pre-absorption cycles compared to non-pre-absorbed 
serum. Removal of anti-LPS antibodies from two HIV-infected inhibitory sera tested 
(Figure 5.8 B and C) also enhanced the killing, but removal of more antibody after 6 
(Figure 5.8 C) or 12 (Figure 5.8 B) cycles reduced the killing.  
 
This observation is consistent with the hypothesis that high titres of anti-LPS antibodies 
are responsible for the impaired killing observed in the phagocytosis and blood cell 
killing assays, since when the titre of anti-LPS antibody decreases, killing of Salmonella 
opsonised with these sera is enhanced. However, the results also  indicate that removal 
of too much anti-LPS antibody decreases killing, suggesting that anti-LPS antibodies 
have a role in cell-mediated immunity and that it is the concentration of anti-LPS 
antibody that impairs killing.  
 
5. 3. 10 R EMOV AL O F AN TIBO DIE S TO LP S FROM DIFF ER ENT SERO V ARS  
OR COM PON EN TS OF LP S S.  TYPHIMURIUM DO ES NO T RESTORE 
KILLING OF S.  TYPHIMURIUM D23580 BY WASHED BLOOD CELLS 
It was important to confirm that the target antigen of the inhibitory antibodies is the 
OAg of LPS, and that the enhanced killing of Salmonella opsonised with anti-LPS 
antibody depleted serum was due to the removal of antibodies to the OAg chain rather 
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than antibodies targeting the core or lipid A of LPS. To test this, we repeated the pre-
absorption cycles using purified lipid A and Rb, Rc, Rd and Re rough mutants of 
Salmonella as antigens. These Salmonella rough mutants have varying truncations in the 
core region of LPS. Killing of Salmonella Typhimurium D23580 opsonised with HIV-
infected inhibitory serum from either of two adults with antibodies to lipid A or the core 
oligosaccharides removed was still impaired (Figure 5.9 A, B) and killing could not be 
restored after 6 pre-absorption cycles. This indicates that the inhibitory antibodies 
specifically target the OAg of Salmonella Typhimurium.  
 
Blood-cell mediated killing of Salmonella opsonised with HIV-infected inhibitory serum 
which had undergone 6 pre-absorption cycles using purified LPS from Salmonella 
Enteritidis or Salmonella Minnesota did not restore killing either (Figure 5.9 C, D). S. 
Enteritidis belongs to group D Salmonella and S. Minnesota, group L, and the O-antigens 
for these three serovars are known to be non-cross-reactive suggesting that it is 
antibody targeting the OAg of S. Typhimurium (i.e. anti-O:4,5 antibodies) which inhibits 
the killing of S. Typhimurium by serum from some HIV-infected adults. 
 
5. 3. 11 HIGH C ON CEN TR ATI ONS O F PURIFIED O-AN TIGEN ANTI BODI ES  
INHIBIT CELL-MEDIATED KILLING OF S.  TYPHIMURIUM D23580 
We obtained affinity purified OAg S. Typhimurium antibodies from 3 sera from each 
group of subjects (see Chapter 6). The purified anti-OAg antibodies allow us to further  
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Figure 5.9 Effect of pre-absorbing HIV-infected sera with different components of 
Salmonella LPS and LPS from S. Enteritidis and S. Minnesota on blood cell killing 
of S. Typhimurium D23580. 
(A, B) Two HIV-infected inhibitory sera underwent 6 pre-absorption cycles with 
Salmonella lipid A and LPS from Rb, Rc, Rd, Re – Salmonella mutants with truncations in 
the core oligosaccharide, prior to opsonising S. Typhimurium D23580 and incubating 
with washed blood cells. Serum which had not been pre-absorbed (Before) was used as 
a control and 6 pre-absorption cycles with Salmonella Typhimurium LPS (STM LPS 6) 
shown for comparison.  (C and D) Effect of 1, 6 or 12 S. Enteritidis LPS (SEN) and S. 
Minnesota LPS (SMN) pre-absorption cycles on 2 HIV-infected inhibitory sera prior to 
opsonisation of S. Typhimurium D23580. Initial Salmonella concentration 1 x 105 
cfu/ml with decrease Salmonellae showing killing of bacteria. Data are representative of 
one experiment with sera from 2 HIV-infected Malawian adults.  
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characterise the role of OAg antibodies in cell-mediated immunity to NTS. S. 
Typhimurium D23580 opsonised with 50% fresh HIV-uninfected serum and 50% PBS 
undergoes a 2.0 log10 kill by washed peripheral blood cells, providing a model into 
which we can test the effect of anti-OAg antibodies. In theory, if anti-OAg antibodies are 
responsible for inhibiting cell-mediated killing of NTS then killing of Salmonella 
opsonised with 50% HIV-uninfected fresh serum and 50% OAg antibody will be 
reduced. Opsonisation of S. Typhimurium D23580 with 50% serum and 50% purified 
LPS antibodies added at the titre in the source serum, or diluted with PBS, from 3 HIV-
uninfected serum did not affect the killing of Salmonella (Figure 5.10 A, B, C). The same 
level of kill was effected whether bacteria were opsonised with 50% fresh serum and 
50% PBS, or 50% serum and 50% purified OAg antibody from, and adjusted to the 
concentration found in HIV-infected non-inhibitory serum (Figure 5.10 D, E, F). 
However, inhibition of Salmonella killing by blood cells was observed when Salmonella 
were opsonised with 50% serum and 50% OAg antibodies purified from 3 HIV -infected 
inhibitory sera (Figure 5.10 G, H, I). This inhibition did not occur with sufficient dilution 
of the purified OAg antibody. Figure 5.10 G, shows that the inhibitory effect of the OAg 
antibodies was not present when using a 1:64 dilution of these antibodies. For the 2 
other HIV-infected inhibitory serum, the purified OAg antibodies needed to be diluted 
to 1:8 (Figure 5.10 H) and 1:16 (Figure 5.10 I) before killing of Salmonella was similar to 
that for bacteria opsonised with fresh serum and PBS rather than fresh serum and OAg 
antibodies. This established that inhibition of killing by OAg antibodies is 
concentration-dependent. 
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Figure 5.10 Effect of anti-OAg antibodies on killing of S. Typhimurium D23580 by 
washed blood cells.  
S. Typhimurium D23580 was opsonised with 50% fresh HIV-uninfected serum and 50% 
PBS (Serum/PBS) or 50% fresh HIV-uninfected serum and 50% purified anti-OAg 
antibodies from 3 HIV-uninfected African adult sera (A,B,C), 3 HIV-infected non-
inhibitory sera (D,E,F) or 3 HIV-infected non-inhibitory serum (G, H, I). Purified anti-
OAg antibodies were added at the titre in each of the sera they are purified from (e.g . 
1:2; 50% fresh HIV-uninfected serum, 50% purified OAg antibody) and then diluted 2 
fold with PBS (1:4 (50% fresh HIV-uninfected serum, 25% purified OAg antibody, 25% 
PBS), 1:8, 1:16, 1:31, 1:64). Each panel represents OAg antibodies purified from the ser a 
of one African adult.  
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Purified OAg antibodies from these HIV-infected inhibitory sera were at a higher 
concentration than those from HIV-uninfected or non-inhibitory serum which 
suggested it is the titre, and not the source, of anti-OAg antibodies which inhibits blood 
cell killing of Salmonella. To confirm this, OAg antibodies purified from HIV-uninfected 
serum were concentrated to the titre found in the HIV-infected inhibitory serum. 
Salmonellae were opsonised with 50% fresh serum and 50% purified OAg antibodies, 
and killing by blood cells determined. When Salmonellae were opsonised with these 
antibodies then the killing was impaired with a 2.0 log10 growth observed (Figure 5.11 
A). Normal killing occurred when these antibodies were diluted with PBS to 1:8 of the 
starting concentration. To further test this, Salmonella were opsonised with 50% fresh 
serum and 50% OAg antibody purified from a HIV-infected inhibitory serum, but 
diluted to the titre of OAg antibody found in HIV-uninfected serum. This time these 
antibodies, although from the HIV-infected inhibitory serum, were able to kill 
Salmonella, even at the first dilution used as the titre was already adjusted to that of the 
HIV-uninfected serum (Figure 5.11 B). This confirmed that it is the high titre of antibody 
found in some HIV-infected serum which reduces killing of Salmonella by blood cells 
and not a difference in antibodies between HIV-infected and HIV un-infected serum.  
 
5. 3. 12 P URIFIED ANTI -SAL MONELLA TYPHIMURIUM O-AN TIGEN  
ANTIBODIES HAVE AN OPSONIC FUNCTION 
Using human serum which had anti-Salmonella antibodies removed (see Chapter 4) as a 
complement source, we were able to identify whether anti-S. Typhimurium OAg  
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Figure 5.11 Effect of anti-OAg antibodies on killing of S. Typhimurium D23580 by washed 
blood cells.  
(A)S. Typhimurium D23580 was opsonised with 50% fresh HIV-uninfected serum and 50% PBS 
(Serum/PBS), or 50% fresh HIV-uninfected serum and 50% purified anti-OAg antibodies from 
HIV-uninfected African adult sera but concentrated to the titre found in HIV-infected inhibitory 
serum (1:2 titre in HIV-inf inhib serum), and then diluted 2 fold with PBS (1:4 titre in HIV-inf 
inhib serum, 1:8, 1:16). Effect of killing of anti-OAg antibodies purified from the same HIV-
uninfected serum and concentrated to the titre found in this serum is shown by the dashed lines 
(1:2 titre in HIV-uninf serum) and when diluted 2 fold with PBS (1:4 titre in HIV-uninf serum). 
(B) Opsonisation with anti-OAg antibodies purified from HIV-infected inhibitory serum and 
diluted to the titre found in HIV un-infected serum, and again diluted 2 fold with PBS. Dashed 
lines correspond to inhibition of killing when OAg antibodies from HIV-infected inhibitory sera 
are added at their source titre (1:2 titre in HIV-inf inhib serum) or diluted 2 fold with PBS (1:4 
titre in HIV-inf inhib serum). Each panel represents one experiment with data from 
serum/antibodies from one African adult.  
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antibodies were able to induce cell-killing of Salmonella by acting as opsonins to 
stimulate phagocytosis and uptake of the bacteria. We know that Salmonella are 
effectively killed by blood cells when this antibody-depleted serum is supplemented 
with heat-inactivated human serum as an antibody source (see Chapter 4).  
 
Salmonellae opsonised with 60% complement and 40% anti-OAg antibodies (added at 
the concentration found in the source serum) from HIV-uninfected serum were killed by 
blood cells (1.5 log10 kill after 180 min) whereas killing did not occur following 
opsonisation with complement and PBS (1.5 log10 growth) (Figure 5.12 A). However, 
this kill was reduced as the OAg antibodies were diluted, with loss of killing when 
purified OAg antibodies were diluted to 1:8 with PBS. When purified OAg antibodies 
from one of the HIV-infected inhibitory serum were used together with complement to 
opsonise the bacteria, then again killing was induced in contrast to opsonisation with 
complement in the absence of OAg antibodies (Figure 5.12 B), although this time killing 
was lost at a 1:4 dilution. This shows that both anti-OAg antibodies from HIV-uninfected 
and HIV-infected serum can opsonise Salmonella and induce cell-killing. Overall, the 
blood cell-mediated killing of Salmonella opsonised with pre-absorbed serum and OAg 
antibodies was reduced compared to that when heat-inactivated human serum, which 
contains no complement but a range of antibodies to Salmonella was used as the 
antibody source, suggesting that the OAg could be one of the targets of opsonic antibody 
but that antibody to other antigens also enhances killing of NTS.   
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Figure 5.12 Blood cell killing of S. Typhimurium D23580 opsonised with human 
complement and diluted purified anti-OAg antibodies. 
S. Typhimurium D23580 was opsonised with whole fresh HIV-uninfected serum (whole 
serum), 60% HIV-uninfected pre-absorbed serum as complement source (PA serum) 
and 40% PBS (PA +PBS), 60% pre-absorbed serum and heat-inactivated human serum 
as an antibody source (PA+HI serum) or 60% pre-absorbed serum and 40% purified 
anti-OAg antibodies from (A) HIV-uninfected African sera or (B) HIV-infected inhibitory 
sera. Purified anti-OAg antibodies were added at the titre found in the source serum 
(PA+OAg Abs 1:2) and then diluted 2 fold with PBS (PA + OAg Abs 1:4). Each panel 
represents one experiment using purified OAg antibodies from 2 African adults.   
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5.4 DISCUSSION 
NTS infections have been associated with HIV since the onset of the AIDS epidemic (57). 
In Sub-Saharan Africa, high mortality rates are observed in HIV-infected adults who 
succumb to invasive NTS disease (30). Recurrent infections are common and the 
emergence of multi-drug resistant strains makes treatment with antibiotics challenging. 
Currently there is no available vaccine for NTS. An OAg conjugate is a potential vaccine 
candidate, but until now the functional activity of the OAg antibodies in cell-mediated 
immunity has not been investigated.  
 
Through the use of a blood cell killing assay, and FACS-based phagocytosis and 
oxidative burst assays we were able to assess cell-mediated killing of NTS in healthy 
and HIV-infected African adults. These assays use human blood phagocytes rather than 
a cell-line and opsonises with 100% serum as a source of antibody and complement to 
make the assays as close to physiological conditions as possible. Using fresh human 
blood phagocytes from healthy HIV-uninfected adults allows us to focus on the effect of 
HIV-infected serum and humoral components of these sera and the function of antibody 
in these sera. For the blood cell killing assay, incubating opsonised Salmonella in RPMI 
rather than washed blood cells confirms that killing in this assay is cell-mediated.  
 
Using the blood cell killing assay, we observed reduced killing by peripheral washed 
blood cells of Salmonella Typhimurium opsonised with serum from some HIV-infected 
adults. The inhibition was not observed in all HIV-infected adults, but rather in a group 
126 
 
of sera which had higher anti-Salmonella Typhimurium LPS IgG and IgA antibody titres 
as shown by ELISA, compared to healthy HIV-uninfected African adults.  
 
All serum had functional complement (61), which rules out complement deficiency or 
failure to deposit complement on the surface of the bacteria as an explanation for 
reduced killing, and that impaired killing of Salmonella was observed only when 
opsonised with HIV-infected sera, which have higher serum anti-LPS titres, suggested 
that antibodies targeting the LPS of Salmonella are causing the inhibition. A galE- 
mutant of S. Typhimurium D23580 which lacks an OAg chain, underwent a 3 log10 kill 
when opsonised with these HIV-infected inhibitory sera, suggesting that antibodies 
targeting the OAg of S. Typhimurium were responsible for inhibiting the killing of the 
wild-type isolate. Killing of S. Typhimurium D23580 opsonised with HIV-infected 
inhibitory serum which had anti-S. Typhimurium LPS antibodies removed was 
increased compared to whole untreated serum, but killing was not enhanced when 
antibodies  to S. Enteritidis or S. Minnesota LPS, lipid A or to the core oligosaccharide 
were removed, providing further evidence for the involvement of anti-LPS antibodies in 
inhibiting killing of S. Typhimurium by peripheral blood cells.  
 
The purification of anti- S. Typhimurium OAg antibodies by affinity chromatography 
(see Chapter 6) from HIV-uninfected and HIV-infected sera allowed the further 
characterisation of the role of anti-OAg antibodies in immunity to NTS. Inhibition of 
killing was observed when Salmonellae were opsonised with 50% serum and 50% OAg 
antibodies purified from 3 HIV-infected inhibitory sera, added at the source serum titre. 
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This inhibition could be removed by diluting the purified OAg antibody indicating a 
concentration-dependent inhibition of killing by OAg antibodies. OAg antibodies from 
these HIV-infected inhibitory sera were at a higher concentration than those from the 
other groups of sera, which suggests it is the titre, and not the source of anti-OAg 
antibodies which inhibits blood cell killing of Salmonella. Further support for this 
conclusion was the reduction in killing of Salmonella opsonised with 50% fresh serum 
and 50% OAg antibodies from a HIV-uninfected serum, concentrated to the elevated 
titre detected in one of the inhibitory serum and also, the increase in killing of 
Salmonella opsonised with 50% fresh serum and 50% OAg Abs purified from an HIV-
infected inhibitory serum but diluted to the titre found in a HIV-infected non-inhibitory 
serum.  
 
It has previously been shown that opsonic antibody plays an important role in 
immunity to NTS (145;151) but the identity of such opsonic antibody remains unclear. 
It is difficult to ascertain from the results discussed above whether anti-OAg antibodies 
can act in an opsonic manner and enhance killing of NTS by peripheral blood cells. To 
try to answer this question, we used human serum which has been pre-absorbed with 
whole bacteria to deplete it of all anti-Salmonella antibody, resulting in a human 
complement source which can be used to opsonise the bacteria (see Chapter 4). We 
know that when this antibody-depleted serum is supplemented with heat-inactivated 
human serum as an antibody source, killing is restored (see Chapter 4). When purified 
OAg antibodies, from either HIV-uninfected non-inhibitory or HIV-infected bactericidal 
inhibitory serum, were used as an antibody source, killing was restored and this killing 
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could be removed by dilution of the antibody source. Killing was not to the same level as 
that when heat-inactivated human serum containing antibodies to a range of antigens 
was used as the antibody source. This suggests that antibodies targeting the OAg could 
be one of the targets of opsonic antibody. To further examine this, the assays would 
need to be repeated with purified antibodies to other targets of Salmonella, such as the 
outer membrane proteins which have been shown to be important for protective 
immunity to Salmonella (61;160;182). 
  
Further support for the role of opsonic antibodies to the OAg was also provided by the 
assays in which anti-LPS antibodies were removed from the serum through step-wise 
incubation with purified S. Typhimurium LPS. Removal of some LPS antibodies 
increased killing of Salmonella Typhimurium D23580, but opsonisation of Salmonella 
with serum which had undergone 12 cycles of pre-absorption reduced the killing, 
suggesting that removing too much anti-LPS antibody impaired killing, and that at the 
right concentration, anti-OAg antibodies can enhance killing of NTS, but at elevated 
titres found in some HIV-infected adults, they can inhibit killing. 
 
We can speculate that the decreased phagocytic response of neutrophils and monocytes 
of bacteria opsonised with HIV-infected inhibitory serum compared to Salmonella 
opsonised with HIV-uninfected or HIV-infected non-inhibitory serum suggests that the 
inhibition observed for the blood cell killing isolates is phagocytosis mediated. The 
oxidative burst response of neutrophils and monocytes was not reduced in the presence 
of the HIV-infected serum which is surprising given that phagocytosis is a necessary 
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intermediate step in inducing the oxidative burst. Although it may be explained by a 
lower threshold required for the detection of oxidative burst activity than for 
phagocytosis in the assays used. 
 
Complement as well as antibody is required for optimal phagocytosis and killing by 
blood cells (151). Therefore, we can hypothesise as previously proposed in relation to 
cell-free killing (61), that excess anti-LPS antibodies which bind to the OAg of LPS 
protruding from the surface of the bacteria could form a shield which diverts 
complement deposition away from the surface of the bacteria thus minimising the 
interaction between C3 and the C3 receptor on the phagocyte, and reducing uptake of 
the bacteria by lack of stimulation of the complement receptors on the phagocytes. This 
shield of LPS-antibodies could also block the access of other opsonic antibodies to their 
targets nearer the surface of the bacteria. For example, antibodies to the outer 
membrane proteins, in particular ompD (182), on the surface of the bacteria have been 
shown to be protective against Salmonella infection, and the excess presence of LPS-
antibodies binding to the bacteria could block the access of these antibodies to the 
target antigens on the surface of the bacteria. These mechanisms have been suggested 
as reasons for impaired bactericidal activity in some HIV-infected sera (61). The 
observation that anti-LPS antibodies from healthy HIV-uninfected and HIV-infected 
adults can be opsonic and can induce killing at the right concentration but killing is 
enhanced if heat-inactivated serum is used, suggests that antibodies to other antigens 
as well as those to the OAg are opsonic. Alternatively, killing could be enhanced further 
when heat-inactivated serum is used as an antibody source compared to purified anti-
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OAg antibodies, because complement fragments present in the heat-inactivated serum 
could be deposited on the bacteria. 
 
A surprising observation was the significantly higher anti-LPS IgA titres observed in the 
HIV-infected inhibitory serum compared to the HIV-uninfected or HIV-infected non-
inhibitory serum. IgA is known to have no opsonic activity (203;204) and has been 
previously shown to interfere with phagocytosis-mediated killing of pathogens (203). It 
is possible that IgA interferes with C3 fixation (203) or anti-LPS IgA could bind to the 
OAg and block binding of IgG, which is opsonic. Alternatively, both anti-LPS IgG and IgA 
could bind and IgA could reduce the binding of IgG to the FcR on the phagocyte by steric 
hindrance (205). To test whether elevated titres of anti-LPS IgA are responsible for 
inhibiting the killing of Salmonellae opsonised with HIV-infected inhibitory serum, these 
antibodies would need to be isolated from the sera. Unfortunately, due to limited serum 
volumes we have not been able to characterise the role of the various isotypes of anti-
LPS antibody and study whether this is the inhibiting mechanism. 
 
This work contributes another explanation as to the association between HIV and high 
incidence of NTS bacteraemia in HIV-infected African adults. A loss of Th17 cells from 
the gut mucosa leading to failure to maintain the epithelial barrier which causes easier 
dissemination of bacteria into the blood (60) , and cytokine dysregulation, in particular 
of IL-10, IL-12 and TNFα in advanced HIV infection (62), have so far been suggested as 
explanations for the association between HIV and NTS.  Our group has also previously 
identified that high titres of anti-LPS antibodies block antibody-dependent 
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complement-mediated cell-free killing (61) by either blocking the access of antibodies 
to the outer membrane proteins and / or diverting complement deposition away from 
the surface of the membrane, thus preventing insertion of the membrane attack 
complex. Together, this work suggests that those HIV-infected adults who have a 
reduced ability to phagocytose and kill Salmonella by peripheral blood cells are also not 
able to kill Salmonella antibody via cell-free bactericidal killing. This could help explain 
the high incidence of bacteraemia observed in HIV-infected African adults as reduced 
phagocytosis of bacteria due to the presence of excess anti-LPS antibodies would result 
in the bacteria spending longer in the extracellular space where bactericidal anti-LPS 
antibodies are also unable to kill NTS, resulting in extracellular survival and 
development of bacteraemia. Phagocytosis of Salmonella opsonised with HIV-infected 
inhibitory serum was not completely absent, but rather significantly reduced compared 
to HIV-uninfected or non-inhibitory serum which signifies that some bacteria are taken 
up into the intracellular niche and can be killed by oxidative burst. However, recurrent 
NTS infections are observed in the context of HIV infection and it is likely that only a 
few of the bacteria which are phagocytosed need to resist killing via expression of SPI-1 
genes in order to be able to reside in the intracellular niche, and together with cytokine 
dysregulation, establish recurrent infection.  
 
There is currently no vaccine available for NTS, and given the evidence of protective 
immunity when prototype OAg conjugate vaccines have been tested in rabbits and mice 
(156-158), the development of polysaccharide conjugate vaccines for protection against 
NTS in humans is a promising avenue. However, immune responses in mouse models 
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and man can be very different  and although this work suggests that anti-OAg 
antibodies are opsonic and induce clearance of Salmonella from the blood, in some 
humans the presence of excess anti-LPS antibodies inhibits both the uptake of bacteria 
into an intracellular location and bactericidal killing whilst in the extracellular space 
(61), which advises against the use of an OAg-conjugate as an effective vaccine for 
protection against NTS. It is important to further understand how HIV affects the 
immune response to NTS and to vaccinations, as HIV-infected adults as well as young 
children are increasingly susceptible to invasive NTS disease, and would consequently 
benefit the most from a vaccine. The other targets of protective opsonic antibody need 
to be identified to further inform vaccine development.  
 
5.5 CONCLUSIONS 
Killing of an invasive isolate of NTS, Salmonella Typhimurium D23580, by peripheral 
washed blood cells was impaired when bacteria were opsonised with sera from some 
HIV-infected adults. A high titre of anti- S. Typhimurium LPS antibody in these sera 
appears to inhibit the killing of S. Typhimurium by reducing phagocytosis and clearance 
of the Salmonella by peripheral adult blood cells. Pre-absorption of anti-LPS antibodies 
restored killing, and opsonisation of Salmonellae with high titres of purified anti-OAg 
antibodies inhibited killing of the bacteria by blood cells. This inhibition is 
concentration dependent and at the titre found in healthy Malawian adults, the anti-OAg 
antibodies can be opsonic and induce cell-mediated killing of Salmonella. In conclusion, 
this work argues for and against production of an OAg vaccine, as although anti-OAg 
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antibodies can be opsonic and induce cell-mediated killing of bacteria, at high titres 
they appear to block both bactericidal and opsonic mechanisms of immunity to NTS.  
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CHAPTER 6. 
 PURIFICATION OF ANTIBODIES TO O-ANTIGEN OF 
 S . TYPHIMURIUM FROM HUMAN SERUM  
BY AFFINITY CHROMATOGRAPHY 
 
6.1 INTRODUCTION 
There is an imperative need for a vaccine which will provide protection against invasive 
nontyphoidal Salmonella disease, particularly in Africa. Given the evidence that 
antibodies against the O-antigen (OAg) of lipopolysaccharide (LPS) of Salmonella 
provide protection against challenge in animal studies (156;157), then designing a 
vaccine which will increase production of antibodies to this antigen is a potential 
option. However, recent studies in HIV-infected adults (61) suggest that an excess of 
antibody targeting the OAg of S. Typhimurium actually impairs immunity to NTS. In 
order to further characterise the role of these antibodies in cell-mediated immunity to 
NTS, particularly in the context of HIV-infected African adults (Chapter 5), we needed to 
isolate them from human serum.  
 
Monoclonal and polyclonal antibodies are conventionally purified by affinity 
chromatography (206;207) using the highly specific nature of the interaction between 
antigen and antibody. The antigen is chemically immobilized to a solid support under 
conditions that retain its antibody-binding capacity. When serum is passed through a 
column containing the antigen attached to the support, only those antibodies with 
specific affinity for the antigen are bound. After washing, the bound antibodies are 
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eluted, thereby purifying them from the original sample. Although this method for 
recovering antibodies is potentially selective, rapid and simple, the recovery is often 
low (208). Appropriate conditions need to be determined to permit efficient 
purification of the desired antibodies without altering their native structure (209).  
 
Salmonella LPS consists of lipid A, which anchors LPS into the bacterial membrane, 
linked to the 3-deoxy-D-manno-octulosonic acid (KDO) terminus of the conserved core 
oligosaccharide region, and the OAg chain is attached to the core oligosaccharide. The 
OAg chain is the immunodominant portion and extends as a repeating polymer from the 
end of the core region (210). The composition of the OAg chain varies between 
serovars. In S. Typhimurium, the OAg repeat (O:4,5) consists of a trisaccharide 
backbone, with a branch of abequose, usually O-acetylated at C-2, which confers 
serogroup specificity (factor 4,5) (Figure 6.1 A) (211). 
 
Since LPS is an endotoxin, LPS detoxification is usually performed by acetic acid 
hydrolysis or by hydrazinolysis (212), with the former commonly preferred as it retains 
the O-acetyl groups along the OAg chain. Acid hydrolysis cleaves the labile linkage 
between Lipid A and KDO leaving the OAg chain attached to the core region (Figure 6.1 
A). Many approaches have been used to bind LPS or detoxified OAg from various 
bacteria to resins for use in affinity purification and, despite the high toxicity, CNBr -
activated resin has been the most commonly used (213;214). Girard and Goichot 
attached LPS to an aminohexyl-Sepharose resin by activation with benzoquinone (215), 
while Fox and Hechemy tested epoxy-activated resin for the attachment of Escherichia 
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coli LPS (216). The bound LPS showed low antibody binding capacity, which may be due 
to limited availability of antibody-binding sites on LPS resulting from steric hindrance 
and/or partial hydrolysis as a result of the alkaline pH used for the LPS coupling to the 
resin.  
 
For anti-NTS OAg antibody purification, affinity columns are not commercially available, 
and as a consequence we had to develop our own process for purifying antibodies to 
this antigen. We compared two alternative strategies for inserting hydrazide groups 
into the OAg of S. Typhimurium prior to linking to commercially available N-
hydroxysuccinamide (NHS)-Sepharose resin. The resulting affinity columns were tested 
for their ability to isolate antibodies from human serum against the OAg  and core of 
LPS from S. Typhimurium D23580, a characteristic invasive African isolate of NTS 
(217). 
 
6.2 OBJECTIVES 
The aim of this project was to develop a method to isolate antibodies specific to the OAg 
of Salmonella Typhimurium from human serum. Since commercial affinity columns are 
not available, we tested two different chemistries to identify the best method for linking 
the OAg and oligosaccharide core from S. Typhimurium to the resin to produce reusable 
affinity columns. Antigen binding and elution buffers were optimised to ensure the 
highest yield of functional specific antibodies were obtained, which could be used for 
further assays to identify their role in cell-mediated immunity to NTS. 
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6.3 RESULTS 
6.3.1 PURIFICATION OF O-ANTIGEN  
The LPS of Salmonella comprises lipid A, which is attached to a core oligosaccharide, 
which in turn is linked to an OAg chain composed of repeating sugar units (Figure 6.1). 
In order to purify antibodies to the OAg of Salmonella, we first needed to separate OAg 
and the core oligosaccharide from lipid A so that it can be activated and attached to the 
resin. Salmonella Typhimurium D23580, a characteristic invasive Malawian NTS isolate 
was used as a source of LPS. The OAg was purified following a method develo ped at 
Novartis Vaccines Institute for Global Health (NVGH), Siena, Italy. The purification and 
subsequent characterisation were performed by Francesca Micoli and Massimiliano 
Gavini at NVGH. The purification uses acetic acid hydrolysis of Salmonella fermentation 
culture to remove lipid A and release OAg into the supernatant, which can then be 
recovered by centrifugation, and impurities such as proteins and nucleic acids removed 
by filtration. This method is preferred to other methods that require hot pheno l LPS 
extraction and LPS detoxification (158;202;212). 
 
The resulting purified OAg attached to the oligosaccharide core contained 0.4% protein 
and 0.15% nucleic acid as determined by micro BCA. The chromogenic kinetic limulus 
amoebocyte lysate assay was used to measure the endotoxin level which was <0.01 
UI/µg.  HPLC-SEC analysis was used to estimate the molecular size distribution of OAg 
populations and identified the presence of two main populations with different average 
MW, with an average number of repeating units per OAg chain of 71 and 25. KDO  
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Figure 6.1 Structure of S. Typhimurium LPS.  
The structure of the S. Typhimurium OAg chain linked to the core region after acetic 
acid hydrolysis. Acid hydrolysis removes Lipid A leaving the OAg chain attached to the 
core region and the KDO group of the core region exposed.  
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quantification using HPLC-SEC confirmed the presence of one KDO per OAg chain. A 
TNBS assay which is used for total NH2 groups quantification, confirmed that the 
purified OAg contained 24.1% NH2 groups which can react with adipic dihydrazie 
(ADH) to form a stable bond between linker and antigen.  
 
6. 3. 2 AC TIV ATI ON O F PURIFI ED O -ANTI GEN  WI TH ADH AN D C OUPLI NG 
TO NHS-SEPHAROSE COLUMN 
To produce an affinity column the antigen needs to be linked to the resin to form a 
surface to which the antibodies in the serum can bind and be eluted from. Since the 
purified OAg and core cannot bind directly to the resin, it first needs to react with 
another compound which can act as a linker between the antigen and resin and 
facilitate binding of OAg to the commercial NHS –Sepharose resin. We used adipic 
dihydrazide (ADH) as a linker as it is a symmetrical molecule with two hydrazide 
groups:  one group can react with the ketone or aldehyde groups of the OAg and the 
other is able to react with N-hydroxy succinamide groups on the resin thus linking the 
antigen to the resin.  
 
Two different chemistries were used for inserting reactive hydrazide groups into the 
OAg prior to linking to commercially-available NHS-Sepharose. For the first method, the 
carbonyl group of the KDO sugar at the end of the core region which was exposed after 
acetic acid hydrolysis and removal of lipid A, was linked through reductive amination to 
the NH2 group of one ADH molecule, with the formation of an amine linkage. This 
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produced OAg-ADH, with one ADH molecule attached at the end of the core region of 
the OAg chain, thus not modifying the OAg chain (Figure 6.2 A). For the second method, 
OAg underwent an oxidative step with sodium metaperiodate prior to activation with 
ADH. The oxidation with sodium metaperiodate produces aldehyde groups along the 
length of the OAg chain which can then react with the NH2 group of ADH by reductive 
amination (Figure 6.2 B). The resulting OAgoxADH chain is modified with multiple ADH 
linkers introduced along the polysaccharide chain. Once the ADH had been linked to the 
OAg to produce OAgADH or OAgoxADH, the activated OAg-core was applied to 
commercial NHS-Sepharose columns to form an affinity matrix. In theory, the presence 
of more than one ADH linker per OAg chain in OAgoxADH could favour the OAg binding 
to the NHS-Sepharose, but in fact 3.7 mg of OAgoxADH and 4.3 mg of OAg-ADH were 
linked per ml of resin for each column. The resulting affinity columns will, in theory 
bind antibodies specific to the O-antigen and core polysaccharide from human serum, 
allowing purification of antibodies to the core as well as the O-antigen. 
 
6.3.3 TESTING ANTIGENIC INTEGRITY OF ACTIVATED O-ANTIGEN 
To determine if the hydrolysis and subsequent activation of OAg with ADH had 
impaired the antigenic structure of the OAg, the two affinity columns we had prepared 
were tested using a commercial preparation of purified polyclonal rabbit anti-
Salmonella Typhimurium O:4,5 antibodies. 300 µl of the O:4,5 antibody preparation 
(with an antibody concentration corresponding to 1666 ELISA units) was applied to an 
NHS-Sepharose column with 4.3 mg OAgADH linked and also to an NHS-Sepharose  
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Figure 6.2 Reaction schemes for production of activated OAg. 
Reaction scheme for OAg-ADH: the ketone group of the terminus KDO is linked to ADH 
by reductive amination (A). Reaction scheme for OAgoxADH: diol groups are oxidised to 
aldehyde groups by NaIO4. These aldehyde groups can then react with ADH by reductive 
amination (B). 
A 
B 
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column with 3.7 mg of OAgoxADH attached. The recovery of antibody in the flow 
through, washes (containing unbound antibody) and eluates were quantified by ELISA 
using plates coated with purified S. Typhimurium LPS. 92% of the applied antibodies 
bound to the OAgADH column (Figure 6.3 A) and 96% bound to the OAgoxADH column 
(Figure 6.3 B), with the remaining applied antibodies detected in the flow through or 
wash fractions. 89% of the bound anti-Salmonella antibodies were successfully eluted 
from the column using 0.1M glycine, 0.1 M NaCl pH 3 as the elution buffer. 90% of the 
antibodies which were bound to the OAgoxADH column were also eluted using the same 
buffer. The high percentages of purified anti-Salmonella Typhimurium rabbit antibodies 
which bound to the resins confirmed that the purification and activation of OAg had not 
affected the antigenic structure of the OAg and that the prepared columns are suitable 
for antibody purification.  
 
6.3.4 PURIFICATION OF ANTIBODIES FROM HUMAN SERUM 
The main aim of this chapter is to purify antibodies from serum taken from HIV -
uninfected and HIV-infected African adults. Therefore, once we had confirmed the 
functional antigenic integrity of both activated OAg-NHS-sepharose columns, we tried to 
purify anti-OAg antibodies from human serum. Serum from a healthy, HIV-uninfected 
adult was treated with ammonium sulphate to precipitate the proteins and to reduce 
the presence of contaminants which could interfere with the interactions between the 
immobilised OAg and the corresponding polyclonal antibodies.  
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Figure 6.3 Activated OAg from S. Typhimurium D23580 coupled to NHS-Sepharose 
can reversibly bind antibody.  
ELISA profile for the binding and elution of anti-Salmonella Typhimurium O:4,5 IgG 
antibody from an OAg-ADH (A) and OAgoxADH NHS-Sepharose column (B). 300 µl of 
anti-Salmonella Typhimurium O:4,5 rabbit antiserum (Biorad), with an antibody 
concentration corresponding to 1666 ELISA units, was applied to the column (load). 
Flow through (FT) containing unbound antibody was collected, and the column washed 
with 6 ml PBS (W1-3), followed by 6 ml 50 mM NaPi, 500 mM NaCl pH 7.2 (W4-6). 
Antibody was eluted with 5 ml 0.1 M glycine, 0.1 M NaCl pH 3 in 500 µl fractions (E1-
10). All fractions were collected and the concentration of anti-LPS IgG antibody in each 
fraction was tested by ELISA. Reciprocal of concentration of antibody giving an OD of 1 
at λ 405nm is plotted against column fraction collected. Data are representative of two 
experiments. 
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300 µl of the resulting serum protein solution (with an antibody concentration 
corresponding to 1000 ELISA units) were applied to the 2 columns. More than 75% of 
the antibodies in the applied serum protein solution bound to the each resin as shown 
by the low signal in both ELISAs for the flow through and wash fractions (Figure 6.4 A 
and B). Bound antibodies were again eluted with 0.1 M glycine, 0.1 M NaCl pH 3 and 
immediately neutralised with 2 M Tris pH 9. For the OAgADH column (Figure 6.4 A), 
eluting under these conditions, only 14% of the bound antibodies were detected in the 
eluate fractions in the ELISA. For the OAgoxADH column, the recovery of purified 
antibody decreased to 2% (Figure 6.4 B). It is difficult to ascertain if the modification of 
the OAg chain due to the attachment of multiple ADH molecules causes the observed 
decrease in antibody recovery as although the OAg chain modifications do not appear to 
affect the binding of antibody to the antigen, they may affect the release of antibody. 
To ensure that the purified antibodies we detected in the ELISA using plates coated with 
LPS were specifically against the OAg rather than other LPS components such as the 
lipid A or core oligosaccharide, we repeated the ELISA using plates coated with OAg 
purified from S. Typhimurium D23580. The same titres were obtained for the column 
fractions regardless of the antigen used to coat the plates, confirming that the antibody 
we were detecting were specific for the OAg. Since LPS is commercially available, plates 
for all the following ELISAs were coated using LPS rather than OAg.  
 
Despite the apparent binding of over 75% of human anti-LPS antibody to both columns, 
the recovery of these antibodies was very low, particularly with OAgoxADH.  Given that  
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Figure 6.4 Activated OAg from S. Typhimurium D23580 coupled to NHS-Sepharose 
can reversibly bind human polyclonal antibodies.  
ELISA profile for the binding and elution of human anti-Salmonella Typhimurium antibodies 
from an (A) OAg-ADH and (B) OAgoxADH NHS-Sepharose column. 300 µl of ammonium 
sulphate-precipitated human serum proteins with an anti-Salmonella Typhimurium antibody 
concentration corresponding to 1000 ELISA unites was applied to the column (load). Flow 
through (FT) containing unbound antibody was collected, and the column washed with 6 ml 
PBS (W1-3), followed by 6 ml 50 mM NaPi, 500 mM NaCl pH 7.2 (W4-6). Bound antibodies were 
eluted with 5 ml 0.1 M glycine, 0.1 M NaCl pH 3 in 500 µl fractions (E1-10). All fractions were 
collected and the concentration of anti-LPS IgG antibody in each fraction was tested by ELISA. 
Reciprocal of concentration of antibody giving an OD of 1 at λ 405nm is plotted against column 
fraction collected. Each panel represents data using one column and is representative of 3 
experiments. 
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the binding capacity of the OAgADH to NHS-Sepharose resin was similar to OAgoxADH, 
that it is easier to prepare as only one step is required for its synthesis compared to two 
steps for the OAgoxADH, and that the yield of purified antibody, although still low, is 
higher than that for the OAgoxADH, OAgADH was selected as the most suitable activated 
antigen for use for affinity purification of OAg antibodies.  
 
6. 3. 5 OPTIMI SING BIN DING OF AN TI BO DIES TO O AGADH -NHS -
SEPHAROSE COLUMNS 
Ammonium sulphate precipitation is commonly used to concentrate proteins within the 
serum although antibody is lost during this step. We investigated whether the binding 
of antibodies from non-precipitated whole serum was increased compared to the 
binding of antibodies in ammonium sulphate protein precipitate solution.  When whole 
serum (antibody concentration corresponding to 1425 ELISA units) which had not 
undergone ammonium sulphate precipitation, was applied to the OAg-ADH column 
(Figure 6.5 A), binding of antibody to the column was reduced, with only 50% of the 
applied antibodies binding to the resin. 15% of applied antibodies were lost in the flow 
through and 35% lost in the wash fractions. The recovery of purified antibodies was 
11%. We decided to use ammonium sulphate pre-treatment of the serum before 
applying the serum to the column as although antibodies are lost during the 
precipitation step, the overall binding of antibody was higher (75%, Figure 6.3 A).   
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Figure 6.5 Decreased binding of anti-OAg antibodies from non-precipitated human serum 
or from Vivaspin treated human serum preparation. 
300 µl of whole human serum (with an anti-OAg Salmonella Typhimurium antibody 
concentration corresponding to 1425 ELISA units), which had not been treated with ammonium 
sulphate prior to applying to the column, was loaded onto an OAgADH column (A). Flow 
through (FT) containing unbound antibody was collected, and the column washed with 6 ml 
PBS (W1-3), followed by 6 ml 50 mM NaPi, 500 mM NaCl pH 7.2 (W4-6). Bound antibodies were 
eluted with 3 ml 0.1 M glycine, 0.1 M NaCl pH 3 and collected in 500 µl fractions (E1-6). All 
fractions were collected and the concentration of anti-LPS IgG antibody in each fraction was 
tested by ELISA. Reciprocal of concentration of antibody giving an OD of 1 at λ405nm is plotted 
against column fraction collected. (B) 300 µl of ammonium sulphate precipitated human serum 
preparation (Load – with an antibody concentration of 1250 ELISA units) was passed through a 
10 kDa Vivaspin column to remove small impurities prior to loading on an OAgADH column. The 
solution post-Vivaspin treatment was applied to the column (Ab post-Vivaspin, 900 ELISA 
units), and flow through, washes and eluates collected as described above. 50 µl of the PBS 
solution which came through the Vivaspin column (PBS post-Vivaspin) was also tested in the 
ELISA to detect if antibody was lost during centrifugation. Data are from one experiment. 
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It is likely that the increased binding of antibodies in the protein preparation compared 
to whole serum is a consequence of removing impurities within the serum which can 
interfere with the antigen-antibody interaction. In an attempt to further remove small 
impurities from the protein preparation precipitated from human serum prior to 
applying to the column, the ammonium sulphate antibody precipitate was centrifuged 
using Vivaspin columns with a 10 kDa molecular weight cut-off. In theory, the resulting 
protein solution will contain less impurities and the binding of antibody to the OAg may 
be increased.  
 
To verify if any antibody was lost during the Vivaspin pre-treatment, we quantified the 
anti-LPS antibody titre in the serum before and after the Vivaspin treatment using an 
ELISA. A protein preparation from human serum, corresponding to 1250 ELISA units 
was applied to the Vivaspin column, and 900 ELISA units were quantified post-
treatment, confirming that 28% of the antibodies applied to the Vivaspin column were 
lost during this process (Figure 6.5 B). Antibodies were detected in the PBS solution 
which passed through the Vivaspin column, which accounts for some of the lost 
antibody. Some antibody probably remained attached to the membrane within the spin 
column. 
 
The OAgADH column was loaded with 300 µl of the protein precipitate which had 
undergone Vivaspin treatment (with an antibody concentration corresponding to 900 
ELISA units) and incubated overnight at 4°C. The column was washed to remove any 
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unbound antibody and 8% of the bound antibodies were eluted with 0.1 M glycine, 0.1 
M NaCl, pH 3. Given that the binding of antibody was around 75%, which was the same 
as the binding for antibodies which had not undergone Vivaspin pre-treatment (Figure 
6.3 A), that the yield was not enhanced, and that 28% of the antibodies were lost during 
the Vivaspin pre-treatment, then this is not a viable option.  
 
6. 3. 6 COMP ARIN G ELUTI ON OF AN TIBO DIES FR OM O AGADH C OLUMN  
WITH GLYCINE AT FOUR  DIFFERENT PH AS THE ELUTION BUFFER  
Although the recovery of anti-Salmonella Typhimurium rabbit antibodies from the 
OAgADH column was high using 0.1 M glycine, 0.1 M NaCl pH 3, the recovery of human 
anti-Salmonella antibodies under these conditions was low. Glycine at acidic pH is 
commonly used as an elution buffer (209). With the aim of improving the recovery of 
antibody from the OAgADH column, we tested 0. 1M glycine, 0.1 M NaCl at decreasing 
pH; pH 3, pH 2.8, pH 2.6 and pH 2.4.  
 
Four OAg-ADH NHS Sepharose columns were prepared, each with 3.5 mg of OAg-ADH 
linked to the resin, using the same batch of purified activated OAg. Precipitated human 
serum proteins from the same donor as in the previous experiments (with an antibody 
concentration corresponding to 1300 ELISA units), were applied to each column. The 
amount of antibody lost in the flow through and washes and detected in the eluates was 
quantified using an ELISA. The relative amount detected in the flow through and wash 
fractions was low, and comparable for all four columns confirming that antibody had 
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bound to all four columns (Figure 6.6 A-D). A different elution buffer was tested in a 
different column and the recovery of antibody compared. Elution with 0.1 M glycine, 0.1 
M NaCl pH 3 eluted 9% of the bound antibody (Figure 6.6 A), pH 2.8 removed 16% of 
the bound antibody (Figure 6.6 B), 12% was recovered in eluates using the buffer at pH 
2.6 (Figure 6.6 C) and pH 2.4 was optimal and eluted 26% of the bound antibodies 
(Figure 6.6 D).   
 
6. 3. 7 COMP ARIN G ELUTI ON OF AN TIBO DIES FR OM O AGADH C OLUMN  
WITH FOUR DIFFERENT ELUTION BUFFERS 
The ideal elution buffer efficiently releases the bound antibody, without causing lasting 
damage to the native structure of the protein. Depending on the interactions involved 
between the antibody, antigen and resin, buffers with different elution mechanisms are 
required. The use of 20% ethanol, an organic solvent, 100 mM Tris pH 9 as an alkaline 
buffer, 8 M urea as a denaturant and 4 M MgCl2 which raises the ionic strength of the 
solvent, with an accompanying weak chaotropic effect, were studied to identify if a 
buffer using an alternative elution mechanism to glycine at acidic pH could be more 
effective and increase the recovery of purified antibodies.  
 
Four OAg-ADH NHS columns were prepared, each with 3.5 mg from the same batch of 
activated OAg-ADH linked to the resin. Precipitated human serum proteins (with an 
antibody concentration corresponding to 1300 ELISA units), were applied to each 
column. The relative amount of unbound antibodies detected in the flow through and  
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Figure 6.6 Elution of anti-OAg antibodies from human serum using glycine with a 
decreasing pH. 
Four OAgADH-NHS-Sepharose columns were loaded with 300 µl of ammonium sulfate-
precipitated human serum proteins with an anti-Salmonella Typhimurium antibody 
concentration corresponding to 1300 ELISA units (load) and the flow through (FT) 
collected. Each column was washed with 6 ml PBS (W1-3), 6 ml 50 mM NaPi, 500 mM 
NaCl pH 7.2 (W4-6). 5 ml of different elution buffers were passed through each column: 
(A) 0.1 M glycine, 0.1 M NaCl pH 3, (B) 0.1 M glycine, 0.1 M NaCl pH 2.8, (C) 0.1 M 
glycine, 0.1 M NaCl pH 2.6 and (D) 0.1 M glycine, 0.1 M NaCl pH 2.4. Eluates were 
collected in 500 µl fractions (E1-10). Concentration of anti-OAg IgG antibody in each 
fraction was tested by ELISA using LPS coated plates. Reciprocal of concentration of 
antibody giving an OD of 1 at λ405nm is plotted against column fraction collected. Each 
panel represents data using one column and is representative of 3 experiments. 
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wash fractions was very low and comparable for all four columns (Figure 6.7 A-D). 4 M 
MgCl2 in 10 mM Tris pH 9 was the most effective of the four elution buffers tested, 
eluting 18% of the bound antibody (Figure 6.7 B). Ethanol (Figure 6.7 A) and urea 
(Figure 6.7 D) removed 7% of the bound antibodies from the column, and 100 mM Tris 
pH 9 removed only 1% of the bound antibody (Figure 6.7 C). None of the buffers tested 
were as effective as 0.1 M glycine, 0.1 M NaCl pH 2.4 in releasing bound anti-OAg 
antibodies from the OAgADH columns. 
 
6.3.8 SEQUENTIAL ELUTION OF ANTI-O-ANTIGEN ANTIBODIES 
Polyclonal antibodies can have different affinities for the same antigen and as a 
consequence different elution buffers may be required to disrupt the antigen-antibody 
interaction. Although we previously identified that glycine at pH 2.4 eluted the most 
bound antibody, MgCl2 also removed 18% of the antibody which was bound to another 
OAg-ADH column. Given that different antibodies may require different elution 
mechanisms, we determined if the recovery of human polyclonal anti-OAg antibodies 
could be increased by sequentially passing these two buffers through a column with 
anti-OAg antibodies attached. One OAg-ADH column was loaded with 300 µl 
precipitated human serum proteins (antibody concentration corresponding to 1300 
ELISA units) and the amount of antibody in the flow through, washes and eluates 
quantified using an ELISA. Bound antibodies were sequentially eluted with 10 ml 0.1 M 
glycine, 0.1 M NaCl pH2.4, and 10 ml 4 M MgCl2 in 10 mM Tris pH 7 with 6 ml PBS 
passed through the column between the two buffers. 28% of the bound antibody was  
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Figure 6.7 Ability of different buffers to elute bound anti-OAg IgG antibodies from 
human or rabbit serum.  
Four OAgADH-NHS-Sepharose columns were loaded with 300µl of ammonium sulfate-
precipitated human serum proteins with an anti-Salmonella Typhimurium antibody 
concentration corresponding to 1300 ELISA units (load) and the flow through (FT) 
collected. Each column was washed with 6 ml PBS (W1-3), 6 ml 50 mM NaPi, 500 mM 
NaCl pH 7.2 (W4-6). 5 ml of different elution buffers were passed through each column: 
(A) 20% ethanol, (B) 4 M MgCl2 in 10 mM Tris base pH 7, (C) 100 mM Tris base pH 9, 
and (D) 8 M urea pH 7 and the eluates collected and neutralised if required (E1-10). 
Concentration of anti-OAg IgG antibody in each fraction was tested by ELISA using LPS 
coated plates. Reciprocal of concentration of antibody giving an OD of 1 at λ  405nm is 
plotted against column fraction collected. Each panel represents data using one column 
and is representative of 3 experiments. 
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removed with 0.1 M glycine, 0.1 M NaCl pH 2.4 (Figure 6.8 B), but no further antibody 
was removed when MgCl2 was passed through the column, suggesting that when the 
two buffers were tested with separate columns, they were removing the same 
population of low affinity antibody.    
 
300 µl of commercial rabbit anti-O:4,5 Salmonella Typhimurium antibodies (antibody 
concentration corresponding to 1666 ELISA units) was applied to an OAg-ADH column, 
and sequential elution repeated, this time using all four buffers which have different 
elution mechanisms; MgCl2, ethanol, urea and glycine pH 2.4 (Figure 6.8 A). Eluting with 
3 ml 4 M MgCl2 in 10 mM Tris pH 7, only removed 44% of the bound antibodies. No 
antibodies were removed using 3 ml 8 M urea or 3 ml 20% ethanol, but elution with 3 
ml 0.1 M glycine, 0.1 M NaCl pH 2.4, a further 31% of the bound antibodies were 
recovered.   
 
6. 3. 9 DECR EASIN G THE AMO UNT OF ACTI VATED O-AN TI GEN  C OUPL ED 
TO NHS -S EPH ARO SE IN CREAS ES THE RECO VERY OF PURI FI ED 
ANTIBODY 
Despite using optimal binding and elution conditions, the recovery of purified antibody 
still remained low. One explanation for the low recovery of antibody could be due to an 
excess of OAg in the column, which could form multiple high and low affinity sites. 
Antibody from low affinity sites is more easily removed as the interaction between the 
antigen and the resin is easier to disrupt. Therefore, if the number of overall binding  
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Figure 6.8 Sequential elution of antibody.  
(A)300 µl of anti-Salmonella Typhimurium O:4,5 rabbit antiserum (Biorad), with an antibody 
concentration corresponding to 1666 ELISA units, was applied to the OAg-ADH column (load), 
flow through (FT) containing unbound antibody collected, and the column washed with 6ml 
PBS (W1-3), followed by 6 ml 50 mM NaPi, 500 mM NaCl pH 7.2 (W4-6). Bound antibody was 
sequentially eluted with 3 ml 4 M MgCl2 in 10 mM Tris base pH 7; then 3 ml 20% ethanol; 3 ml 8 
M urea pH 7; and 3 ml 0.1 M glycine, 0.1 M NaCl pH 3 with 6 ml PBS passed through the column 
between buffers. Eluates were collected in 500 µl fractions (E1-10). (B) OAg-ADH column was 
loaded with 300 µl precipitated human serum with an IgG antibody concentration 
corresponding to 1250 ELISA units, and bound antibody was eluted with 10 ml 0.1 M glycine, 
0.1 M NaCl pH 3, 6 ml PBS followed by 10 ml 4 M MgCl2 in 10 mM Tris base pH 7. Concentration 
of anti-OAg IgG antibody in each fraction was tested by ELISA using LPS coated plates. 
Reciprocal of concentration of antibody giving an OD of 1 at λ 405nm is plotted against column 
fraction collected. Each panel represents data using one column and is representative of 3 
experiments.  
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sites is reduced, in particular the number of high affinity binding sites, then maybe more 
antibodies will bind to the low affinity sites where they can be more easily eluted.  
 
To test this hypothesis, we investigated how varying the ratio of OAg coupled to NHS-
Sepharose in the column affects the recovery of purified antibodies. 3.5 mg OAg-ADH 
per ml of resin was immobilised on the columns used for previous extractions, and we 
investigated the effect of decreasing the amount of OAgADH immobilised on the column 
to 1 mg and 0.5 mg per ml of resin.  Equal amounts of precipitated human serum 
proteins were applied to three new columns which had 3.5 mg, 1 mg or 0.5 mg of 
OAgADH linked to NHS-Sepharose and the amount of antibody linked to the column 
quantified by detecting the amount of antibody detected in the flow through and 
washes. 80% of the loaded antibodies were retained for each column, regardless of the 
amount of OAg linked to the matrix (Figure 6.9 A-C). 0.1 M glycine, 0.1 M NaCl pH 2.4, 
which we had verified was the most effective elution buffer, was used to elute bound 
antibody. 26% of the antibody bound to the 3.5 mg OAgADH column were eluted 
(Figure 6.9 A), and the recovery of purified antibody increased to 51% for the column 
with 1 mg OAgADH attached to the resin (Figure 6.9 B). The yield decreased to 19% for 
the column with the lowest amount of OAgADH linked (Figure 6.9 C). This indicates that 
the antibody-antigen ratio is an important factor for determining reversible antibody 
interactions. 
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Figure 6.9 Variation in amount of activated OAg immobilised to NHS-Sepharose affects 
recovery of bound antibody from affinity columns. 
300 µl ammonium sulfate-treated human serum containing anti-Salmonella Typhimurium 
antibodies corresponding to 1200 ELISA units, was applied to three OAg-ADH columns each 
with varying concentration of OAg-ADH linked to 1 ml NHS-Sepharose: (A) 3.5 mg/ml, (B) 1 
mg/ml, (C) 0.5 mg/ml and the flow through (FT) was collected. Each column was washed with 6 
ml PBS (W1-3), 6 ml 50 mM NaPi, 500 mM NaCl pH 7.2 (W4-6) and bound antibody was eluted 
with 5 ml 0.1 M glycine, 0.1 M NaCl pH 2.4 (E1-10). Concentration of anti-OAg IgG antibody in 
each fraction was tested by ELISA using LPS coated plates. Reciprocal of concentration of 
antibody giving an OD of 1 at λ 405nm is plotted against column fraction collected. Each panel 
represents data using one column and is representative of 3 experiments. 
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6. 3. 10 PURIFIC ATION  OF AN TI -O -ANTI GEN ANTI BODI ES  FROM HIV -
INFECTED MALAWIAN ADULT SERUM 
The main aim of this project was to develop a method which could be used to affinity 
purify anti-OAg antibodies from various human serum to enable further 
characterisation of the role of these antibodies in cell-mediated immunity to NTS. All of 
the method development and optimisations were performed using serum from a 
healthy HIV-uninfected adult, which was known to contain antibodies to the LPS of 
Salmonella Typhimurium D23580 as this is in plentiful supply allowing the same sera to 
be used for method optimisation and comparison of modifications. The maximum yield 
we had obtained following all possible optimisations was 51% with this serum (Figure 
6.9 B).  
 
We confirmed that the developed method was applicable to other sera by applying a 
protein precipitation solution of serum taken from a HIV-infected African adult. Anti-
Salmonella Typhimuirum OAg IgA and IgM as well as IgG were removed from the serum, 
confirming that the produced columns are not isotype selective and are able to remove 
IgG, IgA and IgM antibodies specific to the OAg. The percentage of IgA eluted was 34% 
(Figure 6.10 B) and 26% for IgM (Figure 6.10 C). The recovery of IgG against the OAg 
was increased to 58% for this serum (Figure 6.10 A). This serum has a higher anti-LPS 
antibody titre compared to the HIV-uninfected serum which was used for all of the 
method developments, which may contribute to the higher yield of purified antibody.  
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Figure 6.10 Purification of IgG, IgA and IgM antibodies to OAg of S. Typhimurium from a 
HIV-infected African adult serum.  
ELISA profile for the elution of human anti-S. Typhimurium antibodies from serum from a HIV-
infected African adult. 300 µl of ammonium sulphate-precipitated human serum proteins with 
an anti-Salmonella Typhimurium antibody concentration corresponding to 10000 (IgG) ELISA 
units was applied to an OAgADH column (load). Flow through (FT) containing unbound 
antibody was collected, and the column washed with 6ml PBS (W1-3), followed by 6 ml 50 mM 
NaPi, 50 mM NaCl pH 7.2 (W4-6). Bound antibodies were eluted with 10 ml 0.1 M glycine, 0.1 M 
NaCl pH 2.4 in 500 µl fractions (E1-20). All fractions were collected and the concentration of 
anti-LPS IgG (A), IgA (B) or IgM (C) antibody in each fraction was tested by ELISA for antibody 
to LPS. Reciprocal of concentration of antibody giving an OD of 1 at λ 405nm is plotted against 
column fraction collected. Each panel represents data using one column and is representative of 
5 experiments.  
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6.4 DISCUSSION 
One of the overall aims of this PhD is to study the role of antibody to Salmonella in cell-
mediated immunity in the context of HIV-infected adults. High titres of antibodies 
against the OAg of Salmonella Typhimurium have been observed in a subset of HIV-
infected adults in Malawi and these have been shown to inhibit killing by complement 
(61). To enable further characterisation of the potential opsonic role of  these antibodies 
in cell-mediated immunity to NTS we needed to isolate them from human serum. Since 
commercial columns do not exist, we developed a new approach to affinity purify these 
antibodies.   
 
We successfully coupled purified activated OAg from invasive African S. Typhimurium 
D23580, to NHS-Sepharose using ADH as a linker, to produce an affinity column.  
Insertion of hydrazide groups onto the OAg was carried out using two different 
procedures and resulted in the cross-linking of purified activated O-Ag to an N-
hydroxysuccinamide matrix. In one case (OAgADH), one OAg chain was linked via the 
KDO group at the end of the core region to a single ADH molecule. This method does not 
alter the available epitopes along the saccharide chain. The other immobilised antigen, 
OAgoxADH, underwent prior oxidation resulting in multiple ADH molecules linked to 
the OAg chain, potentially enhancing the binding capacity of the OAg to the NHS-
Sepharose but also modifying the OAg chain structure.  Since the OAg remains attached 
to the oligosaccharide core, the antibodies which are purified from the human serum 
will contain antibodies targeting the core as well as antibodies specific for the OAg. 
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One of the main caveats when selecting and producing an affinity column is that  
modification of the antigenic structure often occurs during activation or coupling of the 
ligand to the matrix, and the affinity of an antigen for the corresponding antibody is 
frequently reduced (216). Both OAgADH and OAgoxADH columns bound more than 
90% of the applied commercial anti-Salmonella O:4,5 rabbit antiserum and more than 
75% of the polyclonal antibodies from human serum, suggesting that the acid 
hydrolysis used to purify OAg and activation with ADH had not altered the antigenic 
determinants present on the OAg chain. Binding of antibodies in the human serum to 
the resin could not be improved by using whole serum or precipitated human serum 
proteins which had passed through a Vivaspin column to remove small impurities. Both 
resins gave a similar high recovery of commercial rabbit anti-Salmonella O:4,5 
antibodies. However, when human serum was applied to the resins, the recovery of 
antibodies was lower than that observed for the rabbit antiserum. The yield of human 
purified antibody was higher for the OAgADH column compared to the OAgoxADH 
column, and consequently this OAg activation method is preferred.  
 
Human serum is polyclonal and contains many different antibodies which recognize and 
bind different epitopes on the same antigen with different binding affinities. Such 
antigen-antibody binding involves many weak interactions, including hydrogen bonds, 
van der Waals forces, ionic and hydrophobic interactions (218-220). Therefore effective 
elution of polyclonal antibodies may require many different elution buffers (209;221). 
Glycine at acidic pH is commonly used to elute antibodies from antigen-affinity columns 
and for our columns, 0.1 M glycine, 0.1 M NaCl pH 2.4 was the most effective elution 
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buffer. Other elution buffers such as 20% ethanol to investigate the effect of an organic 
solvent, 100 mM Tris pH 9 as alkaline buffer, 8 M urea as a denaturant and 4 M MgCl2 to 
raise the ionic strength of the solvent, with an accompanying weak chaotropic effect 
were tested in an attempt to increase the recovery, and MgCl2 removed 18% of the 
bound antibody. When combined sequentially with glycine, MgCl2 was unable to elute 
any remaining bound antibody suggesting that both buffers remove the same sub-
population of antibody.  
 
It is also possible that the majority of antibodies applied to the column could have been 
successfully removed following elution under acidic conditions, but that all of the eluted 
antibodies were not fully renatured and therefore no longer able to bind to LPS coated 
plates in the ELISA. However, Narhi et al confirmed that antibodies can refold to their 
native conformation following elution with glycine at a low pH provided they are 
neutralised and dialysed immediately (221). We did not investigate the effect of the 
elution buffers on their conformation and so although we neutralised and dialysed the 
eluted antibodies immediately, we cannot exclude than an irreversible denaturation 
occurred.  We can only presume that the remainder of the antibodies which are not 
accounted for in the flow through, washes or eluates remain bound to the OAg-resin and 
could not be eluted using any of the conditions tested.  
 
We verified that the ratio of antigen to antibody affected antibody elution. Reduction in 
the amount of OAgADH coupled to the resin from 3.5 mg to 1 mg per ml of resin, 
doubled the recovery of purified antibody and decreasing the concentration of linked 
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OAgADH further to 0.5 mg per ml of resin decreased the recovery, verifying that the 
ratio of antigen to antibody affected antibody elution. Differential loading of the antigen 
on the resin could result in different OAg chain conformations and a different exposure 
of the epitopes and/or determine a different interaction with the corresponding 
antibodies.  
 
The present study describes the successful coupling of OAg from S. Typhimurium to 
NHS-Sepharose resin to produce an affinity matrix that is capable of purifying specific 
IgG, IgA and IgM antibodies from polyclonal human serum. The columns tested were 
used at least ten times, with no deleterious effect on the recovery of antibodies and it 
would be interesting to investigate further if this process could be increased to a large 
scale purification of antibodies against both the OAg from Salmonella and other 
bacterial polysaccharides. Since the antibodies which were removed from the serum 
could be antibody against the core region, as well as the OAg, the purified antibody 
could be absorbed with the core oligosaccharide to remove these antibodies and leave 
anti-OAg specific antibody in the eluates prior to use.  
  
6.5 CONCLUSIONS 
We developed a method to purify anti-S. Typhimurium D23580 antibodies from human 
serum using affinity chromatography. Purified Salmonella Typhimurium OAg, attached 
to the core oligosacccharide was activated with ADH via two different chemistries 
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before linking to NHS-Sepharose resin. One method modified the OAg chain 
(OAgoxADH) and the other method did not alter the chain (OAgADH). Both columns 
reversibly bound polyclonal rabbit antibodies, with high recovery of purified antibody. 
OAgADH was the preferred column for extractions from human serum as the OAg chain 
is not modified. Although 75% of antibodies in precipitated human serum which was 
applied to the column bound, the initial recovery of purified antibody was low. Different 
elution buffers were tested and 0.1 M glycine, 0.1 M NaCl pH 2.4 removed the most 
functional antibody. Using two buffers sequentially did not increase the recovery of 
antibody. Optimal yields were obtained by decreasing the amount of activated OAg per 
ml of resin from 3.5 mg to 1 mg OAgADH. The highest recovery of anti-S. Typhimurium 
OAg-core antibody from a HIV-uninfected serum was 51% and 58% for HIV-infected 
adult serum which has a higher anti-LPS titre. The purified antibodies can be used to 
further study the role of anti-OAg antibodies in immunity to NTS.     
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CHAPTER 7. 
 OPSONIC ANTIBODY AND IMMUNITY TO NTS IN MALAWIAN 
CHILDREN WITH BACTERAEMIA 
 
7.1 INTRODUCTION 
NTS are a major cause of invasive bacterial disease in African children (18-20). In 
Malawi, NTS are the commonest cause of bacteraemia (21), with case fatality rates of 
24% in children (28;199). NTS bacteraemia is associated with malnutrition, young age, 
HIV infection and malaria (18;20;21) in African children. NTS bacteraemia mainly 
occurs in children aged 4-24 months (20;49). Few cases of NTS bacteraemia were 
observed in children less than 4 months, suggesting that maternal antibody protects 
during this phase and that as levels of maternal antibody decrease, children are 
increasingly susceptible to bacterial infection (50). It has previously been shown that a 
lack of antibody in healthy young Malawian children’s sera corresponded with absent 
bactericidal killing (50) and reduced killing by peripheral blood cells (151) .  
 
In order to develop a vaccine for NTS for use in Africa, an improved understand ing of 
the acquisition of antibody in response to NTS infection and the protective efficacy of 
such antibody is required. In this chapter we investigated peripheral blood cell killing of 
an African isolate of Salmonella after opsonisation with antibody from Malawian 
children with NTS bacteraemia.  
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7.2 OBJECTIVES 
The aim of this work was to study opsonic antibody to NTS in Malawian children with 
NTS bacteraemia. Using serum from Malawian children infected with NTS and a follow-
up sample four weeks post infection, we investigated whether antibody in these 
children can facilitate phagocytic cell-mediated killing of NTS.  
 
7.3 RESULTS 
7.3.1 STUDY PARTICIPANTS 
Sera were available for 156 children aged 0 to 14 years who presented to QECH, 
Blantyre, Malawi with NTS bacteraemia between 1st January 2006 and 31st December 
2006 and whom had been recruited into a prospective study of NTS bacteraemia in 
African children. Invasive Salmonella infection was confirmed by blood culture. Blood 
was venesected from the children upon recruitment and serum prepared from the 
clotted blood and stored at -80⁰C (acute samples). Serum samples were also prepared 
from children in convalescence 4 weeks after the onset of Salmonella infection 
(convalescent samples), and stored at -80⁰C. 119 acute and 119 convalescent samples 
were available for assays to assess the opsonic activity of antibody in cell-mediated 
killing assays and anti-Salmonella antibody level analysis, and for 82 children paired 
acute and convalescent samples were available.  
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7. 3. 2 SALMON ELLAE OP S ONIS ED WI TH ACUTE AN D C ONV AL ES CENT 
SER A FROM SOME CHILDR EN C OUL D NO T BE KILL ED BY P ERIPHER AL  
WASHED ADULT BLOOD CELLS 
We first investigated if S. Typhimurium D23580, a representative invasive Malawian 
isolate of NTS, opsonised with serum from children with NTS bacteraemia (acute sera) 
and sera taken 4 weeks after admission (convalescent sera) could be killed by blood 
cells. Washed peripheral blood cells from a healthy adult donor were inoculated with 
opsonised Salmonellae at a concentration of 1 x 105 cfu/ml at 37⁰C, and viable 
Salmonellae numbers were determined after 45, 90 and 180 min.  
 
Salmonellae opsonised with 76% (90/119) of the acute sera underwent at least a 1 log10 
kill after 180 min (median kill -2.0, range 1.7 to -3.0) (Figure 7.1), which is designated 
as the ‘normal kill’ in this assay when using sera from healthy HIV-uninfected adults 
which contains antibody and complement. Bacterial growth or a kill of less than 1 log10 
was observed with 24% (29/119) of the acute sera tested. Opsonisation of Salmonellae 
with 61% (73/119) of the convalescent sera resulted in a 1 log10 kill or greater by 
washed peripheral blood cells, with killing of Salmonella absent or impaired when 
opsonised with 39% (46/119) of the convalescent sera (Figure 7.1). Blood cell killing of 
Salmonellae opsonised with convalescent sera (median kill -1.1, range 1.9 to -3) was 
significantly reduced compared to acute sera (median kill -2.0, range 1.7 to -3, Mann-
Whitney U test p=0.0002). The acute sera were from children presenting to QECH with 
NTS bacteraemia, almost all of whom had commenced antibiotic treatment prior to 
venesection, and so the increased kill observed when opsonising with acute sera may be  
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Figure 7.1 Blood cell killing of S. Typhimurium D23580 opsonised with acute and 
convalescent sera. 
In vitro killing of S. Typhimurium D23580 opsonised with 119 acute sera from 
Malawian children with NTS bacteraemia, and 119 convalescent sera from children 4 
weeks post-infection. Blood cell killing of convalescent sera was significantly reduced 
compared to killing of acute sera (MW test p=0.0002). Initial concentration of 
Salmonellae is 1 x 105 cfu/ml, with log change in Salmonellae concentration after 180 
min incubation with washed adult peripheral blood cells shown. Negative values show a 
decrease in viable Salmonellae and positive values show an increase in viable 
Salmonellae compared with the initial starting concentration. Each circle represents 
killing of Salmonella opsonised with serum from one child. The dotted horizontal line 
indicates normal blood cell killing of Salmonella opsonised with healthy adult Malawian 
serum and the solid black horizontal lines indicate median kill.  
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due to the antibiotics killing the bacteria. More than 90% of the children were taking 
gentamicin, ciprofloxacin or ceftriaxone at the time that their acute blood sample was 
taken. S. Typhimurium D23580 is sensitive to gentamicin, ciprofloxacin, ceftriaxone and 
is resistant to ampicillin, chloramphenicol and cotrimoxazole.   
 
 
7. 3. 3 EFF EC T O F AGE ON C ELL -M EDI ATED IMMUNITY TO N TS IN  
BACTERAEMIC CHILDREN 
We next investigated if an immature immune system could explain why some sera  from 
children with acute NTS bacteraemia and children in convalescence could not kill S. 
Typhimurium D23580. Similar to previous studies of NTS bacteraemia in children, of 
the 119 children recruited to QECH over a one year period with acute NTS bacteraemia, 
77% were under 36 months, and the median age was 16 months. Only 8 acute sera and 
9 convalescent sera were from children aged less than 4 months old, which is consistent 
with the observation of MacLennan et al (50) that maternal antibody protects from 
birth to 4 months of age and that once maternal antibody titres wane, a peak in cases of 
NTS bacteraemia is observed.  
 
Although there was no correlation between age and killing of Salmonellae opsonised 
with acute (Spearman rs=0.06, p=0.49, 95% CI -0.12 to 0.24) (Figure 7.2 A) or 
convalescent sera (Spearman rs=-0.12, p=0.17, 95% CI -0.30 to 0.06) (Figure 7.2 B) after 
180 min by washed blood cells, 59% (17/29) of the acute sera and 70% (32/46) of the  
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Figure 7.2 No correlation between age and impaired killing of Salmonella 
opsonised with acute and convalescent sera. 
There was no correlation between killing of Salmonellae opsonised with acute sera (A) 
(rs = 0.06, 95% CI -0.12 to 0.24, p=0.49) or convalescent sera (B) (rs = -0.12, 95% CI -0.3 
to 0.06, p=0.17) by washed peripheral blood cells after 180 min and the age of the child 
from whom the serum was taken. Each circle represents killing of Salmonellae 
opsonised with serum from one child. The dotted horizontal line indicates normal blood 
cell killing of Salmonellae opsonised with healthy adult Malawian serum.  
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convalescent sera which were unable to induce cell-mediated killing of bacteria were 
from children under 24 months old. At this age, the children do not have a fully mature 
immune system which could account for why some of the acute and convalescent sera 
cannot kill Salmonella.  
 
7.3.4 HIV INFECTION AND BACTERAEMIC CHILDREN 
HIV infection is known to be associated with NTS bacteraemia in African children and 
adults (30). We assessed whether a lack of opsonic activity of some acute and 
convalescent sera was associated with HIV-co-infection. 47 of the acute sera were from 
children who were HIV-infected, but 75% (35/47) of these sera were able to induce a 
1.0 log10 kill of S. Typhimurium D23580. For the convalescent sera, 38 were from HIV -
infected children, with 50% (19/38) of these sera able to kill S. Typhimurium D23580. 
46% (12/26) of the acute sera and 41% (19/46) of the convalescent sera which were 
unable to facilitate blood cell killing of S. Typhimurium D23580 were from HIV-infected 
children. The median kill by sera from HIV-infected acute bacteraemic children was not 
significantly different compared to the median kill by sera from HIV-uninfected acute 
sera (median kill for acute HIV+ve -1.7 versus HIV-ve -2, Mann Whitney test p=0.48) 
(Figure 7.3 A). Again, the presence of antibiotics in the serum makes interpretation of 
this result difficult. However, for the convalescent sera, the median kill for HIV-infected 
serum was significantly lower than that for HIV-uninfected serum (-0.8 versus -1.4, 
Mann Whitney test p=0.03) (Figure 7.3 B).  
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Figure 7.3 Blood cell killing of S. Typhimurium D23580 opsonised with HIV-
infected acute and convalescent sera from African children with NTS bacteraemia. 
(A)Blood cell killing of Salmonellae opsonised with HIV-infected (HIV +ve) or HIV-
uninfected (HIV-ve) acute sera or, (B) HIV-infected/un-infected convalescent sera from 
Malawian children. Initial concentration of Salmonellae is 1 x 105 cfu/ml with change in 
viable Salmonellae shown after 180 min incubation with washed adult peripheral blood 
cells. Negative results show a decrease in viable Salmonellae. Each circle represents 
killing of Salmonellae opsonised with serum from one child. The dotted horizontal line 
indicates normal blood cell killing of Salmonellae opsonised with healthy adult 
Malawian serum and the solid black horizontal lines indicate median kill.   
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7. 3. 5 AN TI-SALMONELLA E AN TIBODY TI TR ES AND BLOO D -C ELL  
KILLING OF SALM ONELLAE OP SO NIS ED WITH AC UTE AND 
CONVALESCEN T CHILDREN’S SERA  
Antibody and complement are required for optimal cell killing of Salmonella (151), and 
therefore, the observed absence of killing of Salmonella opsonised with 24% of the 
acute and 39% of the convalescent sera could be the result of a lack of antibody or 
complement. We presume that complement remains functional in all of the sera, a s sera 
were optimally prepared and frozen at -80⁰C since separating from clotted blood. 
However, deposition of C3 by these sera on the surface of Salmonella Typhimurium 
D23580 was not tested, so we cannot confirm lack of complement deposition, or 
increased complement consumption, which can occur in sepsis, as an explanation for a 
lack of Salmonella killing by some of the acute and convalescent sera.  
 
To investigate if an absence of antibody against S. Typhimurium D23580 in some of 
these sera could explain the reduced killing, the binding of IgG, IgA and IgM to S. 
Typhimurium D23580 were quantified using flow cytometry. All antibody assays in this 
chapter were performed by Dr Esther Gondwe, in work prior to this PhD as part of a 
larger study on the role of bactericidal antibody in immunity to NTS in children with 
bacteraemia. The protective anti-Salmonella titres in the assay were set at 1.5 U, which 
has previously been found to be the threshold required for antibody-mediated killing of 
NTS (50). 84% (100/119) of the acute sera had anti-Salmonella IgG levels exceeding 1.5 
U, but 23/100 of these acute sera were not able to kill Salmonellae (Figure 7.4 A). 16% 
(19/119) of the acute sera had IgG titres less than 1.5 U, but Salmonellae opsonised with  
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Figure 7.4 Blood cell killing of S. Typhimurium D23580 and anti-Salmonella IgG, 
IgA and IgM levels in sera from Malawian children. 
In vitro killing of S. Typhimurium D23580 opsonised with serum from acute and 
convalescent sera by adult washed blood cells after 180 min compared with anti-
Salmonella IgG (A, B), IgA (C, D) and IgM (E, F) levels in the serum used to opsonise the 
bacteria. Each circle corresponds to serum from one child. Dotted vertical line 
corresponds to 1.5 U of antibody which is the threshold required to induce antibody-
mediated killing of bacteria and the dotted horizontal line indicates threshold of blood 
cell killing of Salmonellae opsonised with healthy adult Malawian serum.  
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13/19 of these sera were killed by peripheral blood cells. Killing of Salmonellae in the 
absence of sufficient IgG could be antibiotic-mediated. Salmonellae opsonised with 6 
sera which had less than 1.5 U IgG, also had less than 1.5 U of IgA and IgM and were 
unable to kill Salmonella, suggesting a lack of total anti-Salmonella antibody in these 
sera. 
 
Anti-Salmonella IgG levels less than 1.5 U were present only in 3 (2.5%) of the 119 
convalescent sera, but opsonisation with 2 of these sera resulted in killing of 
Salmonellae by peripheral blood cells (Figure 7.4 B). IgG levels exceeding 1.5 U were 
detected in 97.5% (116/119) of the convalescent sera tested, but Salmonellae 
opsonised with 45 of these sera were not killed by peripheral blood cells. There was a 
weak correlation between anti-Salmonella IgG titre for the acute sera (rs =0.17, p=0.05, 
95% CI -0.01 to 0.34) but no correlation for the convalescent sera (rs =0.01, p=0.86, 
95% CI -0.16 to 0.20) and killing by washed peripheral blood cells. 
 
59% (70/119) of the acute children’s sera had IgA levels above the 1.5  U protective 
threshold. 19/70 of these failed to induce blood cell killing of Salmonella (Figure 7.4 C). 
41% (49/119) of the acute sera had anti-Salmonella IgA levels less than 1.5 U. 
Salmonellae opsonised with 39/49 of these sera were killed by peripheral blood cells 
which could be the result of antibiotic-mediated killing or IgG inducing cell-mediated 
killing of the bacteria. 6 of the 10 sera which had less than 1.5 U of IgA, also had less 
than 1.5 U of IgG anti-Salmonella antibody which is likely to explain why these sera 
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were not able to induce blood cell killing of S. Typhimurium D23580.  For the 
convalescent sera (Figure 7.4 D), only 8 (7%) sera had IgA levels less than 1.5 U. All 8 of 
these sera had >1.5 U of IgG and IgM so it is not clear why 2 of these sera were not able 
to kill Salmonella. No correlation between S. Typhimurium IgA level and killing by blood 
cells was observed for the groups of acute (rs =0.06, p=0.37, 95% CI -0.12 – 0.24) or 
convalescent (rs =0.14, p=0.58, 95% CI -0.23-0.13) sera. This is to be expected as IgA is 
not opsonic and consequently the presence of anti-Salmonella IgA antibody is unlikely 
to have an effect on cell-mediated killing of the bacteria. 
 
23% (27/119) of the acute sera had anti-Salmonella IgM titres less than 1.5 U, with 
blood cell-killing absent for 8 of these sera (Figure 7.4 E). 6 of these sera also had less 
than 1.5 U of IgG and the other 2 sera had borderline levels of IgG (1.84 U) which could 
explain the lack of blood cell-killing by these sera. Killing was also absent for 21 sera 
which had anti-Salmonella IgM titres more than 1.5 U. Only 3 convalescent sera had 
anti-Salmonella IgM titres below 1.5 U (Figure 7.4 F), and 2 of these 3 sera failed to 
induce blood cell killing of Salmonella, despite the presence of IgG. As for IgA, there was 
no correlation between anti-IgM levels and killing of Salmonellae opsonised with acute 
(rs =0.09, p=0.28, 95% CI -0.08 to 0.27) or convalescent (rs=-0.05, p=0.58, 95% CI -0.23 
to 0.13) sera by washed blood cells. This is to be expected as IgM cannot directly act as 
an opsonin itself since human phagocytes lack an FcR for IgM, but IgM can have an 
indirect opsonic effect through its enhanced ability to fix complement. 
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7. 3. 6 ANTI -S ALMONELLA  AN TI BO DY L EV EL S IN CR EAS E AF TER  
INFECTION 
The previous result suggested that anti-Salmonella antibody levels were increased for 
the convalescent phase sera compared to the acute phase sera. To confirm this, anti-
Salmonella IgG, IgA and IgM levels in the 82 paired sera which were available from 
Malawian children both at presentation with acute NTS bacteraemia and at 
convalescence were compared (Figure 7.5). The median anti-Salmonella IgG level for 
the 82 acute sera was four times lower than the median level in convalescence (53.69 U 
compared to 230.8 U, Mann-Whitney test p<0.0001). The median anti-Salmonella IgA 
levels were also significantly increased for the convalescent sera compared to the acute 
sera (median 43.49 U compared to 7.06 U, Mann-Whitney test p<0.0002). The same was 
found for anti-Salmonella IgM levels, with the median IgM level rising from 4.52 U for 
the acute sera to 151.2 U for the convalescent sera (Mann-Whitney test p<0.0001). 
These observations confirmed that, as expected, anti-Salmonella antibody levels 
increase after infection with Malawian isolates of NTS.  
 
7. 3. 7 BLO O D CEL L KILLING O F SALMONELLA  IS ENHANC ED WHEN  
OPSONISED WITH DILUTIONS OF ACUTE AND CONVALESCEN T SERA 
Following the previous observation that some sera were unable to induce cell-mediated 
killing of Salmonella despite the presence of high levels of anti-Salmonella antibodies, 
we investigated the effect of diluting antibody within the acute and convalescent sera 
on opsonisation and induction of cell-mediated clearance of the bacteria from the blood.  
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Figure 7.5 Anti-Salmonella antibody levels are elevated in convalescent sera 
compared to acute sera in children with NTS bacteraemia. 
Anti-Salmonella Typhimurium D23580 IgG, IgA and IgM levels in serum from 82 
Malawian children with NTS bacteraemia (acute) and 4 weeks after infection 
(convalescent) as assessed by flow cytometry, with median titre indicated with a black 
line.   
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Using a method we had previously optimised (see Chapter 4), Salmonellae were 
opsonised with 40% acute or convalescent sera, which was heat-inactivated to destroy 
endogenous complement and diluted 5 fold with PBS (dilution range 1:5 – 1:78,125) 
and 60% antibody-depleted fresh human serum as a complement source. 6 acute 
(Figure 7.6 A) and 6 convalescent sera (Figure 7.6 B) were first tested. When opsonised 
with undiluted serum, only 1 of the 6 acute sera induced over a 1 log 10 kill of S. 
Typhimurium, but when the sera were diluted 1:5 and supplemented with complement, 
all six effected at least a 1 log10 kill of Salmonellae by washed blood cells (Figure 7.6 A). 
When diluted to 1:25, killing was diminished for 2 sera. At a serum dilution of 1:125, kill 
was lost for 3 further sera with only one serum able to kill at 1:625, but this kill was lost 
at a serum dilution of 1:3125. For the 6 convalescent sera (Figure 7.6 B), only 2 of the 
sera when used undiluted effectively opsonised Salmonellae and induced a 1 log10 kill or 
greater by washed blood cells.  Salmonellae underwent at least a 1 log10 kill by blood 
cells when opsonised with complement and heat-inactivated sera diluted to 1:5 and 
1:25. At a dilution of 1:125, only 4 sera could sustain Salmonella killing, with 3 sera 
unable to kill at 1:625, with killing lost for the final serum at a dilution of 1:3125. 
 
These results indicate that blood cell killing can be enhanced when antibody is diluted. 
Those sera which were unable to induce cell-mediated killing when used undiluted as 
opsonins were able to kill when diluted. To determine if killing could be enhanced for 
all sera, all 119 acute (Figure 7.6 C) and 119 convalescent sera (Figure 7.6 D) were 
diluted and tested in the cell killing assay. 39% (35/90) of the acute sera that could  
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Figure 7.6 Blood cell killing of Salmonella opsonised with diluted children’s sera. 
Killing of S. Typhimurium D23580 opsonised with 60% antibody-depleted serum and with 40% 
diluted (1:5, 1:25, 1:125, 1:625, 1:3125, 1:15625) heat-inactivated acute (A) or convalescent (B) 
children’s serum as an antibody source. Log10 change in Salmonellae after 180 min plotted 
against 1/antibody dilution, with negative results showing killing of Salmonellae and positive 
results representing bacterial growth. Log10 change in Salmonellae observed at the maximum 
dilution of (C) acute or (D) convalescent heat-inactivated serum which induces at least a 1 log10 
kill of Salmonella by peripheral washed blood cells. Sera on the y axis show sera which could not 
kill when diluted and kill/growth when used undiluted as an opsonin. Log10 change in 
Salmonellae induced by blood cells with Salmonellae opsonised with whole (E) acute or (F) 
convalescent serum plotted against the maximum dilution of the heat-inactivated serum which 
induces a 1 log10 kill of Salmonella. Each circle represents data for serum from one child.  
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induce blood cell killing of Salmonella when whole serum was used to opsonise the 
bacteria, could not kill when diluted, even at dilutions as small as 1:5. 59% (17/29) of 
the acute sera which were unable to induce a kill when used whole as an opsonin could 
kill when diluted, but 12/119 of the sera could not kill when used whole or diluted. 6 of 
these sera had lacked IgG, IgA and IgM titres in the whole serum, so the inability to kill 
when diluted and supplemented with exogenous complement is likely due to the 
absence of anti-Salmonella antibody.  
 
83% (61/73) of the convalescent sera which could effect a 1 log10 blood cell kill of 
Salmonella when whole serum was used as an opsonin, could also kill when diluted 
(Figure 7.6 D). Absence of killing for the other 12 sera when diluted, again was likely to 
be due to insufficient antibody titres. For the 46 convalescent sera which were unable to 
facilitate killing when used undiluted, 26 were able to effect a 1 log10 kill when diluted, 
but 20 sera were unable to kill when used as a whole serum opsonin or when diluted 
and supplemented with human complement.  
 
The serum dilution range over which antibody could be diluted and still effectively 
opsonise bacteria was similar for both groups of sera, with killing of Salmonellae 
observed at serum dilutions of 1:5 to 1:15625 (Figure 7.6 C and D). One convalescent 
serum could still kill following dilution to 1:78,125. The highest dilution at which the 
sera could kill Salmonella correlated with whole serum killing for the acute (Figure 7.6 
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E) (Spearman rs =0.24, p=0.0070 95% CI 0.06 to 0.41) and convalescent sera (Figure 7.6 
F) (Spearman rs =0.23 p=0.01 95% CI 0.05 to 0.40).  
 
7. 3. 8 KILLIN G OF SAL MONELLA  OPS ONIS ED WITH DILU TED ANTI BODY  
BY P ERIPHER AL BL OO D CEL LS COMP AR ED WI TH AN TI-SALMONELLA  
ANTIBODY LEVELS 
We next investigated if the serum anti-Salmonella antibody levels correlated with the 
degree to which the sera could be diluted and still effect a killing of Salmonella. There 
was no correlation between anti-Salmonella IgG levels and the final dilution of serum 
which could still effect a -1 log10 kill when used to opsonise S. Typhimurium D23580 for 
the acute (rs = -0.14, p=0.12 95% CI -0.31 to 0.04) (Figure 7.7 A) or convalescent sera (rs 
=-0.03, p=0.67, 95% CI -0.22 to 0.14) (Figure 7.7 B). There was a negative correlation 
between the anti-Salmonella levels and the final dilution of sera which could still effect a 
-1 log10 kill when used as an opsonin for the acute IgA (rs = -0.22, p=0.02, 95% CI -0.38 
to 0.02) (Figure 7.7 C), acute IgM (rs =-0.24, p=0.006, 95% CI -0.41 to -0.06) (Figure 7.7 
E) and convalescent IgM (rs =-0.2, p=0.02, 95% CI -0.37 to -0.01) (Figure 7.7 F). No 
correlation was observed between convalescent IgA antibody titres and final dilution of 
sera (rs=0.04, p=0.65, 95% CI -0.14 to 0.22) (Figure 7.7 D).   
 
7.4 DISCUSSION  
NTS bacteraemia is a common cause of invasive disease in Africa. In this chapter we 
have reported 156 cases of paediatric NTS bacteraemia at QECH, Malawi in a 1 year  
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Figure 7.7 Anti-Salmonella antibody titre and maximum dilutions of sera able to 
effect Salmonella killing. 
Anti-Salmonella IgG (A and B), IgA (C and D), IgM (E and F) levels in each of the acute (A, 
C, E) and convalescent (B, D, F) children’s sera plotted against final dilutions of heat- 
inactivated serum which when supplemented with a human complement source could 
effectively opsonise Salmonella and induce a 1 log10 kill of Salmonella by washed adult 
peripheral blood cells. Each circle represents data for serum from one child.  
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period from 1st January 2006 to 31st December 2006 highlighting the frequency of NTS 
infection. In keeping with previous NTS studies in Malawi (18;50) 84% of the children 
presenting to hospital with NTS bacteraemia were under 3 years of age. Although age 
did not correlate with ability to induce cell-mediated killing of NTS in the cohort of 
children studied in this chapter, 59% of sera from children at acute presentation and 
70% of children in convalescence which were unable to kill Salmonella were under 24 
months. At this age, children have not reached full maturity of their immune system and 
may be unable to initiate a rapid successful immune response against invading bacteria.  
 
 
The availability of serum from Malawian children with acute NTS bacteraemia and at 
convalescence a month post-infection, provides a useful resource to study the 
acquisition of antibody during infection and how such antibody can kill Salmonella, as 
previous studies on immunity to NTS in African children have used sera from healthy 
children (50;151). The presence of antibiotics in the acute sera makes it difficult to 
ascertain the effect of blood-cell killing of Salmonella opsonised with acute sera. The 
increased kill effected by opsonisation with the acute sera is likely to be attributable to 
the effect of the antibiotics. Sera taken from children with NTS bacteraemia before 
administration of antibiotics would therefore be more informative. However, killing of 
Salmonella opsonised with acute sera could also be antibody-driven, as although it 
might be expected that children at acute presentation have no anti-Salmonella antibody, 
hence the reason they have NTS bacteraemia, they may actually have antibody as a 
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result of acute NTS infections, as the time of recruitment to the study follows an 
incubation and symptomatic period of infection prior to arrival at the hospital.  
 
The children were infected with a range of invasive NTS isolates and not S. 
Typhimurium D23580, and this may explain why some children’s sera were unable to 
kill S. Typhimurium D23580, because if the children were infected with S. Enteritidis 
and produce antibody to their infecting strain, then this may no t be protective against S. 
Typhimurium, in particular S. Typhimurium D23580. However, the majority of sera 
were able to effectively opsonise and activate blood cell killing of S. Typhimurium 
D23580, suggesting that in some cases the antibodies produced during infection with 
different strains of Salmonella are cross-protective targeting common antigens.  
 
It has previously been shown that serum from HIV-uninfected Malawian adults which 
contain anti-Salmonella antibody titres >1.5 U, facilitate a 2.0 log10 kill of Salmonella by 
washed blood cells (151) . All except 3 convalescent sera had >1.5 U IgG against S. 
Typhimurium D23580 post-infection. However, the presence of antibody did not 
necessarily correlate with protection against NTS infection, as 39% of the convalescent 
sera were unable to activate cell-mediated killing of Salmonella when whole sera were 
used for opsonisation. The impaired ability of these children to mount an appropriate 
antibody response to their infection could be the result of young age, an immature 
immune system or co-morbidities such as HIV, malaria and malnutrition. This 
observation could also be a result of the minimal antibody threshold used in the 
analysis. The flow cytometry assay used to quantify serum antibody titres may not be 
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sufficiently sensitive to quantify the threshold antibody titre needed to effect killing , 
and could give a saturated signal if there are large amounts of antibody binding to the 
bacteria. Furthermore, a lack of killing for some of the acute and convalescent sera 
could be due to impaired C3 deposition on the bacteria. This, however, is unlikely as the 
sera were optimally prepared and stored, but was not tested.  
 
The observation that blood cell killing of Salmonellae opsonised with diluted 
convalescent sera was enhanced compared to whole serum for some children, could be 
an example of the Neisser-Wechsberg prozone phenomenon, where an excess of 
antibody inhibits killing, but as antibody is diluted killing is restored (222). For cell-
mediated killing of Salmonella, excess total anti-Salmonella antibody could block or 
divert complement deposition or, alternatively, complement could be limiting in our 
assay, and when the sera are diluted and supplemented with exogenous complement 
(i.e. complement is no longer limiting), cell-mediated killing of Salmonella is enhanced. 
Our observation that killing is enhanced in some of these bacteraemic sera when serum 
is diluted suggests that there is something inhibiting the killing and when sera are 
diluted, killing is enhanced. We have previously observed that in some HIV-infected 
Malawian adults, high anti-OAg antibody titres inhibit cell-mediated killing of NTS, but 
at lower titres, these antibodies can be opsonic (see Chapter 5). Therefore, the high-
antibody titres measured in the sera could be directed against the OAg of Salmonella 
and could be inhibiting the killing, but when diluted, the titre of these OAg antibodies 
decreases to a level at which they can be opsonic, or at lower titres complement 
deposition and access of antibodies to other targets such as those on the bacterial 
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membrane can occur, which could enhance killing by blood cells. Since the flow 
cytometry assay we use to quantify anti-Salmonella antibody titres measures antibody 
binding to a range of antigens on the whole bacteria, we do not know what proportion 
of the elevated anti-Salmonella antibody titres target the OAg. Performing ELISAs to 
quantify the antibody response to OAg, as well as to other Salmonella antigens such as 
flagellin, and outer membrane proteins would help understand this better.  
 
This chapter supports previous observations that antibody plays an important role in 
cell-mediated immunity to NTS (151)  and strengthens the rationale for development of 
a NTS vaccine that accelerates the natural process of antibody acquisition against NTS 
(50). However, we need to determine if the findings of impaired cell-dependent killing 
in the presence of high anti-Salmonella antibody titres is only an in vitro observation or 
whether this phenomenon occurs in vivo, in post-vaccinated individuals who have high 
anti-Salmonella antibody titres.  
 
7.5 CONCLUSIONS 
NTS bacteraemia is common in young Malawian children. In sera from some children, 
this antibody can induce cell-mediated killing of Salmonella but the high titres of 
antibody which are produced in response to infection with invasive isolates o f NTS may 
not necessarily be protective. Diluting and supplementing these sera with exogenous 
complement enhanced killing in these sera, suggesting that absent in vitro killing with 
undiluted serum could be a result of high levels of anti-Salmonella antibody diverting 
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complement deposition, insufficient complement levels, the presence of inhibitory anti-
OAg antibodies or a combination of all of these that only when serum is diluted, the 
opsonic potential of antibodies present in the serum is revealed. This work supports the 
development of a vaccine which induces antibody against Salmonella for use in Africa.    
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CHAPTER 8. 
SENSITIVITY OF MALAWIAN SALMONELLA  ISOLATES 
TO KILLING BY ANTIBODY 
 
8.1 INTRODUCTION 
In Sub-Saharan Africa, nontyphoidal Salmonellae are a major cause of bacterial blood 
stream infections (18-20;43). Multi-drug resistant (MDR) NTS have recently been 
reported in many African countries (43;49;223;224) and this makes treatment difficult.  
In Malawi, 90% of invasive NTS isolates are resistant to ampicillin, chloramphenicol and 
cotrimoxazole, but are still sensitive to ceftriaxone and ciprofloxacin (21;49;224). 
However, it is unlikely to be long before resistance to these antibiotics emerges. It is 
therefore essential that an alternative strategy is developed which provides protection 
against NTS, such as a vaccine.  
 
Salmonellae are facultative intracellular organisms which are adapted to survive within 
macrophages (84), but are also capable of extracellular growth in the blood. 
Consequently, both cell-mediated and humoral immunity are required to control 
infection when bacteria are residing within phagocytes and are in transit from cell to 
cell (74). Antibody protects against the uncontrolled spread of NTS through 
opsonisation and uptake by blood phagocytes (151) and also through activating 
complement-mediated lysis of the bacteria (50). The sensitivity of Malawian NTS 
isolates to opsonic and bactericidal antibody therefore needs to be assessed to 
determine how effective antibody will be in preventing NTS bacteraemia. 
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8.2 OBJECTIVES 
As part of a larger study investigating the sensitivity of Malawian NTS isolates to 
bactericidal antibody, we examined the sensitivity of a subset of Malawian NTS isolates 
to opsonic antibody and killing by peripheral blood cells. 
 
8.3 RESULTS 
8. 3. 1 SER OV AR DI STRI BU TION AND CASE F A TALI TY RATES OF N TS  
BACTERAEMIA 
In this study, 350 NTS isolates were cultured from blood taken from children admitted 
to the Queen Elizabeth Central Hospital, Blantyre, Malawi, between 1st August 2003 and 
31st July 2004. The median age of children with NTS bacteraemia was 13 months and 
51% were boys. 91% of the isolates were Salmonella Typhimurium, 8% were 
Salmonella Enteritidis. One isolate was S. Bovismorbificans, one S. Sundsvall, one 
untypable and seven were identified as Salmonella Typhi. 94% of the Salmonella 
Typhimurium isolates were multi-drug resistant (MDR) and 48% of the S. Enteritidis 
were MDR. Case fatality rates were 19.0% for those children infected with S. 
Typhimurium and 22.7% for those infected with S. Enteritidis.  
 
8. 3. 2 S EN SITI VITY OF M AL AWIAN N TS  IS OLATES TO KILLIN G BY  
ANTIBODY 
In work prior to this thesis, serum bactericidal assays were performed by Dr Chisomo 
Msefula to screen the NTS isolates and determine if the sensitivity to bactericidal 
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antibody varied. Serum bactericidal assays were performed on the available 329 
isolates (94% of the isolates cultured from bacteraemic children). These assays assess 
the sensitivity of Salmonella to antibody-induced complement-mediated lysis of the 
bacteria. Each clinical isolate was tested with an aliquot of sera from the same pool of 
ten healthy HIV-uninfected Malawian adults (pooled Malawian serum).  
 
The majority of the isolates were killed after 180 min exposure to antibody and 
complement (Figure 8.1). 19% of the clinical isolates were killed by at least 3.0 log10 
(1000 fold reduction in bacterial numbers compared to the initial concentration of 
bacteria) after 180 min and were classified as ‘highly susceptible’ isolates. 72% of the 
isolates tested were killed between 1.4 log10 and 3.0 log10 and were classified as 
‘susceptible’. This ‘susceptible’ group included Salmonella Typhimurium D23580, an 
isolate which we routinely use in our laboratory as a characteristic, representative 
Malawian isolate (217). 8% of the isolates were in the range of 0 – 1.4 log10 kill and 
these were classified as ‘moderately resistant’. Only 5 isolates, (1.5% of the total isolates 
tested), were fully resistant to serum killing and increased in numbers after 180 min. 
These 5 isolates were classified as ‘resistant’.  
 
8. 3. 3 SEN SI TIVITY OF MAL AWIAN NTS I SOL ATES TO O PS ONIC  
ANTIBODY AND KILLING BY PERIPHERAL BLOOD CELLS  
Eleven NTS isolates which represented a range of susceptibilities to antibody-induced 
complement-mediated killing were selected for further investigation. One of the eleven 
isolates was ‘highly susceptible’; three were ‘susceptible’ (including S. Typhimurium  
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Figure 8.1 Sensitivity of Malawian invasive NTS isolates to bactericidal antibody.  
Sensitivity of 329 NTS isolates to serum killing at 180 min in the serum bactericidal 
assay using pooled sera from Malawian adults demonstrating ‘highly susceptible’, 
‘susceptible’, ‘moderately resistant’ and ‘resistant’ groups. 
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D23580), three ‘moderately resistant’ and four ‘resistant’ to killing by the pooled sera in 
the SBA. Six were S. Typhimurium and five were S. Enteritidis.  
 
To determine if the susceptibility to opsonic antibody varies for the invasive Malawian 
NTS isolates, blood cell killing assays were performed with the eleven selected NTS 
isolates (Figure 8.2 A). The isolates were opsonized with aliquots from the same batch 
of adult pooled Malawian serum as used for the serum bactericidal assays. The 
opsonised ‘highly susceptible’ isolate underwent the greatest kill by peripheral blood 
cells, with an average kill of -1.8 log10. The ‘susceptible’ group underwent a -1 to -1.7 
log10 kill. The ‘resistant’ and ‘highly resistant’ underwent a -0.5 to -1 log10 kill and -0.5 
log10 kill to 1.0 log growth respectively. Killing of the eleven NTS isolates tested in the 
blood cell assay correlated with killing in the serum bactericidal assays (Figure 8.2 B) 
(Spearman rs=0.90, 95% CI 0.64 to 0.97, p=0.0002).  
 
8. 3. 4 S EN SITI VITY OF I SOL A TES TO PH AGO CYTOSI S AND OXI DATI VE 
BURST 
The phagocytic response of peripheral washed blood cells to the eleven opsonised 
isolates was assessed using a flow cytometry-based assay (Figure 8.3 A and B). The 
isolates were opsonised with pooled Malawian serum or PBS (non-opsonised). The 
mean percentage phagocytosing neutrophils for the ‘highly susceptible’/’susceptible’ 
isolates was 73% (range 65.15 – 79.50) and not significantly different from that (69%  
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Figure 8.2 Antibody-dependent killing of NTS isolates by washed peripheral blood 
cells. 
(A) Killing of the eleven Malawian NTS isolates at 180 min in the Salmonella cell killing 
assay by washed peripheral blood cells following opsonisation with pooled Malawian 
sera. Each vertical set of three circles represents data from three independent 
experiments. (B) Killing of each NTS isolate opsonised by the adult Malawian pooled 
sera, by blood cells (means of each set of 3 results from A) compared with killing by 
serum alone (values from Figure 8.1). rs = Spearman’s correlation.  
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Figure 8.3 Antibody-dependent oxidative burst and phagocytosis by peripheral 
blood cells following stimulation with invasive Malawian NTS isolates.  
Phagocytic response by neutrophils (A) and monocytes (B) and oxidative burst activity 
by neutrophils (C) and monocytes (D) in washed peripheral adult blood in response to 
stimulation with each NTS isolate opsonised with pooled Malawian serum (circles) or 
opsonised with PBS (triangles). Each vertical set of three circles or triangles represents 
data from three independent experiments with one isolate.  
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(range 62.92 – 80.07)) for the ‘moderately resistant’/’resistant’ isolates (student’s t-test 
p=0.09) (Figure 8.3 A). The mean percentage phagocytosing monocytes (Figure 8.3 B) 
for the ‘highly susceptible’/’susceptible’ isolates and ‘moderately resistant’/’resistant’ 
isolates was the same (mean 28%).  Opsonisation of the eleven isolates with PBS (non-
opsonised) did not lead to phagocytic activity for neutrophils or monocytes (Figure 8.3 
A and B). 
 
The ability of the eleven isolates to stimulate oxidative burst activity in neutrophils was 
similar for both groups (mean oxidative burst response for ‘highly 
susceptible’/’susceptible’ isolates was 1729 U (range 1102 U to 2443 U) and 1612 U for 
‘moderately resistant’/’resistant’  isolates (range 857 U to 2276 U)) (Student’s t-test 
p=0.45)) (Figure 8.3 C). The mean oxidative burst by monocytes (Figure 8.3 D) was not 
significantly different for ‘highly susceptible’/’susceptible’ isolates and the ‘moderately 
resistant’/’resistant’ isolates (means 207 U and 178 U) (Student’s t-test p=0.34). 
Stimulation of neutrophils and monocytes with non-opsonised isolates (Figure 8.3 C 
and D) did not induce oxidative burst activity. 
 
8. 3. 5 ANTI BO DY AN D COMPL EM ENT DEPO SITI ON ON M AL AWI AN  
ISOLATES 
Cell-mediated and cell-independent killing of invasive NTS isolates is dependent on 
both binding of antibody to the bacteria, and complement deposition on the surface of 
the bacteria. To determine whether variation in susceptibility to bactericidal antibody 
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observed in the 329 NTS isolates and variation in the susceptibility of blood cell killing 
of 11 isolates is due to reduced antibody binding to some isolates, flow cytometric anti-
Salmonella IgG binding assays using the same pooled sera as before were performed on 
the eleven isolates (Figure 8.4 A). The minimum binding of IgG required to induce 
complement lysis of S. Typhimurium D23580 is 1.5 U (50). Binding of IgG to each of the 
eleven isolates was greater than 1.5 U.   
 
Complement deposition assays were performed on the same eleven isolates, again using 
the same batch of pooled Malawian sera and the deposition of C3 and the C5b -9 
membrane attack complex was measured by flow cytometry. For C3 deposition (Figure 
8.4 B), the median deposition was 3700 U (range 2800 U to 4700 U), which exceeds 100 
U - the C3 deposition level previously shown to be required to kill S. Typhimurium (50). 
For C5b-9 (Figure 8.4 C), the median level was 22 U (range 13 U to 36 U), again 
exceeding the level of 0.6 U which is required to effect bacterial lysis. There was no 
correlation between C3 or C5b-9 deposition and sensitivity to antibody-mediated killing 
for each isolate (Spearman rs = -0.35, 95% CI 0.28 to -0.77, p=0.27) and (Spearman rs = 
0.30, 95% CI 0.74 to 0.34, p=0.35) respectively.  
 
The results of these assays suggest that the difference in sensitivity to antibody-
dependent complement-mediated killing of various NTS isolates do not relate to the 
amount of anti-Salmonella IgG antibody or complement components binding to the 
surface of the isolate. 
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Figure 8.4 Antibody and complement deposition on eleven Malawian NTS isolates. 
(A)  Titre of IgG antibody in pooled Malawian adult sera binding to 11 isolates (selected 
from the isolates tested in Figure 8.2, which represent a range of sensitivities to 
antibody-mediated killing) plotted against SBA result at 180 min for each isolate. (B) C3 
and (C) C5b-9 membrane attack complex from pooled Malawian sera on each NTS 
isolate. Vertical dashed lines represent minimum thresholds of IgG binding and 
complement deposition required to kill S. Typhimurium D23580. There was no 
correlation between C3 or C5b-9 deposition and sensitivity to antibody-mediated killing 
for each isolate (rs = -0.35, 95% CI 0.28 to -0.77, p=0.27) and (rs = 0.30, 95% CI 0.74 to 
0.34, p=0.35) respectively.  
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8.4 DISCUSSION 
This chapter re-emphasizes that NTS is a major cause of bacteraemia amongst children 
in Malawi. Within a 12 month period, there were 350 cases of NTS bacteraemia in 
children admitted to one hospital in Blantyre, Malawi. In keeping with other 
observations in African countries, infection with Salmonella Typhimurium was more 
common than Salmonella Enteritidis (50;225). 89% of the isolates were also multi-drug 
resistant highlighting the need for a vaccine for use in African countries.  
 
In order to develop effective vaccines against invasive NTS diseases, the relative 
sensitivity of common invasive isolates to antibody needs to be established, and this 
was the main aim of this study. The susceptibility to antibody-dependent complement-
mediated killing of 329 isolates from bacteraemic children, and sensitivity to ops onic 
antibody of eleven isolates was assessed using a pool of serum from 10 healthy, HIV-
uninfected Malawian adults. The same batch of pooled sera was used throughout and 
provided a broad range of antibody specificities. Healthy adults from Blantyre were 
chosen as antibody to NTS is acquired during childhood, and these adults are likely to 
have been exposed to similar NTS isolates used in this study. The serum bactericidal 
assay used in this study assesses bactericidal activity in 100% human serum and is 
more likely to reflect killing in vivo than some bactericidal assays which use diluted 
animal serum. Likewise for the cell killing assays, fresh human peripheral blood cells 
from healthy subjects were used rather than cultured phagocytic cell lies. Cell lines are 
technically difficult to maintain and may not express the appropriate FcR phenotype to 
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mimic human phagocytes in vivo. Through the use of human serum as opsonins and 
human blood phagocytes, the assays help to match physiological conditions. 
 
The susceptibility of the NTS isolates to antibody-dependent complement-mediated 
killing varied. The majority (74%) of the NTS isolates were ‘moderately susceptible’, 
16% were ‘highly susceptible’, less than 10% were ‘moderately resistant’ and 1.5% 
were ‘resistant’ to killing via this mechanism. A range of susceptibility to killing of 
opsonised Salmonella by peripheral washed blood cells was observed for our collection 
of isolates. Surprisingly, phagocytosis by neutrophils and monocytes and the oxidative 
burst response, measured by flow cytometry, was similar for all isolates.  The batch to 
batch variation in the efficiency of fluorescent-labelling the NTS isolates can be a major 
variable in the opsonophagocytosis assay and may contribute to this finding. Shaio et al 
monitored the phagocytic index for six strains of Salmonella Typhimurium, and found 
that at high serum concentrations, the phagocytic index was hardly discernible between 
the isolates, but at 1% serum, differences were observed (226).  Therefore, we may 
have observed optimal uptake for all eleven isolates as there was excess antibody and 
complement present and any differences in sensitivity to opsonic antibody would not be 
detected.  
 
To try to account for the differences in susceptibility to antibody we examined the 
binding of antibody and complement to the isolates. The binding of IgG and deposition 
of C3 and C5b-9 on each of the isolates far exceeded the thresholds needed to drive 
killing of the bacteria, suggesting that the lack of killing for some isolates is not due to a 
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lack of antibody or complement binding. Joiner et al showed that for Salmonella 
Montevideo, the C5b-9 membrane attack complex forms but fails to be inserted into the 
cell membrane thus impairing cell lysis (186). It is possible that we are detecting MAC 
formation in our assay but that the MAC is formed too far away for insertion into the 
membrane or that it falls off. 
 
Interestingly, susceptibility to antibody-mediated cell-dependent killing correlated with 
susceptibility to cell-free lysis of the bacteria. This suggests that opsonic antibody may 
not be able to compensate for the lack of antibody-dependent cell-independent killing of 
‘resistant’ NTS isolates as previously postulated (151). ‘Resistant’ NTS isolates may 
have inherent mechanisms that confer general broad resistance to killing by immune 
effectors. This concept is supported by the finding that resistance to both modalities of 
killing occurs despite no obvious reduction in antibody-binding, complement 
deposition, phagocytosis of the bacteria or stimulation of the oxidative burst function.  
The observed large group of susceptible isolates could reflect the high prevalence of 
infection with Salmonella Typhimurium D23580-related isolates during this period in 
Malawi, which have this level of sensitivity to antibody or the dominance of these 
isolates may be a consequence of their relative susceptibility to antibody-mediated 
killing. 
 
It is unclear why invasive disease caused by NTS that are highly susceptible to antibody 
killing occurs. It is possible that children infected with these NTS isolates don’t have 
Salmonella-specific antibody, but the mean age of infection for children infected by this 
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group of isolates was not lower than the ages of other groups. It is also possible that 
these isolates adopt a more serum-resistant phenotype in vivo, or that the infected 
children have an underlying susceptibility to  Salmonella infection.  
 
8.5 CONCLUSIONS 
In conclusion, some NTS isolates from bacteraemic children in Malawi were found to be 
sensitive to opsonic and bactericidal antibody, suggesting that an antibody-inducing 
vaccine might successfully protect against the majority of invasive NTS isolates, 
particularly in communities where multi-drug resistant isolates are common. Some 
isolates were resistant to both opsonic and bactericidal antibody and therefore a 
vaccine which induces T-cell immunity as well as antibody would be optimal as it 
minimises the risk of strain replacement with antibody-resistant isolates.  
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CHAPTER 9. 
 GENERAL DISCUSSION 
 
NTS are a major cause of invasive disease in Sub-Saharan Africa (18;21;199), with 
mortality rates as high as 24% in children with NTS bacteraemia (18) and 45% for HIV-
infected adults (30). With the emergence of multidrug resistance (21), a vaccine which 
provides protection against NTS is urgently needed. In order to develop a vaccine for 
use in Africa, a further understanding of the immune response to NTS is required. It has 
previously been shown that antibody plays an important role in immunity to NTS in 
African children and adults (50;61;151) and the aim of this PhD was to further 
understand the role of opsonic antibody in cell-mediated immunity to NTS.  
 
The availability of sera from children with NTS bacteraemia, and adults infected with 
HIV from field studies in Malawi, provided a useful resource for studying cell-mediated 
immunity in the most affected populations who are at greatest need of a vaccine. The 
preliminary project which defined the optimal guidelines for handling serum minimised 
the waste of such limited African sera. The findings that serum could undergo three 
freeze-thaw cycles and be stored at 4⁰C for extended periods of time , or at 22⁰C for 9 
days was surprising given that complement is known to be labile and the accepted view 
that freeze-thaw cycles should be avoided. The observation of no detrimental effect on 
serum bactericidal activity following delayed separation of serum from clotted blood 
stored at 4⁰C or 22⁰C for up to four days post-venesection, has diagnostic and clinical 
implications as well as important implications for resource poor settings, such as clinics 
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in Africa, where equipment and storage facilities such as -80⁰C freezers may not be 
available.   
 
Another aim of this PhD was to optimise our existing in vitro antibody cell-mediated 
killing assay to ascertain the minimal titres of serum that can still drive cell-mediated 
killing. Although commonly used for opsonophagocytic assays for other bacteria 
(192;196), baby rabbit serum was found not to be a suitable exogenous complement 
source as it was toxic to Salmonellae at high concentrations, and could not induce blood 
cell killing of Salmonellae when used at low concentrations together with anti-
Salmonella antibody. Human antibody-depleted serum was found to be a suitable 
complement source for use in our blood cell killing assay and it keeps assay conditions 
more closely related to those in vivo in man. The complement and antibody 
requirements for this assay were compared with those for cell-free antibody-dependent 
complement-mediated killing of NTS. Antibody and complement thresholds for cell-free 
killing of Salmonella were much lower than those required for cell-killing. By identifying 
antibody-depleted human serum as a suitable complement source and the percentage of 
complement and antibody required to opsonise Salmonella and induce killing by 
peripheral blood cells in our blood cell killing assay, we have identified an assay which 
can be used to measure titres of natural and vaccine-induced opsonic antibody for 
killing of NTS.  
 
NTS infections are commonly associated with HIV infection (30) and we studied the role 
of antibody in cell-mediated immunity in HIV-infected Malawian adults to try to better 
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understand the cause of this association. Impaired phagocytosis and killing of 
Salmonella opsonised with sera from some HIV-infected Malawian adults by washed 
peripheral blood cells was observed. It has long been known that a factor within serum 
can block bactericidal activity of serum against common gram negative bacilli (227). We 
previously identified that high titres of anti-OAg antibodies found in serum from HIV-
infected African adults inhibits bactericidal killing of Salmonella (61). Through the 
development of an affinity chromatography method to purify anti-OAg antibodies, we 
were able to characterise the role of anti-OAg antibodies in cell-mediated immunity to 
NTS. We determined that high titres of anti-OAg antibodies found within the serum 
from some HIV-infected African adults inhibit blood cell killing of Salmonella in a 
concentration-dependent manner, with inhibition diminished as the concentration of 
anti-OAg antibodies was decreased.  Further work is required to determine the precise 
mechanism of OAg-antibody related inhibition of cell-mediated killing. As has been 
proposed for cell-free, antibody-dependent complement-mediated immunity (61), 
excess anti-OAg antibodies could be blocking access of other antibodies to targets on 
the membrane and/or diverting complement access. Further investigation is required 
to identify more fully the inhibition mechanism(s). Alternatively, anti-OAg IgA 
antibodies could interfere with C3 fixation or block the binding of IgG or hinder the 
binding of IgG to the FcR. Purification of these anti-OAg IgA antibodies from the sera 
would be useful. Furthermore, biacore analysis of the binding of purified anti-OAg 
antibodies from HIV-infected inhibitory and non-inhibitory sera to the OAg would give 
an insight into whether the affinities of the antibodies for the OAg are different and 
whether this could explain the observed inhibition. Overall, this study contributes 
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another explanation for the high incidence and mortality observed in Africa for HIV -
infected adults with NTS bacteraemia, as it appears that both cell-mediated and cell-free 
(61) mechanisms are impaired in these individuals. 
 
We also studied the role of opsonic antibody in immunity to NTS in children with 
bacteraemia. The majority of these children were under 2 years of age which highlights 
the incidence of NTS bacteraemia in young children and the need for a vaccine which 
accelerates protective natural antibody acquisition for this population. This work also 
supports the importance of antibody in cell-mediated immunity to NTS, as for the 
majority of the children’s sera, antibody acquired during infection effectively opsonised 
Salmonella and triggered killing by washed blood cells suggesting they can provide 
protection against future infection. Anti-Salmonella antibody titres increased post-
infection but high titres of antibodies were not necessarily protective, with blood cells 
failing to kill Salmonella opsonised with some sera. However, when diluted, the majority 
of sera induced blood cell killing suggesting the presence of an in vitro prozone effect 
(222) possibly caused by limited complement, or excess anti-Salmonella or anti-OAg 
antibodies blocking or diverting complement deposition. It is possible that this is an in 
vitro artefact of the assay and would not happen in vivo in vaccinated individuals. 
Further work is required to understand why a subset of children’s sera that contain 
high titres of anti-Salmonella antibody cannot kill S. Typhimurium. Whether high OAg 
antibody titres impair cell-mediated killing of Salmonella in vivo in this subset of 
infected individuals needs further investigation. Although none of the children in the 
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study were infected with S. Typhimurium D23580, almost all of the children could 
induce blood-cell killing of S. Typhimurium D23580 suggesting that antibody induced 
by infection with one NTS isolate is cross-protective and can be opsonic against other 
Malawian isolates of NTS. This could also be explained by the finding that S. 
Typhimurium isolates in Malawi since 2002 are all from the same clade and are part of 
ST313 (217). 
 
A study on the sensitivity of Malawian NTS isolates to antibody-mediated killing 
confirmed that some NTS isolates found in the community in Blantyre, Malawi are 
sensitive to bactericidal antibody, and some isolates are also sensitive to opsonic 
antibody and cell-mediated killing. Resistance to cell-mediated immunity correlated 
with resistance to bactericidal killing for 11 isolates ranging in their level of serum 
resistance, suggesting that a successful NTS vaccine needs to induce both opsonic and 
bactericidal antibody as well as T-cell mediated immunity. Larger studies are required 
in other countries in Sub-Saharan Africa that are affected by the NTS epidemic, to 
determine the relative sensitivity of isolates from these areas to antibody, and the 
overall potential coverage of an antibody-inducing vaccine.  
 
The work undertaken during this PhD reinforces the important role antibody plays in 
immunity against NTS and supports the development of a vaccine which induces the 
production of antibody to Salmonella. In order to do this, the targets of protective 
opsonic and bactericidal antibodies need to be established and this should be the focus 
of future work. Given the evidence of protective immunity when prototype OAg 
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conjugate vaccines have been tested in rabbits and mice (156-158), the development of 
polysaccharide-conjugate vaccines for use in humans is a promising avenue, and a 
conjugate vaccine based on the OAg of Salmonella is currently under development at 
NVGH. Work carried out within this PhD suggests that anti-OAg antibodies can be 
opsonic when present at the serum titre found in healthy Malawian adults, but at the 
serum titres of some HIV-infected adults, they inhibit both cell-dependent and cell-
independent (61) immunity. This cautions against the use of OAg as a vaccine candidate. 
Furthermore, an OAg-based vaccine has the problem of serovar-specificity and 
consequently strain replacement is a concern. Given that not all invasive Malawian 
isolates of NTS are sensitive to opsonic and bactericidal antibody, this could be an issue. 
Therefore, the common target antigens of protective responses to NTS need to be 
identified. Ideally, the vaccine target should induce opsonic and bactericidal antibodies. 
Antibody targeting the outer membrane of Salmonella, in particular ompD (182), have 
been shown to be bactericidal (61) and further studies are required to understand their 
role in opsonisation. A method to purify antibodies to the outer membrane proteins 
from human serum also needs to be developed to enable, as for OAg antibodies, the 
characterisation of their role in cell-mediated immunity to NTS.  
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